0001493152-22-007099.txt : 20220317 0001493152-22-007099.hdr.sgml : 20220317 20220317083042 ACCESSION NUMBER: 0001493152-22-007099 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 74 CONFORMED PERIOD OF REPORT: 20220131 FILED AS OF DATE: 20220317 DATE AS OF CHANGE: 20220317 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Advaxis, Inc. CENTRAL INDEX KEY: 0001100397 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 841521955 STATE OF INCORPORATION: DE FISCAL YEAR END: 1031 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36138 FILM NUMBER: 22746866 BUSINESS ADDRESS: STREET 1: 9 DEER PARK DRIVE STREET 2: SUITE K-1 CITY: MONMOUTH JUNCTION STATE: NJ ZIP: 08852 BUSINESS PHONE: 732 545 1590 MAIL ADDRESS: STREET 1: 9 DEER PARK DRIVE STREET 2: SUITE K-1 CITY: MONMOUTH JUNCTION STATE: NJ ZIP: 08852 FORMER COMPANY: FORMER CONFORMED NAME: GREAT EXPECTATIONS & ASSOCIATES INC DATE OF NAME CHANGE: 19991203 10-Q 1 form10-q.htm
0001100397 false --10-31 2022 Q1 2025-11-30 0001100397 2021-11-01 2022-01-31 0001100397 2022-03-16 0001100397 2022-01-31 0001100397 2021-10-31 0001100397 ADXS:SeriesDConvertibleRedeemablePreferredStockMember 2022-01-31 0001100397 ADXS:SeriesDConvertibleRedeemablePreferredStockMember 2021-10-31 0001100397 2020-11-01 2021-01-31 0001100397 2020-10-31 0001100397 2021-01-31 0001100397 ADXS:SeriesDPreferredStockRedemptionMember 2022-01-31 0001100397 us-gaap:WarrantMember 2021-11-01 2022-01-31 0001100397 us-gaap:WarrantMember 2020-11-01 2021-01-31 0001100397 ADXS:SeriesDConvertableRedeemablePreferredStockMember 2021-11-01 2022-01-31 0001100397 ADXS:SeriesDConvertableRedeemablePreferredStockMember 2020-11-01 2021-01-31 0001100397 ADXS:StockOptionsMember 2021-11-01 2022-01-31 0001100397 ADXS:StockOptionsMember 2020-11-01 2021-01-31 0001100397 ADXS:RestrictedStockUnitsMember 2021-11-01 2022-01-31 0001100397 ADXS:RestrictedStockUnitsMember 2020-11-01 2021-01-31 0001100397 us-gaap:GeneralAndAdministrativeExpenseMember 2021-11-01 2022-01-31 0001100397 us-gaap:GeneralAndAdministrativeExpenseMember 2020-11-01 2021-01-31 0001100397 2021-03-01 2021-03-26 0001100397 2021-03-26 0001100397 2021-03-01 2021-03-25 0001100397 2021-03-25 0001100397 us-gaap:WarrantMember 2022-01-31 0001100397 us-gaap:WarrantMember 2021-10-31 0001100397 us-gaap:WarrantMember srt:MinimumMember 2022-01-31 0001100397 us-gaap:WarrantMember srt:MaximumMember 2022-01-31 0001100397 ADXS:EquityWarrantsMember 2021-10-31 0001100397 ADXS:EquityWarrantsMember 2022-01-31 0001100397 ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2022-01-31 0001100397 ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2021-10-31 0001100397 us-gaap:IPOMember 2022-01-31 0001100397 srt:MinimumMember 2021-06-03 0001100397 srt:MaximumMember 2021-06-03 0001100397 ADXS:WarrantLiabilityMember srt:MaximumMember 2021-01-31 0001100397 ADXS:WarrantLiabilityMember srt:MinimumMember 2021-01-31 0001100397 us-gaap:PrivatePlacementMember 2021-11-01 2022-01-31 0001100397 ADXS:ExercisePriceRangeOneMember 2021-10-31 0001100397 ADXS:ExercisePriceRangeOneMember 2022-01-31 0001100397 ADXS:ExercisePriceRangeOneMember 2020-11-01 2021-10-31 0001100397 ADXS:ExercisePriceRangeOneMember 2021-11-01 2022-01-31 0001100397 ADXS:ExercisePriceRangeTwoMember 2021-10-31 0001100397 ADXS:ExercisePriceRangeTwoMember 2022-01-31 0001100397 ADXS:ExercisePriceRangeTwoMember 2020-11-01 2021-10-31 0001100397 ADXS:ExercisePriceRangeTwoMember 2021-11-01 2022-01-31 0001100397 ADXS:ExercisePriceRangeThreeMember 2021-10-31 0001100397 ADXS:ExercisePriceRangeThreeMember 2022-01-31 0001100397 ADXS:ExercisePriceRangeThreeMember 2020-11-01 2021-10-31 0001100397 ADXS:ExercisePriceRangeThreeMember 2021-11-01 2022-01-31 0001100397 ADXS:ExercisePriceRangeFourMember 2021-10-31 0001100397 ADXS:ExercisePriceRangeFourMember 2022-01-31 0001100397 ADXS:ExercisePriceRangeFourMember 2020-11-01 2021-10-31 0001100397 ADXS:ExercisePriceRangeFourMember 2021-11-01 2022-01-31 0001100397 ADXS:ExercisePriceRangeFiveMember 2021-10-31 0001100397 ADXS:ExercisePriceRangeFiveMember 2022-01-31 0001100397 ADXS:ExercisePriceRangeFiveMember 2020-11-01 2021-10-31 0001100397 ADXS:ExercisePriceRangeFiveMember 2021-11-01 2022-01-31 0001100397 ADXS:ExercisePriceRangeSixMember 2021-10-31 0001100397 ADXS:ExercisePriceRangeSixMember 2022-01-31 0001100397 ADXS:ExercisePriceRangeSixMember 2020-11-01 2021-10-31 0001100397 ADXS:ExercisePriceRangeSixMember 2021-11-01 2022-01-31 0001100397 us-gaap:MeasurementInputExpectedTermMember ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2022-01-31 0001100397 us-gaap:MeasurementInputExpectedTermMember ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2021-10-31 0001100397 us-gaap:MeasurementInputPriceVolatilityMember ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2022-01-31 0001100397 us-gaap:MeasurementInputPriceVolatilityMember ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2021-10-31 0001100397 us-gaap:MeasurementInputRiskFreeInterestRateMember ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2022-01-31 0001100397 us-gaap:MeasurementInputRiskFreeInterestRateMember ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2021-10-31 0001100397 ADXS:WarrantLiabilityMember 2022-01-31 0001100397 ADXS:WarrantLiabilityMember 2021-10-31 0001100397 us-gaap:MeasurementInputExpectedTermMember ADXS:WarrantLiabilityMember 2022-01-31 0001100397 us-gaap:MeasurementInputExpectedTermMember ADXS:WarrantLiabilityMember 2021-10-31 0001100397 us-gaap:MeasurementInputPriceVolatilityMember ADXS:WarrantLiabilityMember 2022-01-31 0001100397 us-gaap:MeasurementInputPriceVolatilityMember ADXS:WarrantLiabilityMember 2021-10-31 0001100397 us-gaap:MeasurementInputRiskFreeInterestRateMember ADXS:WarrantLiabilityMember 2022-01-31 0001100397 us-gaap:MeasurementInputRiskFreeInterestRateMember ADXS:WarrantLiabilityMember 2021-10-31 0001100397 us-gaap:PrivatePlacementMember ADXS:InstitutionalInvestorsMember us-gaap:SeriesDPreferredStockMember 2022-01-01 2022-01-31 0001100397 us-gaap:SeriesDPreferredStockMember us-gaap:PrivatePlacementMember ADXS:InstitutionalInvestorsMember 2022-01-31 0001100397 2022-01-01 2022-01-31 0001100397 us-gaap:SeriesDPreferredStockMember 2022-01-31 0001100397 us-gaap:MeasurementInputExercisePriceMember 2022-01-31 0001100397 us-gaap:MeasurementInputSharePriceMember 2022-01-31 0001100397 us-gaap:MeasurementInputPriceVolatilityMember 2022-01-31 0001100397 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-01-31 0001100397 us-gaap:PreferredStockMember 2020-10-31 0001100397 us-gaap:CommonStockMember 2020-10-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2020-10-31 0001100397 us-gaap:RetainedEarningsMember 2020-10-31 0001100397 us-gaap:PreferredStockMember 2020-11-01 2021-01-31 0001100397 us-gaap:CommonStockMember 2020-11-01 2021-01-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2020-11-01 2021-01-31 0001100397 us-gaap:RetainedEarningsMember 2020-11-01 2021-01-31 0001100397 us-gaap:PreferredStockMember 2021-01-31 0001100397 us-gaap:CommonStockMember 2021-01-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2021-01-31 0001100397 us-gaap:RetainedEarningsMember 2021-01-31 0001100397 us-gaap:PreferredStockMember 2021-10-31 0001100397 us-gaap:CommonStockMember 2021-10-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2021-10-31 0001100397 us-gaap:RetainedEarningsMember 2021-10-31 0001100397 us-gaap:PreferredStockMember 2021-11-01 2022-01-31 0001100397 us-gaap:CommonStockMember 2021-11-01 2022-01-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2021-11-01 2022-01-31 0001100397 us-gaap:RetainedEarningsMember 2021-11-01 2022-01-31 0001100397 us-gaap:PreferredStockMember 2022-01-31 0001100397 us-gaap:CommonStockMember 2022-01-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2022-01-31 0001100397 us-gaap:RetainedEarningsMember 2022-01-31 0001100397 us-gaap:ResearchAndDevelopmentExpenseMember 2021-11-01 2022-01-31 0001100397 us-gaap:ResearchAndDevelopmentExpenseMember 2020-11-01 2021-01-31 0001100397 srt:ChiefExecutiveOfficerMember 2022-01-31 0001100397 ADXS:DevelopmentLicenseAndSupplyAgreementMember ADXS:OSTherapiesMember 2020-04-29 2020-04-30 0001100397 ADXS:DevelopmentLicenseAndSupplyAgreementMember ADXS:OSTherapiesMember 2018-09-03 2018-09-04 0001100397 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2022-01-31 0001100397 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2022-01-31 0001100397 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2022-01-31 0001100397 us-gaap:MoneyMarketFundsMember 2022-01-31 0001100397 us-gaap:FairValueInputsLevel1Member 2022-01-31 0001100397 us-gaap:FairValueInputsLevel2Member 2022-01-31 0001100397 us-gaap:FairValueInputsLevel3Member 2022-01-31 0001100397 us-gaap:FairValueInputsLevel1Member ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2022-01-31 0001100397 us-gaap:FairValueInputsLevel2Member ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2022-01-31 0001100397 us-gaap:FairValueInputsLevel3Member ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2022-01-31 0001100397 ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2022-01-31 0001100397 us-gaap:FairValueInputsLevel1Member us-gaap:PrivatePlacementMember 2022-01-31 0001100397 us-gaap:FairValueInputsLevel2Member us-gaap:PrivatePlacementMember 2022-01-31 0001100397 us-gaap:FairValueInputsLevel3Member us-gaap:PrivatePlacementMember 2022-01-31 0001100397 us-gaap:PrivatePlacementMember 2022-01-31 0001100397 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2021-10-31 0001100397 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2021-10-31 0001100397 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2021-10-31 0001100397 us-gaap:MoneyMarketFundsMember 2021-10-31 0001100397 us-gaap:FairValueInputsLevel1Member 2021-10-31 0001100397 us-gaap:FairValueInputsLevel2Member 2021-10-31 0001100397 us-gaap:FairValueInputsLevel3Member 2021-10-31 0001100397 us-gaap:FairValueInputsLevel1Member ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2021-10-31 0001100397 us-gaap:FairValueInputsLevel2Member ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2021-10-31 0001100397 us-gaap:FairValueInputsLevel3Member ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2021-10-31 0001100397 ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2021-10-31 0001100397 us-gaap:FairValueInputsLevel1Member us-gaap:PrivatePlacementMember 2021-10-31 0001100397 us-gaap:FairValueInputsLevel2Member us-gaap:PrivatePlacementMember 2021-10-31 0001100397 us-gaap:FairValueInputsLevel3Member us-gaap:PrivatePlacementMember 2021-10-31 0001100397 us-gaap:PrivatePlacementMember 2021-10-31 0001100397 ADXS:PreferredStockRedemptionLiabilityMember 2021-10-31 0001100397 ADXS:WarrantLiabilityMember 2021-10-31 0001100397 ADXS:PreferredStockRedemptionLiabilityMember 2021-11-01 2022-01-31 0001100397 ADXS:WarrantLiabilityMember 2021-11-01 2022-01-31 0001100397 ADXS:PreferredStockRedemptionLiabilityMember 2022-01-31 0001100397 ADXS:WarrantLiabilityMember 2022-01-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure ADXS:Integer

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended January 31, 2022

 

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ________ to ________

 

Commission file number 001-36138

 

ADVAXIS, INC.

 

(Exact name of registrant as specified in its charter)

 

Delaware   02-0563870
(State or other jurisdiction of   (IRS Employer
incorporation or organization)   Identification No.)

 

9 Deer Park Drive, Suite K-1, Monmouth Junction, NJ   08852
(Address of principal executive offices)   (Zip Code)

 

(609) 452-9813
(Registrant’s telephone number)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   ADXS   OTCQX® Best Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such fling requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer ☐   Accelerated Filer ☐
Non-accelerated Filer ☒   Smaller Reporting Company ☒
Emerging growth company ☐      

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

The number of shares of the registrant’s Common Stock, $0.001 par value, outstanding as of March 16, 2022 was 145,638,459.

 

 

 

 
 

 

TABLE OF CONTENTS

 

    Page No.
     
PART I FINANCIAL INFORMATION 5
     
Item 1. Financial Statements (unaudited) 5
     
  Condensed Consolidated Balance Sheets 5
     
  Condensed Consolidated Statements of Operations 6
     
  Condensed Consolidated Statements of Cash Flows 7
     
  Notes to the Condensed Consolidated Financial Statements 8
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 20
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk 25
     
Item 4. Controls and Procedures 25
     
PART II OTHER INFORMATION 25
     
Item 1. Legal Proceedings 25
     
Item 1A. Risk Factors 26
     
Item 6. Exhibits 26
     
SIGNATURES 28

 

2
 

 

CAUTIONARY NOTE REGARDING FORWARD LOOKING-STATEMENTS

 

This quarterly report on Form 10-Q (“Form 10-Q”) of Advaxis, Inc. (the “Company”) includes statements that are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, these forward-looking statements can be identified by the use of such terms as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or the negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. They appear in a number of places throughout this Form 10-Q and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned discovery and development of drug candidates, the strength and breadth of our intellectual property, our ongoing and planned preclinical studies and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, the degree of clinical utility of our product candidates, particularly in specific patient populations, expectations regarding clinical trial data, our results of operations, financial condition, our available cash, liquidity, prospects, growth and strategies, impacts of the ongoing coronavirus (COVID-19) pandemic, the length of time that we will be able to continue to fund our operating expenses and capital expenditures, our expected financing needs and sources of financing, the industry in which we operate and the trends that may affect our industry or us.

 

By their nature, forward-looking statements involve risks and uncertainties because they relate to the occurrence and timing of events or circumstances, many of which are beyond the control of the Company. As a result of these, we cannot assure you that the forward-looking statements in this Form 10-Q will prove to be accurate. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Form 10-Q, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this Form 10-Q. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate, are consistent with the forward-looking statements contained in this Form 10-Q, they may not be predictive of results or developments in future periods.

 

3
 

 

Some of the material factors that we believe could cause actual results to differ from those anticipated or predicted include:

 

  ● the success and timing of our clinical trials, including patient accrual;
     
  ● our ability to obtain and maintain regulatory approval or reimbursement of our product candidates for marketing;
     
  ● our ability to obtain the appropriate labeling of our products under any regulatory approval;
     
  ● our ability to develop and commercialize our products;
     
  ● the successful development and implementation of our sales and marketing campaigns;
     
  ● the change of key scientific or management personnel;
     
  ● the size and growth of the potential markets for our product candidates and our ability to serve those markets;
     
  ● our ability to successfully compete in the potential markets for our product candidates, if commercialized;
     
  ● regulatory developments in the United States and foreign countries;
     
  ● new products, product candidates or new uses for existing products or technologies introduced or announced by our competitors and the timing of these introductions or announcements;
     
  ● market conditions in the pharmaceutical and biotechnology sectors;
     
  ● our available cash;
     
  ● the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing;
     
  ● our ability to obtain additional funding;
     
  ● any outcomes from our review of strategic transactions and options to maximize stockholder value;
     
  ● the ability of our product candidates to successfully perform in clinical trials and to resolve any clinical holds that may occur;
     
  ● our ability to obtain and maintain approval of our product candidates for trial initiation;
     
  ● the performance of third-party manufacturers;
     
  ● our ability to identify license and collaboration partners and to maintain existing relationships;
     
  ● the performance of our clinical research organizations, clinical trial sponsors, clinical trial investigators and collaboration partners for any clinical trials we conduct;
     
  ● our ability to successfully implement our strategy;
     
  ● our ability to maintain the listing of our common stock on the OTCQX® Best Market (“OTCQX”); and
     
  ● the factors described in the “Risk Factors” section of the Company’s annual report on Form 10-K for the fiscal year ended October 31, 2021 (the “2021 Annual Report on Form 10-K”), as updated and amended in other filings by the Company with the Securities and Exchange Commission (the “SEC”).

 

You should also read carefully the factors described in the “Risk Factors” section of the 2021 Annual Report on Form 10-K. Any forward-looking statements that we make in this Form 10-Q speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this Form 10-Q except as required by the federal securities laws.

 

This Form 10-Q includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe these industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data.

 

4
 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

ADVAXIS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

 

  

January 31, 2022

   October 31, 2021 
   (Unaudited)     
ASSETS          
Current assets:          
Cash and cash equivalents  $36,480   $41,614 
Restricted cash   5,250    - 
Prepaid expenses and other current assets   1,386    1,643 
Total current assets   43,116    43,257 
           
Property and equipment (net of accumulated depreciation)   100    118 
Intangible assets (net of accumulated amortization)   3,238    3,354 
Operating right-of-use asset (net of accumulated amortization)   33    40 
Other assets   11    11 
           
Total assets  $46,498   $46,780 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities:          
Accounts payable  $345   $87 
Accrued expenses   2,131    2,836 
Current portion of operating lease liability   29    28 
Preferred stock redemption liability   87    - 
Common stock warrant liability   1,127    4,929 
Total current liabilities   3,719    7,880 
           
Operating lease liability, net of current portion   5    12 
Total liabilities   3,724    7,892 
           
Contingencies – Note 10   -    - 
           
Series D convertible preferred stock- $0.001 par value; 1,000,000 shares authorized, issued and outstanding at January 31, 2022; Liquidation preference of $5,250 at January 31, 2022.   4,225    - 
           
Stockholders’ equity:          
Preferred stock, $0.001 par value; 4,000,000 and 5,000,000 shares authorized, 0 shares issued and outstanding at January 31, 2022 and October 31, 2021.   -    - 
Common stock - $0.001 par value; 170,000,000 shares authorized, 145,638,459 shares issued and outstanding at January 31, 2022 and October 31, 2021.   146    146 
Additional paid-in capital   467,368    467,342 
Accumulated deficit   (428,965)   (428,600)
Total stockholders’ equity   38,549    38,888 
Total liabilities and stockholders’ equity  $46,498   $46,780 

 

The accompanying notes should be read in conjunction with the financial statements.

 

5
 

 

ADVAXIS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

(In thousands, except share and per share data)

 

   2022   2021 
   Three Months Ended
January 31,		 
   2022   2021 
         
Revenue  $-   $1,615 
           
Operating expenses:          
Research and development expenses   1,654    2,570 
General and administrative expenses   2,510    3,008 
Total operating expenses   4,164    5,578 
           
Loss from operations   (4,164)   (3,963)
           
Other income (expense):          
Interest income, net   1    1 
Net changes in fair value of derivative liabilities   3,802    (27)
Other (expense) income   (4)   12 
Net loss before income taxes   (365)   (3,977)
           
Income tax expense   -    - 
           
Net loss  $(365)  $(3,977)
           
Net loss per common share, basic and diluted  $(0.00)  $(0.05)
           
Weighted average number of common shares, basic and diluted   145,638,459    83,943,982 

 

The accompanying notes should be read in conjunction with the financial statements.

 

6
 

 

ADVAXIS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

(In thousands)

 

   2022   2021 
   Three Months Ended
January 31,		 
   2022   2021 
         
OPERATING ACTIVITIES          
Net loss  $(365)  $(3,977)
Adjustments to reconcile net loss to net cash used in operating activities:          
Share based compensation   26    236 
(Gain) loss on change in value of warrants   (3,802)   27 
Loss on disposal of property and equipment   -    12 
Abandonment of intangible assets   104    - 
Depreciation expense   18    192 
Amortization expense of intangible assets   70    67 
Amortization of right-of-use asset   7    195 
Change in operating assets and liabilities:          
Prepaid expenses, other current assets and deferred expenses   257    463 
Accounts payable and accrued expenses   (447)   394 
Deferred revenue   -    (165)
Operating lease liabilities   (6)   (230)
Net cash used in operating activities   (4,138)   (2,786)
           
INVESTING ACTIVITIES          
Cost of intangible assets   (58)   (210)
Net cash used in investing activities   (58)   (210)
           
FINANCING ACTIVITIES          
Net proceeds of issuance of Series D preferred stock   4,312    - 
Net proceeds of issuance of common stock and warrants   -    8,550 
Warrant exercises   -    2,586 
Net cash provided by financing activities   4,312    11,136 
           
Net increase in cash, cash equivalents and restricted cash   116    8,140 
Cash, cash equivalents and restricted cash at beginning of year   41,614    25,178 
Cash, cash equivalents and restricted cash at end of year  $41,730   $33,318 
           
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed balance sheets that sum to the total of the same such amounts shown in the condensed statements of cash flows:          
           
Cash and cash equivalents   36,480    33,318 
Restricted cash   5,250    - 
Total cash, cash equivalents and restricted cash shown in condensed statements of cash flows   41,730    33,318 
           
SUPPLEMENTAL CASH FLOW INFORMATION          
Cash paid for taxes  $-   $- 

 

The accompanying notes should be read in conjunction with the financial statements.

 

7
 

 

ADVAXIS, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

1. NATURE OF OPERATIONS

 

Advaxis, Inc. (“Advaxis” or the “Company”) is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (“Lm”)-based antigen delivery products. The Company is using its Lm platform directed against tumor-specific targets in order to engage the patient’s immune system to destroy tumor cells. Through a license from the University of Pennsylvania, Advaxis has exclusive access to this proprietary formulation of attenuated Lm called Lm TechnologyTM. Advaxis’ proprietary approach is designed to deploy a unique mechanism of action that redirects the immune system to attack cancer in three distinct ways:

 

  ● Alerting and training the immune system by activating multiple pathways in Antigen-Presenting Cells (“APCs”) with the equivalent of multiple adjuvants;
  ● Attacking the tumor by generating a strong, cancer-specific T cell response; and
  ● Breaking down tumor protection through suppression of the protective cells in the tumor microenvironment (“TME”) that shields the tumor from the immune system. This enables the activated T cells to begin working to attack the tumor cells.

 

Advaxis’ proprietary Lm platform technology has demonstrated clinical activity in several of its programs and has been dosed in over 470 patients across multiple clinical trials and in various tumor types. The Company believes that Lm Technology immunotherapies can complement and address significant unmet needs in the current oncology treatment landscape. Specifically, its product candidates have the potential to work synergistically with other immunotherapies, including checkpoint inhibitors, while having a generally well-tolerated safety profile.

 

Liquidity and Capital Resources

 

Liquidity and Management’s Plans

 

Similar to other development stage biotechnology companies, the Company’s products that are being developed have not generated significant revenue. As a result, the Company has suffered recurring losses and requires significant cash resources to execute its business plans. These losses are expected to continue for the foreseeable future.

 

As of January 31, 2022, the Company had approximately $36.5 million in cash and cash equivalents. Although the Company expects to have sufficient capital to fund its obligations, as they become due, in the ordinary course of business until at least one year from the issuance of these consolidated financial statements, the actual amount of cash that it will need to operate is subject to many factors.

 

The Company recognizes it will need to raise additional capital in order to continue to execute its business plan in the future. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to further scale back its operations.

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

 

Basis of Presentation/Estimates

 

The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) with respect to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and the accompanying unaudited interim condensed consolidated balance sheet as of January 31, 2022 has been derived from the Company’s October 31, 2021 audited financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements furnished include all adjustments (consisting of normal recurring accruals) necessary for a fair statement of the results for the interim periods presented.

 

8
 

 

Operating results for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates include the timelines associated with revenue recognition on upfront payments received, fair value and recoverability of the carrying value of property and equipment and intangible assets, fair value of warrant liability, grant date fair value of options, deferred tax assets and any related valuation allowance and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from these estimates.

 

These unaudited interim condensed consolidated financial statements should be read in conjunction with the financial statements of the Company as of and for the fiscal year ended October 31, 2021 and notes thereto contained in the Company’s 2021 Annual Report on Form 10-K, as filed with the SEC on February 14, 2022.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated.

 

Restricted Cash

 

On January 31, 2022, the Company transferred $5,250,000 into an escrow fund to fund a potential Series D preferred stock redemption.

 

Convertible Preferred Stock

 

Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control, as temporary equity (“mezzanine”) until such time as the conditions are removed or lapse.

 

Derivative Financial Instruments

 

The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For share-based derivative financial instruments, the Company used the Monte Carlo simulation model, the Black Scholes model and a binomial model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the consolidated balance sheet as current or non-current based on whether or not net-cash settlement of the instrument could be required within 12 months after the balance sheet date.

 

9
 

 

Net Income (Loss) per Share

 

Basic net income or loss per common share is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, restricted stock units and other potential common stock outstanding during the period. In the case of a net loss, the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table below sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share:

 

   As of January 31, 
   2022   2021 
Warrants   30,225,397    8,014,220 
Series D convertible redeemable preferred stock   20,000,000    - 
Stock options   888,058    1,047,377 
Restricted stock units   -    5,556 
Total   51,113,455    9,067,153 

 

Recent Accounting Standards

 

In December 2019, the FASB issued ASU 2019-12, Simplification of Income Taxes (Topic 740) Income Taxes (“ASU 2019-12”). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for public companies for annual periods beginning after December 15, 2020, including interim periods within those fiscal years. The Company adopted this standard effective November 1, 2021 and it is not material to the financial results of the Company.

 

In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain convertible instruments, amends guidance on derivative scope exceptions for contracts in an entity’s own equity, and modifies the guidance on diluted earnings per share (“EPS”) calculations as a result of these changes. The standard will be effective for the Company for fiscal years beginning after December 15, 2023 and can be applied on either a fully retrospective or modified retrospective basis. Early adoption is permitted for fiscal years beginning after December 15, 2020. The Company adopted this standard effective November 1, 2021 and it is not material to the financial results of the Company.

 

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed consolidated financial statements.

 

3. PROPERTY AND EQUIPMENT

 

Property and equipment, net consisted of the following (in thousands):

 

   January 31, 2022   October 31, 2021 
Laboratory equipment  $179   $179 
Computer equipment   241    241 
Total property and equipment   420    420 
Accumulated depreciation and amortization   (320)   (302)
Net property and equipment  $100   $118 

 

Depreciation expense for the three months ended January 31, 2022 and 2021 was approximately $18,000 and $192,000, respectively.

 

10
 

 

4. INTANGIBLE ASSETS

 

Intangible assets, net consisted of the following (in thousands):

 

   January 31, 2022   October 31, 2021 
         
Patents  $4,769   $4,836 
Licenses   777    777 
Software   98    98 
Total intangibles   5,644    5,711 
Accumulated amortization   (2,406)   (2,357)
Intangible assets  $3,238   $3,354 

 

The expiration dates of the existing patents range from 2021 to 2039 but the expiration dates can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to further pursue the application. Patent applications having a net book value of approximately $104,000 and $0 were abandoned and were charged to general and administrative expenses in the statement of operations for each of the three months ended January 31, 2022 and 2021, respectively. Amortization expense for intangible assets that was charged to general and administrative expense in the statement of operations aggregated approximately $70,000 and $67,000 for the three months ended January 31, 2022 and 2021, respectively.

 

Management has reviewed its long-lived assets for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. Net assets are recorded on the balance sheet for patents and licenses related to axalimogene filolisbac (AXAL), ADXS-HOT, ADXS-PSA and other products that are in development. However, if a competitor were to gain FDA approval for a similar treatment before the Company or if future clinical trials fail to meet the targeted endpoints, the Company will likely record an impairment related to these assets. In addition, if an application is rejected or fails to be issued, the Company would record an impairment of its estimated book value. Lastly, if the Company is unable to raise enough capital to continue funding its studies and developing its intellectual property, the Company would likely record an impairment to these assets.

 

As of January 31, 2022, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):

 

   Fiscal year ending
October 31,		 
     
2022 (Remaining)  $211 
2023   282 
2024   282 
2025   282 
2026   282 
Thereafter   1,899 
Total  $3,238 

 

5. ACCRUED EXPENSES:

 

The following table summarizes accrued expenses included in the condensed consolidated balance sheets (in thousands):

 

   January 31, 2022   October 31, 2021 
         
Salaries and other compensation  $170   $55 
Vendors   1,524    1,968 
Professional fees   237    613 
Other   200    200 
Total accrued expenses  $2,131   $2,836 

 

11
 

 

6. LEASES

 

Operating Leases

 

The Company previously leased a corporate office and manufacturing facility in Princeton, New Jersey under an operating lease that was set to expire in November 2025. On March 26, 2021, the Company entered into a Lease Termination and Surrender Agreement with respect to this lease agreement. The Lease Termination and Surrender Agreement provides for the early termination of the lease, which became effective on March 31, 2021. In connection with the early termination of the lease, the Company was required to pay a $1,000,000 termination payment. The unapplied security deposit totaling approximately $182,000 was credited against the termination fee for a net payment of approximately $818,000. The Company wrote off of the remaining right-of-use asset of approximately $4.5 million and lease liability of approximately $5.6 million. After consideration of the termination payment and write off of remaining right-of-use asset and lease liability, the Company recorded a net gain of approximately $0.1 million.

 

On March 25, 2021, the Company entered into a new lease agreement for its corporate office/lab with base rent of approximately $29,000 per year, plus other expenses. The lease expires on March 25, 2022 and the Company has the option to renew the lease for one additional successive one-year term upon six months written notice to the landlord. This new lease was accounted for as a short-term lease at inception, and the Company elected not to recognize a right-of-use asset and lease liability. In September 2021, the Company exercised its option to renew the lease, extending the lease term until March 25, 2023. Since the renewed lease term exceeds one-year, the lease no longer qualifies for the short-term lease exception, resulting in the recognition of a right-of-use asset and operating lease liability of approximately $43,000.

 

Supplemental balance sheet information related to leases was as follows (in thousands):

 

   January 31, 2022   October 31, 2021 
Operating leases:           
Operating lease right-of-use assets  $33   $40 
           
Operating lease liability  $29   $28 
Operating lease liability, net of current portion   5    12 
Total operating lease liabilities  $34   $40 

 

Supplemental lease expense related to leases was as follows (in thousands):

 

Lease Cost (in thousands)   Statements of Operations Classification   For the Three
Months Ended
January 31, 2022		     For the Three
Months Ended
January 31, 2021		  
Operating lease cost   General and administrative     7       290  
Variable lease cost   General and administrative   $ 9       437  
Total lease expense       $ 16       727  

 

Other information related to leases where the Company is the lessee is as follows:

 

   January 31, 2022   October 31, 2021 
Weighted-average remaining lease term   1.2 years    1.4 years 
Weighted-average discount rate   3.79%   3.79%

 

Supplemental cash flow information related to operating leases was as follows:

 

   For the Three
Months Ended
January 31, 2022		   For the Three
Months Ended
January 31, 2021		 
Cash paid for operating lease liabilities  $7   $324 

 

12
 

 

Future minimum lease payments under non-cancellable leases as of January 31, 2022 were as follows:

 

Fiscal Year ending October 31,    
2022 (Remaining)  $22 
2023   13 
Total minimum lease payments   35 
Less: Imputed interest   (1)
Total  $34 

 

7. COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY

 

Warrants

 

As of January 31, 2022 and October 31, 2021, there were outstanding and exercisable warrants to purchase 30,225,397 shares of our common stock with exercise prices ranging from $0.30 to $281.25 per share. Information on the outstanding warrants is as follows:

 

Exercise
Price		   Number of Shares
Underlying Warrants		   Expiration Date  Type of Financing
$281.25    25   N/A  Other warrants
$0.25    70,297   July 2024  September 2018 Public Offering
$2.80    327,338   September 2024  July 2019 Public Offering
$0.35    4,578,400   November 2025  November 2020 Public Offering
$0.70    11,244,135   April 2026  April 2021 Registered Direct Offering (Accompanying Warrants)
$0.70    14,005,202   5 years after the date such warrants become exercisable, if ever  April 2021 Private Placement (Private Placement Warrants)
 Grand Total    30,225,397       

 

As of January 31, 2022 and October 31, 2021, the Company had 16,149,898 of its total 30,225,397 outstanding warrants classified as equity (equity warrants).

 

Warrant Liability

 

As of January 31, 2022 and October 31, 2021, the Company had 14,075,499 of its total 30,225,397 outstanding warrants from an April 2021 private offering of common stock and warrants (the “April 2021 Private Placement”) and a September 2018 public offering of common stock and warrants (the “September 2018 Public Offering”) classified as liabilities (liability warrants).

 

The warrants issued in the April 2021 Private Placement will become exercisable only on such day, if ever, that is 14 days after the Company files an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock, $0.001 par value per share from 170,000,000 shares to 300,000,000 shares. These warrants expire five years after the date they become exercisable. As of January 31, 2022, the Company did not have sufficient authorized common stock to allow for the issuance of common stock underlying these warrants. The Company did not receive stockholder authorization to increase the authorized shares from 170,000,000 to 300,000,000 shares at the stockholder’s meeting commenced on June 3, 2021. The Company was subsequently required to file a proxy to seek an increase in the number of authorized shares and did not file such a proxy but rather elected to seek a reverse stock split to, among other things, increase the shares available. Accordingly, based on certain indemnification provisions of the securities purchase agreement, the Company concluded that liability classification is warranted. The Company utilized the Black Scholes model to calculate the fair value of these warrants at issuance and at each subsequent reporting date.

 

13
 

 

In measuring the warrant liability for the warrants issued in the April 2021 Private Placement at January 31, 2022 and October 31, 2021, the Company used the following inputs in its Black Scholes model:

 

   January 31, 2022   October 31, 2021 
Exercise Price  $0.70   $0.70 
Stock Price  $0.136   $0.485 
Expected Term    5.00 years      5.00 years  
Volatility %   108%   106%
Risk Free Rate   1.62%   1.18%

 

The September 2018 Public Offering warrants contain a down round feature, except for exempt issuances as defined in the warrant agreement, in which the exercise price would immediately be reduced to match a dilutive issuance of common stock, options, convertible securities and changes in option price or rate of conversion. As of January 31, 2021, the down round feature was triggered four times and the exercise price of the warrants were reduced from $22.50 to $0.25. The warrants require liability classification as the warrant agreement requires the Company to maintain an effective registration statement and does not specify any circumstances under which settlement in other than cash would be permitted or required. As a result, net cash settlement is assumed and liability classification is warranted. For these liability warrants, the Company utilized the Monte Carlo simulation model to calculate the fair value of these warrants at issuance and at each subsequent reporting date.

 

In measuring the warrant liability for the September 2018 Public Offering warrants at January 31, 2022 and October 31, 2021, the Company used the following inputs in its Monte Carlo simulation model:

 

   January 31, 2022   October 31, 2021 
Exercise Price  $0.25   $0.30 
Stock Price  $0.136   $0.485 
Expected Term   2.61 years     2.87 years  
Volatility %   118%   123%
Risk Free Rate   1.29%   0.77%

 

At January 31, 2022 and October 31, 2021, the fair value of the warrant liability was approximately $1,127,000 and $4,929,000, respectively. For the three months ended January 31, 2022 and 2021, the Company reported income of approximately $3,802,000 and expense of $27,000, respectively, due to changes in the fair value of the warrant liability.

 

8. COMMITMENTS AND CONTINGENCIES

 

Atachbarian

 

On November 15, 2021, a purported stockholder of the Company commenced an action against the Company and certain of its directors in the U.S. District Court for the District of New Jersey, entitled Atachbarian v. Advaxis, Inc., et al., No. 3:21-cv-20006. The plaintiff alleges that the defendants breached their fiduciary duties and violated Section 14(a) and Rule 20(a) of the Securities Exchange Act of 1934 and Rule 14a-9 promulgated thereunder by allegedly failing to disclose certain matters in its Registration Statement on Form S-4 (Commission File No. 333-259065 (the “Registration Statement”) filed in connection with a proposed merger with Biosight Ltd. (the “Previously Proposed Merger”). On December 15, 2021, pursuant to an understanding reached with the plaintiff, the Company made certain other additional disclosures that mooted the demands asserted in the complaint. On December 17, 2021, the plaintiff filed a notice of voluntary dismissal with prejudice. On February 7, 2022, the Company and the plaintiff reached a settlement agreement, which is recorded in accrued expenses in the consolidated balance statement.

 

14
 

 

Purported Stockholder Claims Related to Biosight Transaction

 

Between September 16, 2021, and November 4, 2021, the Company received demand letters on behalf of six purported stockholders of the Company, alleging that the Company failed to disclose certain matters in the Registration Statement, and demanding that the Company disclose such information in a supplemental disclosure filed with the SEC. On October 14, 2021, the Company filed an amendment to the Registration Statement and on November 8, 2021, the Company made certain other additional disclosures that mooted the demands asserted in the above-referenced letters. The six plaintiffs have made a settlement demand. The Company believes it has adequately accrued for a settlement, which is recorded in accrued expenses in the consolidated balance sheet.

 

In addition, the Company received certain additional demands from stockholders asserting that the proxy materials filed by the Company in connection with the Previously Proposed Merger contained alleged material misstatements and/or omissions in violation of federal law. In response to these demands, the Company agreed to make, and did make, certain supplemental disclosures to the proxy materials. At this time, the Company is unable to predict the likelihood of an unfavorable outcome.

 

9. TEMPORARY EQUITY

 

Series D Convertible Preferred Stock Offering

 

On January 31, 2022, the Company closed on an offering with certain institutional investors for the private placement of 1,000,000 shares of Series D convertible redeemable preferred stock (“Series D preferred stock”). The shares to be sold have an aggregate stated value of $5,000,000. Each share of the Series D preferred stock has a purchase price of $4.75, representing an original issue discount of 5% of the stated value. Total net proceeds from the offering, after deducting the financial advisor’s fees and other estimated offering expenses, were approximately $4,312,000.

 

The Company has called a special meeting of stockholders to consider an amendment (the “Amendment”) to the Company’s Amended and Restated Certificate of Incorporation, to effect a reverse stock split of the outstanding shares of common stock by a ratio to be determined by the Board of Directors of the Company within a range to be specified in the proposal put to the stockholders for approval of the Amendment. The investors have agreed in the Purchase Agreement to not transfer, offer, sell, contract to sell, hypothecate, pledge or otherwise dispose of the shares of the Series D preferred stock until the reverse stock split and to vote the shares of the Series D preferred stock purchased in the offering in a manner that “mirrors” the proportions on which the shares of common stock (excluding any shares of common stock that are not voted) are voted on the reverse stock split and the Amendment. The Amendment requires the approval of the majority of the votes associated with the Company’s outstanding stock entitled to vote on the proposal. The certificate of designation provides that the Series D preferred stock will have no voting rights, other than the right to vote as a class on certain specified matters, except that each share of Series D preferred stock will have the right to cast 30,000 votes per share of Series D preferred stock on the reverse stock split.

 

The Series D preferred stock can be converted at the option of the holder at any time after the Company has received stockholder approval for a reverse stock split and filed the requisite amendment with the Delaware Secretary of State’s office to effectuate the reverse stock split, subject to beneficial ownership limitations. The Company will be permitted to compel conversion of the Series D preferred stock after the fulfillment of certain conditions and subject to certain limitations. The Series D preferred stock is convertible into shares of Common Stock at a rate of $0.25 per share for the Series D preferred stock. In addition, on or after the reverse stock split date, and subject to the satisfaction of certain conditions, the Company can cause the holder of the Series D Preferred Stock to convert their shares of Series D Preferred Stock, subject to such beneficial ownership limitations.

 

15
 

 

The Series D preferred stock has a liquidation preference over the common stock, and may be redeemed by the investors. Each holder of the Series D preferred stock has the right to cause the Company to redeem all or part of their shares of the Series D preferred stock from the earlier of receipt of stockholder approval of the reverse stock split or 90 days following the original issue date until 120 days following the original issue date (the “Redemption Date”) in cash at a redemption price equal to 105% of the stated value plus an amount equal to accumulated but unpaid dividends, if any, on such shares (whether or not earned or declared, but excluding interest on such dividends) up to, but excluding, the Redemption Date. Under certain circumstances, the commencement of the period during which the Series D preferred stock may be redeemed may be extended from 90 days following the original issue date to 135 days following the original issue date, in which case the Redemption Date would be extended to 165 days following the original issue date. Should such extension occur, the redemption price would be increased to an amount equal to 110% of the stated value plus an amount equal to accumulated but unpaid dividends, if any, on such shares.

 

The holders of Series D preferred stock will be entitled to dividends, on an as-if converted basis, equal to dividends actually paid, if any, on shares of common stock.

 

The $4.75 million in gross proceeds of the offering are held in an escrow account, along with an additional $500,000 deposited by the Company to cover the aggregate original issue discount as well as the additional amount that would be necessary to fund the 105% redemption price until the expiration of the redemption period for the Series D Preferred Stock, as applicable, subject to the earlier payment to redeeming holders. Upon expiration of the redemption period, any proceeds remaining in escrow will be disbursed to the Company.

 

In connection with the Offering, the Company and the investors entered into a registration rights agreement, pursuant to which the Company is required to file a registration statement with the Securities and Exchange Commission to register for resale the shares that are issued upon the conversion of shares of Series D preferred stock. The registration statement will be filed with the Securities and Exchange Commission on or before the 60th calendar day following the first date on which shares are issued upon the conversion of shares of Series D preferred stock.

 

Since the Series D preferred stock has a redemption feature at the option of the holder, it is classified as temporary equity. At the January 31, 2022 issuance date, the Series D preferred stock was recorded on the balance sheet at approximately $4,225,000, which is the $4,312,000 net proceeds less the $87,000 value of the bifurcated preferred stock redemption liability (see below).

 

Preferred Stock Redemption Liability

 

The Company evaluated the preferred stock redemption feature under ASC 815. Since the preferred stock redemption feature is not considered to be clearly and closely related to the preferred stock host and the redemption feature meets the four characteristics of a derivative under ASC 815, the preferred stock redemption feature is required to be bifurcated from the preferred stock host and valued as a liability. The Company utilized a binomial model to calculate the fair value of the preferred stock redemption feature at issuance.

 

In measuring the preferred stock redemption liability at January 31, 2022 (issuance date), the Company used the following inputs in its binomial model:

 

   January 31, 2022 
Exercise Price  $0.25 
Stock Price  $0.136 
Volatility %   105%
Risk Free Rate   1.00%

 

At January 31, 2022, the fair value of the preferred stock redemption liability was approximately $87,000.

 

16
 

 

10. STOCKHOLDERS’ EQUITY

 

A summary of the changes in stockholders’ equity for the three months ended January 31, 2022 and 2021 is presented below (in thousands, except share data):

 

   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
   Preferred Stock   Common Stock   Additional Paid-In   Accumulated   Total Shareholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
Balance at November 1, 2020      -   $     -    78,074,023   $78   $440,840   $(410,738)  $30,180 
Stock-based compensation   -    -    -    -    236    -    236 
Advaxis public offerings, net of offering costs   -    -    30,666,665    31    8,519    -    8,550 
Warrant exercises   -    -    7,390,000    7    2,579    -    2,586 
Net Loss   -    -    -    -    -    (3,977)   (3,977)
Balance at January 31, 2021   -   $-    116,130,688   $116   $452,174   $(414,715)  $37,575 

 

   Preferred Stock   Common Stock   Additional
Paid-In		   Accumulated   Total
Shareholders’		 
   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
Balance at November 1, 2021       -   $       -    145,638,459   $146   $467,342   $(428,600)  $38,888 
Stock-based compensation   -    -    -    -    26    -    26 
Net Loss   -    -    -    -    -    (365)   (365)
Balance at January 31, 2022   -   $-    145,638,459   $146   $467,368   $(428,965)  $38,549 

 

11. SHARE BASED COMPENSATION

 

The following table summarizes share-based compensation expense included in the condensed consolidated statements of operations (in thousands):

 

   Three Months Ended January 31, 
   2022   2021 
Research and development  $13   $57 
General and administrative   13    179 
Total  $26   $236 

 

Stock Options

 

A summary of changes in the stock option plan for the three months ended January 31, 2022 is as follows:

 

   Shares   Weighted
Average
Exercise Price		   Weighted
Average
Remaining
Contractual Life
In Years		   Aggregate
Intrinsic Value
(in thousands)		 
Outstanding as of October 31, 2021   893,946   $19.32    7.80   $         27 
Cancelled or expired   (5,888)   277.50           
Outstanding as of January 31, 2022   888,058   $17.61    7.55   $- 
Vested and exercisable at January 31, 2022   484,641   $31.80    6.89   $- 

 

17
 

 

The following table summarizes information about the outstanding and exercisable options at January 31, 2022:

 

Options Outstanding     Options Exercisable  
            Weighted     Weighted           Weighted     Weighted  
            Average     Average           Average     Average  
Exercise     Number     Remaining     Exercise     Number     Remaining     Exercise  
Price Range     Outstanding     Contractual     Price     Exercisable     Contractual     Price  
$ .30-$1.00       672,500       8.29     $ 0.54       270,000       8.20     $ 0.50  
$ 1.01-$10.00       55,379       6.80     $ 7.47       54,462       6.79     $ 7.56  
$ 10.01-$100.00       90,432       5.97     $ 29.02       90,432       5.97     $ 29.02  
$ 100.01-$258.30       69,747       3.07     $ 175.51       69,747       3.07     $ 175.51  

 

As of January 31, 2022, there was approximately $125,000 of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining weighted average vesting period of 1.38 years.

 

Potential Acceleration of Stock Options

 

In the event of a merger transaction, similar to the Previously Proposed Merger Agreement, all of the Chief Executive Officer’s 73,777 unvested stock options, pursuant to his employment agreement, would accelerate.

 

12. LICENSING AGREEMENTS

 

OS Therapies LLC

 

On September 4, 2018, the Company entered into a development, license and supply agreement with OS Therapies (“OST”) for the use of ADXS31-164, also known as ADXS-HER2, for evaluation in the treatment of osteosarcoma in humans. Under the terms of the license agreement, as amended, OST will be responsible for the conduct and funding of a clinical study evaluating ADXS-HER2 in recurrent, completely resected osteosarcoma. Under the most recent amendment to the licensing agreement, OST agreed to pay Advaxis $25,000 per month (“Monthly Payment”) starting on April 30, 2020 until it achieved its funding milestone of $2,337,500. Upon receipt of the first Monthly Payment, Advaxis initiated the transfer of the intellectual property and licensing rights of ADXS31-164, which were licensed pursuant to the Penn Agreement, back to the University of Pennsylvania. Contemporaneously, OST will enter negotiations with the University of Pennsylvania to establish a licensing agreement for ADXS31-164 to OST for clinical and commercial development of the ADXS31-164 technology.

 

During the three months ended January 31, 2021, the Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement. The Company therefore transferred and OST took full ownership of the IND application for ADXS31-164 in its entirety along with agreements and promises contained therein, as well as all obligations associated with this IND or any HER2 product/program development.

 

13. FAIR VALUE

 

The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

 

● Level 1 — Quoted prices in active markets for identical assets or liabilities.

 

● Level 2— Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities.

 

18
 

 

● Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities.

 

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of January 31, 2022 and October 31, 2021 (in thousands):

 

   Level 1   Level 2   Level 3   Total 
Fair value measured at January 31, 2022
   Level 1   Level 2   Level 3   Total 
Financial assets at fair value:                    
Cash equivalents (money market funds)  $17,154   $-   $-   $17,154 
Total Financial Assets at Fair Value  $17,154   $-   $-   $17,154 
                     
Financial liabilities at fair value:                    
Preferred stock redemption liability  $-   $-   $87   $87 
Common stock warrant liability, warrants exercisable at $0.25 through September 2024   -    -    7    7 
Common stock warrant liability, warrants exercisable at $0.70 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)   -    -    1,120    1,120 
Total financial liabilities at fair value  $-   $-   $1,214   $1,214 

 

   Level 1   Level 2   Level 3   Total 
Fair value measured at October 31, 2021
   Level 1   Level 2   Level 3   Total 
Financial assets at fair value:                    
Cash equivalents (money market funds)  $17,153   $-   $-   $17,153 
Total Financial Assets at Fair Value  $17,153   $-   $-   $17,153 
                     
Financial liabilities at fair value:                    
Common stock warrant liability, warrants exercisable at $0.30 through September 2024  $-   $-   $27   $27 
Common stock warrant liability, warrants exercisable at $0.70 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)   -    -    4,902    4,902 
Total financial liabilities at fair value  $-   $-   $4,929   $4,929 

 

The following table presents changes in Level 3 liabilities measured at fair value (in thousands) for the three months ended January 31, 2022. Unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category.

 

   Preferred Stock Redemption Liability   Warrant Liabilities   Total 
Fair value at October 31, 2021  $           -   $4,929   $4,929 
Additions   87    -    87 
Change in fair value   -    (3,802)   (3,802)
Fair value at January 31, 2022  $87   $1,127   $1,214 

 

 

19
 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion and analysis contains forward-looking statements about our plans and expectations of what may happen in the future. Forward-looking statements are based on a number of assumptions and estimates that are inherently subject to significant risks and uncertainties, and our results could differ materially from the results indicated by our forward-looking statements as a result of many known or unknown factors, including, but not limited to, those factors discussed in Part I Item 1A. “Risk Factors” in our 2021 Annual Report on Form 10-K, below in Part II Item 1A. “Risk Factors” of this Form 10-Q and in the “Cautionary Note Regarding Forward-Looking Statements” set forth at the beginning of this report.

 

You should read the following discussion and analysis in conjunction with the unaudited financial statements, and the related footnotes thereto, appearing elsewhere in this Form 10-Q, and in conjunction with management’s discussion and analysis and the audited financial statements included in our Annual Report on Form 10-K. In addition, we intend to use our media and investor relations website (www.advaxis.com/investor-relations), SEC filings, press releases, public conference calls and webcasts to communicate with the public about Advaxis, its services and other issues.

 

Overview

 

Advaxis, Inc. (“Advaxis” or the “Company”) is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm Technology antigen delivery products based on a platform technology that utilizes live attenuated Listeria monocytogenes, or Lm, bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy by accessing and directing antigen presenting cells to stimulate anti-tumor T cell immunity, stimulate and activate the innate immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the Tumor Microenvironment, or TME, to enable the T cells to attack tumor cells.

 

The Company believes that Lm Technology immunotherapies can complement and address significant unmet needs in the current oncology treatment landscape. Specifically, our product candidates (i.e., ADXS-PSA, ADXS-503 and ADXS-504) have the potential to optimize checkpoint performance, while having a generally well-tolerated safety profile, and most of our product candidates have an expected low cost of goods.

 

Advaxis is currently winding down or has wound down clinical studies of Lm Technology immunotherapies in three program areas:

 

  ● Human Papilloma Virus (“HPV”)-associated cancers
  ● Personalized neoantigen-directed therapies
  ● Human epidermal growth factor receptor-2 (HER-2) associated cancers

 

All these clinical program areas are anchored in the Company’s Lm TechnologyTM, a unique platform designed for its ability to safely and effectively target various cancers in multiple ways. While we are currently winding down clinical studies of Lm Technology immunotherapies in these three program areas, our license agreements continue with OS Therapies, LLC for ADXS-HER2 and with Global BioPharma, or GBP, for the exclusive license for the development and commercialization of AXAL in Asia, Africa, and the former USSR territory, exclusive of India and certain other countries.

 

Recent Developments

 

COVID-19 Impact

 

The global health crisis caused by the ongoing novel coronavirus (“COVID-19”) pandemic and its resurgences has and may continue to negatively impact global economic activity, which, despite progress in vaccination efforts, remains uncertain and cannot be predicted with confidence. In addition, a new Omicron variant of COVID-19, which appears to be the most transmissible variant to date, has spread globally. The continued impact of the pandemic cannot be predicted at this time, and could depend on numerous factors, including vaccination rates among the population, the occurrence and spread of additional variants of COVID-19, the effectiveness of COVID-19 vaccines against current or future variants and the response by governmental bodies and regulators.

 

20
 

 

In response to COVID-19, the Company implemented remote working and thus far, has not experienced a significant disruption or delay in its operations as it relates to the clinical development or drug production of our drug candidates by third parties. We continue to monitor the COVID-19 pandemic and take steps intended to mitigate the potential risks to our workforce and our operations. The COVID-19 pandemic has, and may continue to, directly or indirectly affect the pace of enrollment in our clinical trials as patients may avoid or may not be able to travel to healthcare facilities and physicians’ offices unless due to a health emergency and clinical trial staff can no longer get to the clinic. Nonetheless, thus far, the COVID-19 pandemic has not had a significant impact on our business or results of operations. However, we remain in contact with the clinical sites in our study and are in discussion with additional sites to combat any potential impact in enrollment. We are unable to determine or predict the extent, duration or scope of the overall impact of the COVID-19 pandemic on our business, operations, financial condition or liquidity.

 

Financings

 

On January 31, 2022, the Company closed on an offering with certain institutional investors for the private placement of 1,000,000 shares of Series D convertible redeemable preferred stock. The shares to be sold have an aggregate stated value of $5,000,000. Each share of the Series D preferred stock has a purchase price of $4.75, representing an original issue discount of 5% of the stated value. The shares of Series D preferred stock are convertible into shares of the Company’s common stock, upon the occurrence of certain events, at a conversion price of $0.25 per share. The conversion, at the option of the stockholder, may occur at any time following the receipt of the stockholders’ approval for a reverse stock split. The Company will be permitted to compel conversion of the Series D preferred stock after the fulfillment of certain conditions and subject to certain limitations. The Series D preferred stock will also have a liquidation preference over the common stock, and may be redeemed by the investors, in accordance with certain terms, for a redemption price equal to 105% of the stated value, or in certain circumstances, 110% of the stated value. The Company and the holders of the Series D preferred stock will also enter into a registration rights agreement to register the resale of the shares of common stock issuable upon conversion of the Series D preferred stock. Total net proceeds from the offering, after deducting the financial advisor’s fees and other estimated offering expenses, were approximately $4.3 million.

 

Results of Operations for the Three Months Ended January 31, 2022 and 2021

 

Revenue

 

Revenue was $0 for the three months ended January 31, 2022 compared to $1,615,000 for the three months ended January 31, 2021. In the prior period, we recognized royalty payments from OST.

 

Research and Development Expenses

 

We invest in research and development to advance our Lm technology through our pre-clinical and clinical development programs. Research and development expenses for the three months ended January 31, 2022 and January 31, 2021 were categorized as follows (in thousands):

 

   Three Months Ended
January 31,		   Increase
(Decrease)		 
   2022   2021   $   % 
                 
Hotspot/Off-the-Shelf therapies  $1,000   $1,200   $(200)   (17)%
Prostate cancer   55    42    13    31%
HPV-associated cancers   (39)   531    (570)   (107)%
Personalized neoantigen-directed therapies   -    132    (132)   (100)%
Other expenses   638    665    (27)   (4)%
Total research & development expense  $1,654   $2,570   $(916)   (36)%
                     
Stock-based compensation expense included in research and development expense  $13   $57   $(44)   (77)%

 

21
 

 

Hotspot/Off-the-Shelf Therapies (ADXS-HOT)

 

Research and development costs associated with our hotspot mutation-based therapy for the three months ended January 31, 2022 decreased approximately 17% to $1,000,000 compared to the same period in 2021. The decrease is attributable to a slowdown in patient enrollment in the HOT-503 study.

 

Prostate Cancer (ADXS-PSA)

 

Research and development costs associated with our prostate cancer therapy for the three months ended January 31, 2022 increased approximately $13,000, or 31%, compared to the same period in 2021. The increase is immaterial. We do not anticipate that we will continue to incur significant costs associated with the wind down of the study.

 

HPV-Associated Cancers (AXAL)

 

The majority of the HPV-associated research and development costs include clinical trial and other related costs associated with our AXAL programs in cervical and head and neck cancers. HPV-associated costs for the three months ended January 31, 2022 decreased approximately $570,000, or 107%, compared to the same period in 2021. The decrease is attributable to wind down costs associated with the closure of our Phase 3 AIM2CERV study in high-risk locally advanced cervical cancer, as well as credit memos issued by our contract research organization associated with the closeout of our Phase 1/2 study in head and neck cancer. We do not anticipate that we will continue to incur significant costs associated with the wind down of our Phase 3 AIM2CERV study.

 

Personalized Neoantigen-Directed Therapies (ADXS-NEO)

 

Research and development costs associated with personalized neoantigen-directed therapies for the three months ended January 31, 2022 decreased approximately $132,000, or 100%, compared to the same period in 2021. The decrease is attributable to wind down costs associated with the termination of our ADXS-NEO study. We do not anticipate that we will continue to incur significant costs associated with the wind down of the study.

 

Other Expenses

 

Other expenses include salary and benefit costs, stock-based compensation expense, professional fees, laboratory costs and other internal and external costs associated with our research & development activities. Other expenses for the three months ended January 31, 2022 decreased approximately $27,000, or 4%, compared to the same period in 2021. The decrease was immaterial.

 

General and Administrative Expenses

 

General and administrative expenses primarily include salary and benefit costs and stock-based compensation expense for employees included in our finance, legal and administrative organizations, outside legal and professional services, and facilities costs. General and administrative expenses for the three months ended January 31, 2022 and January 31, 2021 were as follows (in thousands):

 

   Three Months Ended
January 31,		   Increase
(Decrease)		 
   2022   2021   $   % 
                 
General and administrative expense  $2,510   $3,008   $(498)   (17)%
                     
Stock-based compensation expense included in general and administrative expense  $13   $179   $(166)   (93)%

 

22
 

 

General and administrative expenses for the three months ended January 31, 2022 decreased approximately $498,000, or 17%, compared to the same period in 2021. This decrease primarily relates to (1) a decrease in personnel costs due to decreases in stock compensation and bonus accruals (2) decreases in rent, utilities and depreciation due to the termination of our office lease at our former location and (3) a decrease in legal costs. These decreases were partially offset by increases in (1) proxy solicitation fees related to the Previously Proposed Merger and (2) charges related to the abandonment of non-strategic intellectual property.

 

Changes in Fair Values

 

For the three months ended January 31, 2022, we recorded non-cash income from a decrease in the fair value of the warrant liability of approximately $3,802,000. The decrease in the fair value of liability warrants resulted from resulted from a decrease in our share price from $0.49 at October 31, 2021 to $0.14 at January 31, 2022.

 

For the three months ended January 31, 2021, we recorded non-cash loss from an increase in the fair value of the warrant liability of approximately $27,000. The increase in the fair value of liability warrants resulted from an increase in our share price from $0.34 at October 31, 2020 to $0.73 at January 31, 2021.

 

Liquidity and Capital Resources

 

Management’s Plans

 

Similar to other development stage biotechnology companies, our products that are being developed have not generated significant revenue. As a result, we have historically suffered recurring losses and we have required significant cash resources to execute our business plans. These losses are expected to continue for the foreseeable future.

 

Historically, the Company’s major sources of cash have comprised proceeds from various public and private offerings of its securities (including common stock), debt financings, clinical collaborations, option and warrant exercises, income earned on investments and grants, and interest income. From October 2013 through January 31, 2022, the Company raised approximately $339.4 million in gross proceeds from various public and private offerings of our common stock. The Company has sustained losses from operations in each fiscal year since our inception, and we expect losses to continue for the indefinite future. As of January 31, 2022 and October 31, 2021, the Company had an accumulated deficit of approximately $429.0 million and $428.6 million, respectively, and stockholders’ equity of approximately $38.5 million and $38.9 million, respectively.

 

The COVID-19 pandemic has negatively affected the global economy and created significant volatility and disruption of financial markets. An extended period of economic disruption could negatively affect the Company’s business, financial condition, and access to sources of liquidity. As of January 31, 2022, the Company had approximately $36.5 million in cash and cash equivalents. The actual amount of cash that the Company will need to continue operating is subject to many factors.

 

The Company recognizes that it will need to raise additional capital in order to continue to execute its business plan in the future. There is no assurance that additional financing will be available when needed or that the Company will be able to obtain financing on terms acceptable to it or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to further scale back its operations. The Company believes it has sufficient capital to fund its obligations, as they become due, in the ordinary course of business into the second fiscal quarter of 2024. The Company based this estimate on assumptions that may prove to be wrong, and we could use available capital resources sooner than currently expected.

 

Cash Flows

 

Operating Activities

 

Net cash used in operating activities includes spending associated with our clinical trial programs and general and administrative activities. Net cash used in operating activities was approximately $4,138,000 for the three months ended January 31, 2022 compared to $2,786,000 for the three months ended January 31, 2021. The Company received $1,615,000 in royalty payments from OST in the prior period.

 

23
 

 

Investing Activities

 

Net cash used in investing activities was approximately $58,000 for three months ended January 31, 2022 compared to $210,000 for the three months ended January 31, 2021. The decrease is a result of the abandonment of certain non-strategic intellectual property in the current period.

 

Financing Activities

 

Net cash provided by financing activities was approximately $4,312,000 for the three months ended January 31, 2022 compared to $11,136,000 for the three months ended January 31, 2021. On January 31, 2022, the Company closed on an offering with certain institutional investors for the private placement of 1,000,000 shares of Series D convertible redeemable preferred stock. The shares to be sold have an aggregate stated value of $5,000,000. Each share of the Series D preferred stock has a purchase price of $4.75, representing an original issue discount of 5% of the stated value. Total net proceeds from the offering, after deducting the financial advisor’s fees and other estimated offering expenses, were approximately $4.3 million. The shares of Series D preferred stock are convertible into shares of the Company’s common stock, upon the occurrence of certain events, at a conversion price of $0.25 per share. The conversion, at the option of the stockholder, may occur at any time following the receipt of the stockholders’ approval for a reverse stock split. The Series D preferred stock will also have a liquidation preference over the common stock, and may be redeemed by the investors, in accordance with certain terms, for a redemption price equal to 105% of the stated value, or in certain circumstances, 110% of the stated value.

 

In November 2020, the Company closed on a public offering of 30,666,665 shares of its common stock at a public offering price of $0.30 per share. After deducting the underwriting discounts and commissions and other offering expenses, the net proceeds from the offering were approximately $8.5 million. In addition, the Company also undertook a concurrent private placement of warrants to purchase up to 15,333,332 shares of common stock. The warrants have an exercise price per share of $0.35, are exercisable immediately and will expire five years from the date of issuance. During the three months ended January 31, 2021, warrant holders from the Company’s November 2020 offering exercised 7,390,000 warrants in exchange for 7,390,000 shares of the Company’s common stock. Pursuant to these warrant exercises, the Company received aggregate proceeds of approximately $2.6 million.

 

Off-Balance Sheet Arrangements

 

As of January 31, 2022, we had no off-balance sheet arrangements.

 

Critical Accounting Estimates

 

The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts and related disclosures in the financial statements. Management considers an accounting estimate to be critical if:

 

  ● it requires assumptions to be made that were uncertain at the time the estimate was made, and
     
  ● changes in the estimate or different estimates that could have been selected could have material impact in our results of operations or financial condition.

 

While we base our estimates and judgments on our experience and on various other factors that we believe to be reasonable under the circumstances, actual results could differ from those estimates and the differences could be material. The most significant estimates impact the following transactions or account balances: warrant liability valuation, preferred stock redemption liability valuation and impairment of intangibles.

 

See Note 2 to our condensed consolidated financial statements for a discussion of our significant accounting policies.

 

24
 

 

Recently Issued Accounting Standards Not Yet Effective or Adopted

 

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed consolidated financial statements.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

At January 31, 2022, we had approximately $36.5 million in cash and cash equivalents, which consisted primarily of bank deposits and money market funds. Our investment policy and strategy are focused on preservation of capital and supporting our liquidity requirements. We use a combination of internal and external management to execute our investment strategy and achieve our investment objectives. We typically invest in highly-rated securities (such as money market funds), and our investment policy generally limits the amount of credit exposure to any one issuer. The policy requires investments generally to be investment grade, with the primary objective of minimizing the potential risk of principal loss. Such interest-earning instruments carry a degree of interest rate risk; however, historical fluctuations of interest income have not been significant.

 

We have not been exposed nor do we anticipate being exposed to material risks due to changes in interest rates. A hypothetical 10% change in interest rates during any of the periods presented would not have had a material impact on our financial statements.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

As of the end of the period covered by this report, we conducted an evaluation, under the supervision and with the participation of our chief executive officer and interim principal financial officer of our disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (“the Exchange Act”). Based upon this evaluation, our chief executive officer and principal financial officer concluded that our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is: (1) accumulated and communicated to our management, including our chief executive officer, as appropriate to allow timely decisions regarding required disclosure; and (2) recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms.

 

Changes in Internal Control over Financial Reporting

 

During the quarter ended January 31, 2022, there were no changes in our internal control over financial reporting that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

 

Limitations on Effectiveness of Controls

 

Our management, including our Principal Executive, Financial and Accounting Officers, does not expect that our disclosure controls and procedures or our internal controls over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected.

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings

 

The Company is from time to time involved in legal proceedings in the ordinary course of our business. The Company does not believe that any of these claims or proceedings against us is likely to have, individually or in the aggregate, a material adverse effect on the financial condition or results of operations. For more information regarding legal proceedings involving the Company, please see Note 10 – Commitments and Contingencies to our condensed consolidated financial statements.

 

25
 

 

Item 1A. Risk Factors

 

Our business and financial results are subject to numerous risks and uncertainties. As a result, the risks and uncertainties discussed in Part I, Item 1A. Risk Factors in our annual report on Form 10-K for the fiscal year ended October 31, 2021, (as filed with the SEC on February 14, 2022) should be carefully considered.

 

Item 6. Exhibits

 

Exhibit No.   Description
     
3.1   Certificate of Correction to the Amended and Restated Certificate of Incorporation of Advaxis, Inc., filed with the Secretary of State of the State of Delaware on January 27, 2022, Incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K filed with the SEC on January 28, 2022
     
3.2   Certificate of Correction to the Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Advaxis, Inc., filed with the Secretary of State of the State of Delaware on January 27, 2022, Incorporated by reference to Exhibit 3.2 to Current Report on Form 8-K filed with the SEC on January 28, 2022
     
3.3   Certificate of Correction to the Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Advaxis, Inc., filed with the Secretary of State of the State of Delaware on January 27, 2022, Incorporated by reference to Exhibit 3.3 to Current Report on Form 8-K filed with the SEC on January 28, 2022
     
3.4   Certificate of Correction to the Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Advaxis, Inc., filed with the Secretary of State of the State of Delaware on January 27, 2022, Incorporated by reference to Exhibit 3.4 to Current Report on Form 8-K filed with the SEC on January 28, 2022
     
3.5   Certificate of Correction to the Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Advaxis, Inc., filed with the Secretary of State of the State of Delaware on January 27, 2022, Incorporated by reference to Exhibit 3.5 to Current Report on Form 8-K filed with the SEC on January 28, 2022
     
3.6   Certificate of Correction to the Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Advaxis, Inc., filed with the Secretary of State of the State of Delaware on January 27, 2022, Incorporated by reference to Exhibit 3.6 to Current Report on Form 8-K filed with the SEC on January 28, 2022
     
3.7   Certificate of Correction to the Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Advaxis, Inc., filed with the Secretary of State of the State of Delaware on January 27, 2022, Incorporated by reference to Exhibit 3.7 to Current Report on Form 8-K filed with the SEC on January 28, 2022
     
3.8   Form of Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Redeemable Preferred Stock, Incorporated by reference to Exhibit 3.8 to Current Report on Form 8-K filed with the SEC on January 28, 2022
     
3.9   Amendment No. 2 to the Second Amended and Restated By-Laws of Advaxis, Inc., Incorporated by reference to Exhibit 3.9 to Current Report on Form 8-K filed with the SEC on January 28, 2022
     
3.10   Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Redeemable Preferred Stock, Incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K filed with the SEC on February 1, 2022

 

26
 

 

10.1   Termination Letter from Advaxis, Inc. to Biosight LTD., dated December 30, 2021, Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on December 30, 2021.
     
10.2   Form of Securities Purchase Agreement between Advaxis, Inc. and the investors thereto, dated January 27, 2022, Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on January 28, 2022.
     
10.3   Form of Registration Rights Agreement by and among Advaxis, Inc. and the investors named therein, Incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed with the SEC on January 28, 2022
     
31.1*   Certification of Principal Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002
     
31.2*   Certification of Principal Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002
     
32.1*   Certification of Principal Executive Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002
     
32.2*   Certification of Principal Financial Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002
     
101.INS   XBRL INSTANCE DOCUMENT
     
101.SCH   XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
     
101.CAL   XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
     
101.DEF   XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
     
101.LAB   XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
     
101.PRE   XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

 

* Filed herewith.

 

27
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Corporation has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

March 17, 2022

 

  ADVAXIS, INC.
     
  By: /s/ Igor Gitelman
  Name:  Igor Gitelman
  Title: Chief Accounting Officer, VP of Finance

 

  By: /s/ Kenneth Berlin
  Name:  Kenneth Berlin
  Title: President, Chief Executive Officer and Interim Chief Financial Officer

 

28
 EX-31.1 2 ex31-1.htm

 

EXHIBIT 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18.U.S.C. 7350

(SECTION 302 OF THE SARBANES OXLEY ACT OF 2002)

 

I, Kenneth Berlin, certify that:

 

1. I have reviewed this annual report on Form 10-Q for the quarter ended January 31, 2022 of Advaxis, Inc.;
     
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
   
  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
   
  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

March 17, 2022  
   
By: /s/ Kenneth Berlin  
Name:  Kenneth Berlin  
Title: President, Chief Executive Officer and Interim Chief Financial Officer  

 

 

 

 EX-31.2 3 ex31-2.htm

 

EXHIBIT 31.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18. U.S.C. 7350

(SECTION 302 OF THE SARBANES OXLEY ACT OF 2002)

 

I, Kenneth Berlin, certify that:

 

1. I have reviewed this annual report on Form 10-Q for the quarter ended January 31, 2022 of Advaxis, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
     
  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
     
  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

March 17, 2022  
   
By: /s/ Kenneth Berlin  
Name:  Kenneth Berlin  
Title: President., Chief Executive Officer and Interim Chief Financial Officer  

 

 

 

 EX-32.1 4 ex32-1.htm

 

EXHIBIT 32.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Advaxis, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the quarter ended January 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, the Chief Executive Officer, hereby certifies pursuant to 18 U.S.C. Sec. 1350 as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002 that, to the undersigned’s knowledge:

 

(1) the Report of the Company filed today fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

 

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

March 17, 2022 By: /s/ Kenneth Berlin
  Name:  Kenneth Berlin
  Title: President., Chief Executive Officer and Interim Chief Financial Officer

 

 

 

 EX-32.2 5 ex32-2.htm

 

EXHIBIT 32.2

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Advaxis, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the quarter ended January 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, the Chief Financial Officer, hereby certifies pursuant to 18 U.S.C. Sec. 1350 as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002 that, to the undersigned’s knowledge:

 

(1) the Report of the Company filed today fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

 

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

March 17, 2022 By: /s/ Kenneth Berlin
  Name:  Kenneth Berlin
  Title: President, Chief Executive Officer and Interim Chief Financial Officer

 

 

 

 EX-101.SCH 6 adxs-20220131.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - NATURE OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - ACCRUED EXPENSES link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - TEMPORARY EQUITY link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - SHARE BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - LICENSING AGREEMENTS link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - FAIR VALUE link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Policies) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - ACCRUED EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - TEMPORARY EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - STOCKHOLDERS’ EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - SHARE BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - FAIR VALUE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - NATURE OF OPERATIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - SCHEDULE OF ANTI -DILUTED SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - SUMMARY OF INTANGIBLE ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - INTANGIBLE ASSETS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - SUMMARY OF ACCRUED EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - SCHEDULE OF SUPPLEMENTAL BALANCE SHEET RELATED TO LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - SCHEDULE OF LEASE EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - SCHEDULE OF OTHER INFORMATION RELATED TO LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELLABLE LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - LEASES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - SCHEDULE OF PREFERRED STOCK REDEMPTION LIABILITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - TEMPORARY EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - SUMMARY OF STOCKHOLDERS EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - SUMMARY OF SHARE BASED COMPENSATION EXPENSE (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - SUMMARY OF CHANGES IN STOCK OPTION PLAN (Details) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - SUMMARY OF OUTSTANDING AND EXERCISABLE OPTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - SHARE BASED COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - LICENSING AGREEMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - SCHEDULE OF FAIR VALUE MEASURING UNOBSERVABLE INPUTS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 adxs-20220131_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 adxs-20220131_def.xml XBRL DEFINITION FILE EX-101.LAB 9 adxs-20220131_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series D Convertible Redeemable Preferred Stock [Member] SeriesD Preferred Stock Redemption [Member] Antidilutive Securities [Axis] Warrant [Member] SeriesD Convertable Redeemable Preferred Stock [Member] Stock Options [Member] Restricted Stock Units [Member] Income Statement Location [Axis] General and Administrative Expense [Member] Equity Components [Axis] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Equity Warrants [Member] Warrant Liability [Member] Sale of Stock [Axis] Private Placement [Member] IPO [Member] Derivative Instrument [Axis] Exercise Price Range One [Member] Exercise Price Range Two [Member] Exercise Price Range Three [Member] Exercise Price Range Four [Member] Exercise Price Range Five [Member] Exercise Price Range Six [Member] Measurement Input Type [Axis] Measurement Input, Expected Term [Member] Measurement Input, Price Volatility [Member] Measurement Input, Risk Free Interest Rate [Member] Related Party [Axis] Institutional Investors [Member] Series D Preferred Stock [Member] Measurement Input, Exercise Price [Member] Measurement Input, Share Price [Member] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Research and Development Expense [Member] Title of Individual [Axis] Chief Executive Officer [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Development, License and Supply Agreement [Member] Scenario [Axis] OS Therapies [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Cash and Cash Equivalents [Axis] Money Market Funds [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Award Type [Axis] Through September Two Thousand Twenty Four [Member] Liability Class [Axis] Preferred Stock Redemption Liability [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current assets: Cash and cash equivalents Restricted cash Prepaid expenses and other current assets Total current assets Property and equipment (net of accumulated depreciation) Intangible assets (net of accumulated amortization) Operating right-of-use asset (net of accumulated amortization) Other assets Total assets LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable Accrued expenses Current portion of operating lease liability Preferred stock redemption liability Common stock warrant liability Total current liabilities Operating lease liability, net of current portion Total liabilities Contingencies – Note 10 Series D convertible preferred stock- $0.001 par value; 1,000,000 shares authorized, issued and outstanding at January 31, 2022; Liquidation preference of $5,250 at January 31, 2022. Stockholders’ equity: Preferred stock, $0.001 par value; 4,000,000 and 5,000,000 shares authorized, 0 shares issued and outstanding at January 31, 2022 and October 31, 2021. Common stock - $0.001 par value; 170,000,000 shares authorized, 145,638,459 shares issued and outstanding at January 31, 2022 and October 31, 2021. Additional paid-in capital Accumulated deficit Total stockholders’ equity Total liabilities and stockholders’ equity Statement [Table] Statement [Line Items] Temporary Equity, Par or Stated Value Per Share Temporary Equity, Shares Authorized Preferred Stock, Liquidation Preference, Value Preferred Stock, Par or Stated Value Per Share Preferred Stock, Shares Authorized Preferred Stock, Shares Outstanding Preferred Stock, Shares Issued Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue Operating expenses: Research and development expenses General and administrative expenses Total operating expenses Loss from operations Other income (expense): Interest income, net Net changes in fair value of derivative liabilities Other (expense) income Net loss before income taxes Income tax expense Net loss Net loss per common share, basic and diluted Weighted average number of common shares, basic and diluted Statement of Cash Flows [Abstract] OPERATING ACTIVITIES Net loss Adjustments to reconcile net loss to net cash used in operating activities: Share based compensation (Gain) loss on change in value of warrants Loss on disposal of property and equipment Abandonment of intangible assets Depreciation expense Amortization expense of intangible assets Amortization of right-of-use asset Change in operating assets and liabilities: Prepaid expenses, other current assets and deferred expenses Accounts payable and accrued expenses Deferred revenue Operating lease liabilities Net cash used in operating activities INVESTING ACTIVITIES Cost of intangible assets Net cash used in investing activities FINANCING ACTIVITIES Net proceeds of issuance of Series D preferred stock Net proceeds of issuance of common stock and warrants Warrant exercises Net cash provided by financing activities Net increase in cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash at beginning of year Total cash, cash equivalents and restricted cash shown in condensed statements of cash flows The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed balance sheets that sum to the total of the same such amounts shown in the condensed statements of cash flows: Cash and cash equivalents Restricted cash SUPPLEMENTAL CASH FLOW INFORMATION Cash paid for taxes Organization, Consolidation and Presentation of Financial Statements [Abstract] NATURE OF OPERATIONS Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT Goodwill and Intangible Assets Disclosure [Abstract] INTANGIBLE ASSETS Payables and Accruals [Abstract] ACCRUED EXPENSES Leases LEASES Common Stock Purchase Warrants And Warrant Liability COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Temporary Equity TEMPORARY EQUITY Equity [Abstract] STOCKHOLDERS’ EQUITY Share-based Payment Arrangement [Abstract] SHARE BASED COMPENSATION Licensing Agreements LICENSING AGREEMENTS Fair Value Disclosures [Abstract] FAIR VALUE Basis of Presentation/Estimates Principles of Consolidation Restricted Cash Convertible Preferred Stock Derivative Financial Instruments Net Income (Loss) per Share Recent Accounting Standards SCHEDULE OF ANTI -DILUTED SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE SCHEDULE OF PROPERTY AND EQUIPMENT SUMMARY OF INTANGIBLE ASSETS SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS SUMMARY OF ACCRUED EXPENSES SCHEDULE OF SUPPLEMENTAL BALANCE SHEET RELATED TO LEASES SCHEDULE OF LEASE EXPENSES SCHEDULE OF OTHER INFORMATION RELATED TO LEASES SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELLABLE LEASES Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary, Sale of Stock [Line Items] COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY SCHEDULE OF PREFERRED STOCK REDEMPTION LIABILITY SUMMARY OF STOCKHOLDERS EQUITY SUMMARY OF SHARE BASED COMPENSATION EXPENSE SUMMARY OF CHANGES IN STOCK OPTION PLAN SUMMARY OF OUTSTANDING AND EXERCISABLE OPTIONS SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS SCHEDULE OF FAIR VALUE MEASURING UNOBSERVABLE INPUTS Cash and cash equivalents, at carrying value Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total Laboratory equipment Computer equipment Total property and equipment Accumulated depreciation and amortization Net property and equipment Patents Licenses Software Total intangibles Accumulated amortization Intangible assets 2022 (Remaining) 2023 2024 2025 2026 Thereafter Total Schedule of Goodwill [Table] Goodwill [Line Items] Book value patent applications, net Intangible asset amortization expense Salaries and other compensation Vendors Professional fees Other Total accrued expenses Schedule Of Supplemental Balance Sheet Related To Leases Operating lease right-of-use assets Operating lease liability Total operating lease liabilities Schedule Of Lease Expenses Operating lease cost Variable lease cost Total lease expense Weighted-average remaining lease term Weighted-average discount rate Cash paid for operating lease liabilities 2022 (Remaining) 2023 Total minimum lease payments Less: Imputed interest Total Lease expiration date Lease termination Security deposit Net payment for termination fee Operating lease, Right of use asset Operating lease liability Net gain on leases Rent paid Lease expiration date Lessee finance lease renewal term date Offsetting Assets [Table] Offsetting Assets [Line Items] Exercise Price Grand Total Number of Shares Underlying Warrants Type of Financing Expiration Date Stock Price Expected Term Measurement input percentage Warrants outstanding Number of warrants to purchase common stock Warrant exercise price per share Common stock par or stated value per share Common stock shares authorized Fair value of the warrant liability Income on fair value of warrants Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Measurement input percentage Shares issued Stated value Share purchase price Issue discount Proceeds from issuance or estimated offering Number of votes per share Preferred stock conversion price Temporary equity stock stated value accumulated dividends Temporary equity stock stated value accumulated dividends on extension Payments for proceeds from escrow offering Escrow deposit Temporary equity stock stated value accumulated dividends on extension Temporary equity, carrying amount, attributable to parent Preferred stock, redemption amount Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Beginning balance, value Beginning balance, shares Stock-based compensation Stock-based compensation, shares Advaxis public offerings, net of offering costs Advaxis public offerings, net of offering costs, shares Warrant exercises Warrant exercises, shares Net Loss Ending balance, value Ending balance, shares Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based compensation expense Shares Outstanding, Beginning Balance Weighted Average Exercise Price, Outstanding, Beginning Weighted Average Remaining Contractual Life In Years, Beginning Aggregate Intrinsic Value, Beginning Shares, Cancelled or Expired Weighted Average Exercise Price, Cancelled or Expired Shares, Outstanding, Ending Balance Weighted Average Exercise Price, Outstanding, Ending Weighted Average Remaining Contractual Life In Years, Ending Balance Aggregate Intrinsic Value, Ending Shares, Vested and Exercisable Weighted Average Exercise Price, Vested and Exercisable Weighted Average Remaining Contractual Life In Years, Vested and Exercisable Aggregate Intrinsic Value, Vested and Exercisable Exercise Price Range, lower limit Exercise Price Range, upper limit Number Outstanding, Options Outstanding Weighted Average Remaining Contractual, Options Outstanding Weighted Average Exercise Price, Options Outstanding Number Outstanding, Options Exercisable Weighted Average Remaining Contractual Term Exercisable, Options Exercisable Weighted Average Exercise Price, Options Exercisable Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items] Unrecognized compensation cost related to outstanding stock options Unrecognized compensation cost related to non-vested remaining weighted average vesting period Share-based compensation arrangement by share-based payment award, options, nonvested, number of shares Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Revenue Funding milestone payment Milestone achievement, description Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Cash equivalents (money market funds) Total Financial Assets at Fair Value Common stock warrant liability, warrants exercisable at $0.30 through September 2024 Common stock warrant liability, warrants exercisable at $0.70 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants) Total financial liabilities at fair value Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Measurement , Beginning Balance Fair Value, Measurement, Additions Fair Value, Measurement, Change in fair value Fair Value, Measurement , Ending Balance Common stock warrant liability. Preferred stock redemption liability. Series D Convertible Redeemable Preferred Stock [Member] Payments for rent. Lessee finance lease term of contract. Lessee finance lease renewal term. Schedule Of Supplemental Balance Sheet Information Related To Leases [Table Text Block] Schedule Of Other Information [Table Text Block] Increase decrease in operating lease liabilities. Common Stock Purchase Warrants And Warrant Liability [Text Block] Schedule Of Outstanding Warrants [Table Text Block] SeriesD Preferred Stock Redemption [Member] Type of Financing. Exercise Price Range One [Member] Convertable Preferred Stock [Poliy Text Block] Exercise Price Range Two [Member] Exercise Price Range Three [Member] Exercise Price Range Four [Member] Exercise Price Range Five [Member]. Exercise Price Range Six [Member]. Expiration date description. Equity Warrants [Member] SeriesD Convertable Redeemable Preferred Stock [Member] Warrant Liability [Member] Stock Options [Member] Restricted Stock Units [Member] Finite-lived software, gross. Fair value of the warrant liability. Institutional Investors [Member] Preferred stock discount rate percentage Value of stock issued as a result of the exercise of warrants. Stock issued during period shares warrants exercised. Licensing agreements disclosures [TextBlock] Development, License and Supply Agreement [Member] OS Therapies [Member] Funding milestone payment. Milestone achievement description Schedule of changes in fair value of warrant liabilities [Table Text Block] Temporary Equity Disclosure [Text Block] Proceeds from issuance or estimated offering Number of votes per share Temporary equity stock stated value accumulated dividends. Temporary equity stock stated value accumulated dividends on extension. Temporary equity stock stated value accumulated dividends on expiration. Preferred stock redemption liability [Table Text Block] Equity securities FvNi measurement input term Payments for proceeds from escrow offering Preferred Stock Redemption Liability [Member] Sharebased compensation arrangement by sharebased payment award options outstanding weighted average remaining contractual term ending. Class of warrant or right exercise price of warrants or rights. Common stock warrant liability. Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Gain (Loss) on Disposition of Property Plant Equipment Increase (Decrease) in Prepaid Expense and Other Assets Net Cash Provided by (Used in) Operating Activities Payments to Acquire Intangible Assets Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Schedule Of Outstanding Warrants [Table Text Block] Property, Plant and Equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Accumulated Amortization Finite-Lived Intangible Assets, Net Lease, Cost Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Lessee, Operating Lease, Liability, to be Paid, Year One Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount Lease expiration date [Default Label] Equity Securities, FV-NI, Measurement Input TemporaryEquityStockStatedValueAccumulatedDividendsOnExpiration Shares, Outstanding StockIssuedDuringPeriodValueWarrantsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Revenues Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value EX-101.PRE 10 adxs-20220131_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Cover - shares
 3 Months Ended
Jan. 31, 2022
Mar. 16, 2022
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Jan. 31, 2022  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2022  
Current Fiscal Year End Date --10-31  
Entity File Number 001-36138  
Entity Registrant Name ADVAXIS, INC.  
Entity Central Index Key 0001100397  
Entity Tax Identification Number 02-0563870  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 9 Deer Park Drive  
Entity Address, Address Line Two Suite K-1  
Entity Address, City or Town Monmouth Junction  
Entity Address, State or Province NJ  
Entity Address, Postal Zip Code 08852  
City Area Code (609)  
Local Phone Number 452-9813  
Title of 12(b) Security Common Stock  
Trading Symbol ADXS  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   145,638,459
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jan. 31, 2022
Oct. 31, 2021
Current assets:    
Cash and cash equivalents $ 36,480 $ 41,614
Restricted cash 5,250
Prepaid expenses and other current assets 1,386 1,643
Total current assets 43,116 43,257
Property and equipment (net of accumulated depreciation) 100 118
Intangible assets (net of accumulated amortization) 3,238 3,354
Operating right-of-use asset (net of accumulated amortization) 33 40
Other assets 11 11
Total assets 46,498 46,780
Current liabilities:    
Accounts payable 345 87
Accrued expenses 2,131 2,836
Current portion of operating lease liability 29 28
Preferred stock redemption liability 87
Common stock warrant liability 1,127 4,929
Total current liabilities 3,719 7,880
Operating lease liability, net of current portion 5 12
Total liabilities 3,724 7,892
Contingencies – Note 10
Series D convertible preferred stock- $0.001 par value; 1,000,000 shares authorized, issued and outstanding at January 31, 2022; Liquidation preference of $5,250 at January 31, 2022. 4,225
Stockholders’ equity:    
Preferred stock, $0.001 par value; 4,000,000 and 5,000,000 shares authorized, 0 shares issued and outstanding at January 31, 2022 and October 31, 2021.
Common stock - $0.001 par value; 170,000,000 shares authorized, 145,638,459 shares issued and outstanding at January 31, 2022 and October 31, 2021. 146 146
Additional paid-in capital 467,368 467,342
Accumulated deficit (428,965) (428,600)
Total stockholders’ equity 38,549 38,888
Total liabilities and stockholders’ equity $ 46,498 $ 46,780
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.0.1
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Jan. 31, 2022
Oct. 31, 2021
Preferred Stock, Liquidation Preference, Value $ 5,250  
Preferred Stock, Par or Stated Value Per Share $ 0.001 $ 0.001
Preferred Stock, Shares Authorized 4,000,000 5,000,000
Preferred Stock, Shares Outstanding 0 0
Preferred Stock, Shares Issued 0 0
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 170,000,000 170,000,000
Common stock, shares issued 145,638,459 145,638,459
Common stock, shares outstanding 145,638,459 145,638,459
Series D Convertible Redeemable Preferred Stock [Member]    
Temporary Equity, Par or Stated Value Per Share $ 0.001 $ 0.001
Temporary Equity, Shares Authorized 1,000,000 1,000,000
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.0.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Income Statement [Abstract]    
Revenue $ 1,615
Operating expenses:    
Research and development expenses 1,654 2,570
General and administrative expenses 2,510 3,008
Total operating expenses 4,164 5,578
Loss from operations (4,164) (3,963)
Other income (expense):    
Interest income, net 1 1
Net changes in fair value of derivative liabilities 3,802 (27)
Other (expense) income (4) 12
Net loss before income taxes (365) (3,977)
Income tax expense
Net loss $ (365) $ (3,977)
Net loss per common share, basic and diluted $ (0.00) $ (0.05)
Weighted average number of common shares, basic and diluted 145,638,459 83,943,982
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Jan. 31, 2022
Jan. 31, 2021
OPERATING ACTIVITIES    
Net loss $ (365) $ (3,977)
Adjustments to reconcile net loss to net cash used in operating activities:    
Share based compensation 26 236
(Gain) loss on change in value of warrants (3,802) 27
Loss on disposal of property and equipment 12
Abandonment of intangible assets 104
Depreciation expense 18 192
Amortization expense of intangible assets 70 67
Amortization of right-of-use asset 7 195
Change in operating assets and liabilities:    
Prepaid expenses, other current assets and deferred expenses 257 463
Accounts payable and accrued expenses (447) 394
Deferred revenue (165)
Operating lease liabilities (6) (230)
Net cash used in operating activities (4,138) (2,786)
INVESTING ACTIVITIES    
Cost of intangible assets (58) (210)
Net cash used in investing activities (58) (210)
FINANCING ACTIVITIES    
Net proceeds of issuance of Series D preferred stock 4,312
Net proceeds of issuance of common stock and warrants 8,550
Warrant exercises 2,586
Net cash provided by financing activities 4,312 11,136
Net increase in cash, cash equivalents and restricted cash 116 8,140
Cash, cash equivalents and restricted cash at beginning of year 41,614 25,178
Total cash, cash equivalents and restricted cash shown in condensed statements of cash flows 41,730 33,318
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed balance sheets that sum to the total of the same such amounts shown in the condensed statements of cash flows:    
Cash and cash equivalents 36,480 33,318
Restricted cash 5,250
SUPPLEMENTAL CASH FLOW INFORMATION    
Cash paid for taxes
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
NATURE OF OPERATIONS
 3 Months Ended
Jan. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
NATURE OF OPERATIONS

1. NATURE OF OPERATIONS

 

Advaxis, Inc. (“Advaxis” or the “Company”) is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (“Lm”)-based antigen delivery products. The Company is using its Lm platform directed against tumor-specific targets in order to engage the patient’s immune system to destroy tumor cells. Through a license from the University of Pennsylvania, Advaxis has exclusive access to this proprietary formulation of attenuated Lm called Lm TechnologyTM. Advaxis’ proprietary approach is designed to deploy a unique mechanism of action that redirects the immune system to attack cancer in three distinct ways:

 

  ● Alerting and training the immune system by activating multiple pathways in Antigen-Presenting Cells (“APCs”) with the equivalent of multiple adjuvants;
  ● Attacking the tumor by generating a strong, cancer-specific T cell response; and
  ● Breaking down tumor protection through suppression of the protective cells in the tumor microenvironment (“TME”) that shields the tumor from the immune system. This enables the activated T cells to begin working to attack the tumor cells.

 

Advaxis’ proprietary Lm platform technology has demonstrated clinical activity in several of its programs and has been dosed in over 470 patients across multiple clinical trials and in various tumor types. The Company believes that Lm Technology immunotherapies can complement and address significant unmet needs in the current oncology treatment landscape. Specifically, its product candidates have the potential to work synergistically with other immunotherapies, including checkpoint inhibitors, while having a generally well-tolerated safety profile.

 

Liquidity and Capital Resources

 

Liquidity and Management’s Plans

 

Similar to other development stage biotechnology companies, the Company’s products that are being developed have not generated significant revenue. As a result, the Company has suffered recurring losses and requires significant cash resources to execute its business plans. These losses are expected to continue for the foreseeable future.

 

As of January 31, 2022, the Company had approximately $36.5 million in cash and cash equivalents. Although the Company expects to have sufficient capital to fund its obligations, as they become due, in the ordinary course of business until at least one year from the issuance of these consolidated financial statements, the actual amount of cash that it will need to operate is subject to many factors.

 

The Company recognizes it will need to raise additional capital in order to continue to execute its business plan in the future. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to further scale back its operations.

 
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION
 3 Months Ended
Jan. 31, 2022
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

 

Basis of Presentation/Estimates

 

The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) with respect to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and the accompanying unaudited interim condensed consolidated balance sheet as of January 31, 2022 has been derived from the Company’s October 31, 2021 audited financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements furnished include all adjustments (consisting of normal recurring accruals) necessary for a fair statement of the results for the interim periods presented.

 

 

Operating results for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates include the timelines associated with revenue recognition on upfront payments received, fair value and recoverability of the carrying value of property and equipment and intangible assets, fair value of warrant liability, grant date fair value of options, deferred tax assets and any related valuation allowance and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from these estimates.

 

These unaudited interim condensed consolidated financial statements should be read in conjunction with the financial statements of the Company as of and for the fiscal year ended October 31, 2021 and notes thereto contained in the Company’s 2021 Annual Report on Form 10-K, as filed with the SEC on February 14, 2022.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated.

 

Restricted Cash

 

On January 31, 2022, the Company transferred $5,250,000 into an escrow fund to fund a potential Series D preferred stock redemption.

 

Convertible Preferred Stock

 

Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control, as temporary equity (“mezzanine”) until such time as the conditions are removed or lapse.

 

Derivative Financial Instruments

 

The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For share-based derivative financial instruments, the Company used the Monte Carlo simulation model, the Black Scholes model and a binomial model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the consolidated balance sheet as current or non-current based on whether or not net-cash settlement of the instrument could be required within 12 months after the balance sheet date.

 

 

Net Income (Loss) per Share

 

Basic net income or loss per common share is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, restricted stock units and other potential common stock outstanding during the period. In the case of a net loss, the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table below sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share:

 

   As of January 31, 
   2022   2021 
Warrants   30,225,397    8,014,220 
Series D convertible redeemable preferred stock   20,000,000    - 
Stock options   888,058    1,047,377 
Restricted stock units   -    5,556 
Total   51,113,455    9,067,153 

 

Recent Accounting Standards

 

In December 2019, the FASB issued ASU 2019-12, Simplification of Income Taxes (Topic 740) Income Taxes (“ASU 2019-12”). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for public companies for annual periods beginning after December 15, 2020, including interim periods within those fiscal years. The Company adopted this standard effective November 1, 2021 and it is not material to the financial results of the Company.

 

In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain convertible instruments, amends guidance on derivative scope exceptions for contracts in an entity’s own equity, and modifies the guidance on diluted earnings per share (“EPS”) calculations as a result of these changes. The standard will be effective for the Company for fiscal years beginning after December 15, 2023 and can be applied on either a fully retrospective or modified retrospective basis. Early adoption is permitted for fiscal years beginning after December 15, 2020. The Company adopted this standard effective November 1, 2021 and it is not material to the financial results of the Company.

 

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed consolidated financial statements.

 
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.0.1
PROPERTY AND EQUIPMENT
 3 Months Ended
Jan. 31, 2022
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT

3. PROPERTY AND EQUIPMENT

 

Property and equipment, net consisted of the following (in thousands):

 

   January 31, 2022   October 31, 2021 
Laboratory equipment  $179   $179 
Computer equipment   241    241 
Total property and equipment   420    420 
Accumulated depreciation and amortization   (320)   (302)
Net property and equipment  $100   $118 

 

Depreciation expense for the three months ended January 31, 2022 and 2021 was approximately $18,000 and $192,000, respectively.

 

 
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.0.1
INTANGIBLE ASSETS
 3 Months Ended
Jan. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLE ASSETS

4. INTANGIBLE ASSETS

 

Intangible assets, net consisted of the following (in thousands):

 

   January 31, 2022   October 31, 2021 
         
Patents  $4,769   $4,836 
Licenses   777    777 
Software   98    98 
Total intangibles   5,644    5,711 
Accumulated amortization   (2,406)   (2,357)
Intangible assets  $3,238   $3,354 

 

The expiration dates of the existing patents range from 2021 to 2039 but the expiration dates can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to further pursue the application. Patent applications having a net book value of approximately $104,000 and $0 were abandoned and were charged to general and administrative expenses in the statement of operations for each of the three months ended January 31, 2022 and 2021, respectively. Amortization expense for intangible assets that was charged to general and administrative expense in the statement of operations aggregated approximately $70,000 and $67,000 for the three months ended January 31, 2022 and 2021, respectively.

 

Management has reviewed its long-lived assets for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. Net assets are recorded on the balance sheet for patents and licenses related to axalimogene filolisbac (AXAL), ADXS-HOT, ADXS-PSA and other products that are in development. However, if a competitor were to gain FDA approval for a similar treatment before the Company or if future clinical trials fail to meet the targeted endpoints, the Company will likely record an impairment related to these assets. In addition, if an application is rejected or fails to be issued, the Company would record an impairment of its estimated book value. Lastly, if the Company is unable to raise enough capital to continue funding its studies and developing its intellectual property, the Company would likely record an impairment to these assets.

 

As of January 31, 2022, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):

 

   Fiscal year ending
October 31,		 
     
2022 (Remaining)  $211 
2023   282 
2024   282 
2025   282 
2026   282 
Thereafter   1,899 
Total  $3,238 

 
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.0.1
ACCRUED EXPENSES
 3 Months Ended
Jan. 31, 2022
Payables and Accruals [Abstract]  
ACCRUED EXPENSES

5. ACCRUED EXPENSES:

 

The following table summarizes accrued expenses included in the condensed consolidated balance sheets (in thousands):

 

   January 31, 2022   October 31, 2021 
         
Salaries and other compensation  $170   $55 
Vendors   1,524    1,968 
Professional fees   237    613 
Other   200    200 
Total accrued expenses  $2,131   $2,836 

 

 
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.0.1
LEASES
 3 Months Ended
Jan. 31, 2022
Leases  
LEASES

6. LEASES

 

Operating Leases

 

The Company previously leased a corporate office and manufacturing facility in Princeton, New Jersey under an operating lease that was set to expire in November 2025. On March 26, 2021, the Company entered into a Lease Termination and Surrender Agreement with respect to this lease agreement. The Lease Termination and Surrender Agreement provides for the early termination of the lease, which became effective on March 31, 2021. In connection with the early termination of the lease, the Company was required to pay a $1,000,000 termination payment. The unapplied security deposit totaling approximately $182,000 was credited against the termination fee for a net payment of approximately $818,000. The Company wrote off of the remaining right-of-use asset of approximately $4.5 million and lease liability of approximately $5.6 million. After consideration of the termination payment and write off of remaining right-of-use asset and lease liability, the Company recorded a net gain of approximately $0.1 million.

 

On March 25, 2021, the Company entered into a new lease agreement for its corporate office/lab with base rent of approximately $29,000 per year, plus other expenses. The lease expires on March 25, 2022 and the Company has the option to renew the lease for one additional successive one-year term upon six months written notice to the landlord. This new lease was accounted for as a short-term lease at inception, and the Company elected not to recognize a right-of-use asset and lease liability. In September 2021, the Company exercised its option to renew the lease, extending the lease term until March 25, 2023. Since the renewed lease term exceeds one-year, the lease no longer qualifies for the short-term lease exception, resulting in the recognition of a right-of-use asset and operating lease liability of approximately $43,000.

 

Supplemental balance sheet information related to leases was as follows (in thousands):

 

   January 31, 2022   October 31, 2021 
Operating leases:           
Operating lease right-of-use assets  $33   $40 
           
Operating lease liability  $29   $28 
Operating lease liability, net of current portion   5    12 
Total operating lease liabilities  $34   $40 

 

Supplemental lease expense related to leases was as follows (in thousands):

 

Lease Cost (in thousands)   Statements of Operations Classification   For the Three
Months Ended
January 31, 2022		     For the Three
Months Ended
January 31, 2021		  
Operating lease cost   General and administrative     7       290  
Variable lease cost   General and administrative   $ 9       437  
Total lease expense       $ 16       727  

 

Other information related to leases where the Company is the lessee is as follows:

 

   January 31, 2022   October 31, 2021 
Weighted-average remaining lease term   1.2 years    1.4 years 
Weighted-average discount rate   3.79%   3.79%

 

Supplemental cash flow information related to operating leases was as follows:

 

   For the Three
Months Ended
January 31, 2022		   For the Three
Months Ended
January 31, 2021		 
Cash paid for operating lease liabilities  $7   $324 

 

 

Future minimum lease payments under non-cancellable leases as of January 31, 2022 were as follows:

 

Fiscal Year ending October 31,    
2022 (Remaining)  $22 
2023   13 
Total minimum lease payments   35 
Less: Imputed interest   (1)
Total  $34 

 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.0.1
COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY
 3 Months Ended
Jan. 31, 2022
Common Stock Purchase Warrants And Warrant Liability  
COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY

7. COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY

 

Warrants

 

As of January 31, 2022 and October 31, 2021, there were outstanding and exercisable warrants to purchase 30,225,397 shares of our common stock with exercise prices ranging from $0.30 to $281.25 per share. Information on the outstanding warrants is as follows:

 

Exercise
Price		   Number of Shares
Underlying Warrants		   Expiration Date  Type of Financing
$281.25    25   N/A  Other warrants
$0.25    70,297   July 2024  September 2018 Public Offering
$2.80    327,338   September 2024  July 2019 Public Offering
$0.35    4,578,400   November 2025  November 2020 Public Offering
$0.70    11,244,135   April 2026  April 2021 Registered Direct Offering (Accompanying Warrants)
$0.70    14,005,202   5 years after the date such warrants become exercisable, if ever  April 2021 Private Placement (Private Placement Warrants)
 Grand Total    30,225,397       

 

As of January 31, 2022 and October 31, 2021, the Company had 16,149,898 of its total 30,225,397 outstanding warrants classified as equity (equity warrants).

 

Warrant Liability

 

As of January 31, 2022 and October 31, 2021, the Company had 14,075,499 of its total 30,225,397 outstanding warrants from an April 2021 private offering of common stock and warrants (the “April 2021 Private Placement”) and a September 2018 public offering of common stock and warrants (the “September 2018 Public Offering”) classified as liabilities (liability warrants).

 

The warrants issued in the April 2021 Private Placement will become exercisable only on such day, if ever, that is 14 days after the Company files an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock, $0.001 par value per share from 170,000,000 shares to 300,000,000 shares. These warrants expire five years after the date they become exercisable. As of January 31, 2022, the Company did not have sufficient authorized common stock to allow for the issuance of common stock underlying these warrants. The Company did not receive stockholder authorization to increase the authorized shares from 170,000,000 to 300,000,000 shares at the stockholder’s meeting commenced on June 3, 2021. The Company was subsequently required to file a proxy to seek an increase in the number of authorized shares and did not file such a proxy but rather elected to seek a reverse stock split to, among other things, increase the shares available. Accordingly, based on certain indemnification provisions of the securities purchase agreement, the Company concluded that liability classification is warranted. The Company utilized the Black Scholes model to calculate the fair value of these warrants at issuance and at each subsequent reporting date.

 

 

In measuring the warrant liability for the warrants issued in the April 2021 Private Placement at January 31, 2022 and October 31, 2021, the Company used the following inputs in its Black Scholes model:

 

   January 31, 2022   October 31, 2021 
Exercise Price  $0.70   $0.70 
Stock Price  $0.136   $0.485 
Expected Term    5.00 years      5.00 years  
Volatility %   108%   106%
Risk Free Rate   1.62%   1.18%

 

The September 2018 Public Offering warrants contain a down round feature, except for exempt issuances as defined in the warrant agreement, in which the exercise price would immediately be reduced to match a dilutive issuance of common stock, options, convertible securities and changes in option price or rate of conversion. As of January 31, 2021, the down round feature was triggered four times and the exercise price of the warrants were reduced from $22.50 to $0.25. The warrants require liability classification as the warrant agreement requires the Company to maintain an effective registration statement and does not specify any circumstances under which settlement in other than cash would be permitted or required. As a result, net cash settlement is assumed and liability classification is warranted. For these liability warrants, the Company utilized the Monte Carlo simulation model to calculate the fair value of these warrants at issuance and at each subsequent reporting date.

 

In measuring the warrant liability for the September 2018 Public Offering warrants at January 31, 2022 and October 31, 2021, the Company used the following inputs in its Monte Carlo simulation model:

 

   January 31, 2022   October 31, 2021 
Exercise Price  $0.25   $0.30 
Stock Price  $0.136   $0.485 
Expected Term   2.61 years     2.87 years  
Volatility %   118%   123%
Risk Free Rate   1.29%   0.77%

 

At January 31, 2022 and October 31, 2021, the fair value of the warrant liability was approximately $1,127,000 and $4,929,000, respectively. For the three months ended January 31, 2022 and 2021, the Company reported income of approximately $3,802,000 and expense of $27,000, respectively, due to changes in the fair value of the warrant liability.

 
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.0.1
COMMITMENTS AND CONTINGENCIES
 3 Months Ended
Jan. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

8. COMMITMENTS AND CONTINGENCIES

 

Atachbarian

 

On November 15, 2021, a purported stockholder of the Company commenced an action against the Company and certain of its directors in the U.S. District Court for the District of New Jersey, entitled Atachbarian v. Advaxis, Inc., et al., No. 3:21-cv-20006. The plaintiff alleges that the defendants breached their fiduciary duties and violated Section 14(a) and Rule 20(a) of the Securities Exchange Act of 1934 and Rule 14a-9 promulgated thereunder by allegedly failing to disclose certain matters in its Registration Statement on Form S-4 (Commission File No. 333-259065 (the “Registration Statement”) filed in connection with a proposed merger with Biosight Ltd. (the “Previously Proposed Merger”). On December 15, 2021, pursuant to an understanding reached with the plaintiff, the Company made certain other additional disclosures that mooted the demands asserted in the complaint. On December 17, 2021, the plaintiff filed a notice of voluntary dismissal with prejudice. On February 7, 2022, the Company and the plaintiff reached a settlement agreement, which is recorded in accrued expenses in the consolidated balance statement.

 

 

Purported Stockholder Claims Related to Biosight Transaction

 

Between September 16, 2021, and November 4, 2021, the Company received demand letters on behalf of six purported stockholders of the Company, alleging that the Company failed to disclose certain matters in the Registration Statement, and demanding that the Company disclose such information in a supplemental disclosure filed with the SEC. On October 14, 2021, the Company filed an amendment to the Registration Statement and on November 8, 2021, the Company made certain other additional disclosures that mooted the demands asserted in the above-referenced letters. The six plaintiffs have made a settlement demand. The Company believes it has adequately accrued for a settlement, which is recorded in accrued expenses in the consolidated balance sheet.

 

In addition, the Company received certain additional demands from stockholders asserting that the proxy materials filed by the Company in connection with the Previously Proposed Merger contained alleged material misstatements and/or omissions in violation of federal law. In response to these demands, the Company agreed to make, and did make, certain supplemental disclosures to the proxy materials. At this time, the Company is unable to predict the likelihood of an unfavorable outcome.

 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.0.1
TEMPORARY EQUITY
 3 Months Ended
Jan. 31, 2022
Temporary Equity  
TEMPORARY EQUITY

9. TEMPORARY EQUITY

 

Series D Convertible Preferred Stock Offering

 

On January 31, 2022, the Company closed on an offering with certain institutional investors for the private placement of 1,000,000 shares of Series D convertible redeemable preferred stock (“Series D preferred stock”). The shares to be sold have an aggregate stated value of $5,000,000. Each share of the Series D preferred stock has a purchase price of $4.75, representing an original issue discount of 5% of the stated value. Total net proceeds from the offering, after deducting the financial advisor’s fees and other estimated offering expenses, were approximately $4,312,000.

 

The Company has called a special meeting of stockholders to consider an amendment (the “Amendment”) to the Company’s Amended and Restated Certificate of Incorporation, to effect a reverse stock split of the outstanding shares of common stock by a ratio to be determined by the Board of Directors of the Company within a range to be specified in the proposal put to the stockholders for approval of the Amendment. The investors have agreed in the Purchase Agreement to not transfer, offer, sell, contract to sell, hypothecate, pledge or otherwise dispose of the shares of the Series D preferred stock until the reverse stock split and to vote the shares of the Series D preferred stock purchased in the offering in a manner that “mirrors” the proportions on which the shares of common stock (excluding any shares of common stock that are not voted) are voted on the reverse stock split and the Amendment. The Amendment requires the approval of the majority of the votes associated with the Company’s outstanding stock entitled to vote on the proposal. The certificate of designation provides that the Series D preferred stock will have no voting rights, other than the right to vote as a class on certain specified matters, except that each share of Series D preferred stock will have the right to cast 30,000 votes per share of Series D preferred stock on the reverse stock split.

 

The Series D preferred stock can be converted at the option of the holder at any time after the Company has received stockholder approval for a reverse stock split and filed the requisite amendment with the Delaware Secretary of State’s office to effectuate the reverse stock split, subject to beneficial ownership limitations. The Company will be permitted to compel conversion of the Series D preferred stock after the fulfillment of certain conditions and subject to certain limitations. The Series D preferred stock is convertible into shares of Common Stock at a rate of $0.25 per share for the Series D preferred stock. In addition, on or after the reverse stock split date, and subject to the satisfaction of certain conditions, the Company can cause the holder of the Series D Preferred Stock to convert their shares of Series D Preferred Stock, subject to such beneficial ownership limitations.

 

 

The Series D preferred stock has a liquidation preference over the common stock, and may be redeemed by the investors. Each holder of the Series D preferred stock has the right to cause the Company to redeem all or part of their shares of the Series D preferred stock from the earlier of receipt of stockholder approval of the reverse stock split or 90 days following the original issue date until 120 days following the original issue date (the “Redemption Date”) in cash at a redemption price equal to 105% of the stated value plus an amount equal to accumulated but unpaid dividends, if any, on such shares (whether or not earned or declared, but excluding interest on such dividends) up to, but excluding, the Redemption Date. Under certain circumstances, the commencement of the period during which the Series D preferred stock may be redeemed may be extended from 90 days following the original issue date to 135 days following the original issue date, in which case the Redemption Date would be extended to 165 days following the original issue date. Should such extension occur, the redemption price would be increased to an amount equal to 110% of the stated value plus an amount equal to accumulated but unpaid dividends, if any, on such shares.

 

The holders of Series D preferred stock will be entitled to dividends, on an as-if converted basis, equal to dividends actually paid, if any, on shares of common stock.

 

The $4.75 million in gross proceeds of the offering are held in an escrow account, along with an additional $500,000 deposited by the Company to cover the aggregate original issue discount as well as the additional amount that would be necessary to fund the 105% redemption price until the expiration of the redemption period for the Series D Preferred Stock, as applicable, subject to the earlier payment to redeeming holders. Upon expiration of the redemption period, any proceeds remaining in escrow will be disbursed to the Company.

 

In connection with the Offering, the Company and the investors entered into a registration rights agreement, pursuant to which the Company is required to file a registration statement with the Securities and Exchange Commission to register for resale the shares that are issued upon the conversion of shares of Series D preferred stock. The registration statement will be filed with the Securities and Exchange Commission on or before the 60th calendar day following the first date on which shares are issued upon the conversion of shares of Series D preferred stock.

 

Since the Series D preferred stock has a redemption feature at the option of the holder, it is classified as temporary equity. At the January 31, 2022 issuance date, the Series D preferred stock was recorded on the balance sheet at approximately $4,225,000, which is the $4,312,000 net proceeds less the $87,000 value of the bifurcated preferred stock redemption liability (see below).

 

Preferred Stock Redemption Liability

 

The Company evaluated the preferred stock redemption feature under ASC 815. Since the preferred stock redemption feature is not considered to be clearly and closely related to the preferred stock host and the redemption feature meets the four characteristics of a derivative under ASC 815, the preferred stock redemption feature is required to be bifurcated from the preferred stock host and valued as a liability. The Company utilized a binomial model to calculate the fair value of the preferred stock redemption feature at issuance.

 

In measuring the preferred stock redemption liability at January 31, 2022 (issuance date), the Company used the following inputs in its binomial model:

 

   January 31, 2022 
Exercise Price  $0.25 
Stock Price  $0.136 
Volatility %   105%
Risk Free Rate   1.00%

 

At January 31, 2022, the fair value of the preferred stock redemption liability was approximately $87,000.

 

 
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.0.1
STOCKHOLDERS’ EQUITY
 3 Months Ended
Jan. 31, 2022
Equity [Abstract]  
STOCKHOLDERS’ EQUITY

10. STOCKHOLDERS’ EQUITY

 

A summary of the changes in stockholders’ equity for the three months ended January 31, 2022 and 2021 is presented below (in thousands, except share data):

 

   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
   Preferred Stock   Common Stock   Additional Paid-In   Accumulated   Total Shareholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
Balance at November 1, 2020      -   $     -    78,074,023   $78   $440,840   $(410,738)  $30,180 
Stock-based compensation   -    -    -    -    236    -    236 
Advaxis public offerings, net of offering costs   -    -    30,666,665    31    8,519    -    8,550 
Warrant exercises   -    -    7,390,000    7    2,579    -    2,586 
Net Loss   -    -    -    -    -    (3,977)   (3,977)
Balance at January 31, 2021   -   $-    116,130,688   $116   $452,174   $(414,715)  $37,575 

 

   Preferred Stock   Common Stock   Additional
Paid-In		   Accumulated   Total
Shareholders’		 
   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
Balance at November 1, 2021       -   $       -    145,638,459   $146   $467,342   $(428,600)  $38,888 
Stock-based compensation   -    -    -    -    26    -    26 
Net Loss   -    -    -    -    -    (365)   (365)
Balance at January 31, 2022   -   $-    145,638,459   $146   $467,368   $(428,965)  $38,549 

 
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.0.1
SHARE BASED COMPENSATION
 3 Months Ended
Jan. 31, 2022
Share-based Payment Arrangement [Abstract]  
SHARE BASED COMPENSATION

11. SHARE BASED COMPENSATION

 

The following table summarizes share-based compensation expense included in the condensed consolidated statements of operations (in thousands):

 

   Three Months Ended January 31, 
   2022   2021 
Research and development  $13   $57 
General and administrative   13    179 
Total  $26   $236 

 

Stock Options

 

A summary of changes in the stock option plan for the three months ended January 31, 2022 is as follows:

 

   Shares   Weighted
Average
Exercise Price		   Weighted
Average
Remaining
Contractual Life
In Years		   Aggregate
Intrinsic Value
(in thousands)		 
Outstanding as of October 31, 2021   893,946   $19.32    7.80   $         27 
Cancelled or expired   (5,888)   277.50           
Outstanding as of January 31, 2022   888,058   $17.61    7.55   $- 
Vested and exercisable at January 31, 2022   484,641   $31.80    6.89   $- 

 

 

The following table summarizes information about the outstanding and exercisable options at January 31, 2022:

 

Options Outstanding     Options Exercisable  
            Weighted     Weighted           Weighted     Weighted  
            Average     Average           Average     Average  
Exercise     Number     Remaining     Exercise     Number     Remaining     Exercise  
Price Range     Outstanding     Contractual     Price     Exercisable     Contractual     Price  
$ .30-$1.00       672,500       8.29     $ 0.54       270,000       8.20     $ 0.50  
$ 1.01-$10.00       55,379       6.80     $ 7.47       54,462       6.79     $ 7.56  
$ 10.01-$100.00       90,432       5.97     $ 29.02       90,432       5.97     $ 29.02  
$ 100.01-$258.30       69,747       3.07     $ 175.51       69,747       3.07     $ 175.51  

 

As of January 31, 2022, there was approximately $125,000 of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining weighted average vesting period of 1.38 years.

 

Potential Acceleration of Stock Options

 

In the event of a merger transaction, similar to the Previously Proposed Merger Agreement, all of the Chief Executive Officer’s 73,777 unvested stock options, pursuant to his employment agreement, would accelerate.

 
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.0.1
LICENSING AGREEMENTS
 3 Months Ended
Jan. 31, 2022
Licensing Agreements  
LICENSING AGREEMENTS

12. LICENSING AGREEMENTS

 

OS Therapies LLC

 

On September 4, 2018, the Company entered into a development, license and supply agreement with OS Therapies (“OST”) for the use of ADXS31-164, also known as ADXS-HER2, for evaluation in the treatment of osteosarcoma in humans. Under the terms of the license agreement, as amended, OST will be responsible for the conduct and funding of a clinical study evaluating ADXS-HER2 in recurrent, completely resected osteosarcoma. Under the most recent amendment to the licensing agreement, OST agreed to pay Advaxis $25,000 per month (“Monthly Payment”) starting on April 30, 2020 until it achieved its funding milestone of $2,337,500. Upon receipt of the first Monthly Payment, Advaxis initiated the transfer of the intellectual property and licensing rights of ADXS31-164, which were licensed pursuant to the Penn Agreement, back to the University of Pennsylvania. Contemporaneously, OST will enter negotiations with the University of Pennsylvania to establish a licensing agreement for ADXS31-164 to OST for clinical and commercial development of the ADXS31-164 technology.

 

During the three months ended January 31, 2021, the Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement. The Company therefore transferred and OST took full ownership of the IND application for ADXS31-164 in its entirety along with agreements and promises contained therein, as well as all obligations associated with this IND or any HER2 product/program development.

 
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.0.1
FAIR VALUE
 3 Months Ended
Jan. 31, 2022
Fair Value Disclosures [Abstract]  
FAIR VALUE

13. FAIR VALUE

 

The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

 

● Level 1 — Quoted prices in active markets for identical assets or liabilities.

 

● Level 2— Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities.

 

 

● Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities.

 

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of January 31, 2022 and October 31, 2021 (in thousands):

 

   Level 1   Level 2   Level 3   Total 
Fair value measured at January 31, 2022
   Level 1   Level 2   Level 3   Total 
Financial assets at fair value:                    
Cash equivalents (money market funds)  $17,154   $-   $-   $17,154 
Total Financial Assets at Fair Value  $17,154   $-   $-   $17,154 
                     
Financial liabilities at fair value:                    
Preferred stock redemption liability  $-   $-   $87   $87 
Common stock warrant liability, warrants exercisable at $0.25 through September 2024   -    -    7    7 
Common stock warrant liability, warrants exercisable at $0.70 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)   -    -    1,120    1,120 
Total financial liabilities at fair value  $-   $-   $1,214   $1,214 

 

   Level 1   Level 2   Level 3   Total 
Fair value measured at October 31, 2021
   Level 1   Level 2   Level 3   Total 
Financial assets at fair value:                    
Cash equivalents (money market funds)  $17,153   $-   $-   $17,153 
Total Financial Assets at Fair Value  $17,153   $-   $-   $17,153 
                     
Financial liabilities at fair value:                    
Common stock warrant liability, warrants exercisable at $0.30 through September 2024  $-   $-   $27   $27 
Common stock warrant liability, warrants exercisable at $0.70 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)   -    -    4,902    4,902 
Total financial liabilities at fair value  $-   $-   $4,929   $4,929 

 

The following table presents changes in Level 3 liabilities measured at fair value (in thousands) for the three months ended January 31, 2022. Unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category.

 

   Preferred Stock Redemption Liability   Warrant Liabilities   Total 
Fair value at October 31, 2021  $           -   $4,929   $4,929 
Additions   87    -    87 
Change in fair value   -    (3,802)   (3,802)
Fair value at January 31, 2022  $87   $1,127   $1,214 

 
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Policies)
 3 Months Ended
Jan. 31, 2022
Accounting Policies [Abstract]  
Basis of Presentation/Estimates

Basis of Presentation/Estimates

 

The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) with respect to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and the accompanying unaudited interim condensed consolidated balance sheet as of January 31, 2022 has been derived from the Company’s October 31, 2021 audited financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements furnished include all adjustments (consisting of normal recurring accruals) necessary for a fair statement of the results for the interim periods presented.

 

 

Operating results for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates include the timelines associated with revenue recognition on upfront payments received, fair value and recoverability of the carrying value of property and equipment and intangible assets, fair value of warrant liability, grant date fair value of options, deferred tax assets and any related valuation allowance and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from these estimates.

 

These unaudited interim condensed consolidated financial statements should be read in conjunction with the financial statements of the Company as of and for the fiscal year ended October 31, 2021 and notes thereto contained in the Company’s 2021 Annual Report on Form 10-K, as filed with the SEC on February 14, 2022.

 
Principles of Consolidation

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated.

 
Restricted Cash

Restricted Cash

 

On January 31, 2022, the Company transferred $5,250,000 into an escrow fund to fund a potential Series D preferred stock redemption.

 
Convertible Preferred Stock

Convertible Preferred Stock

 

Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control, as temporary equity (“mezzanine”) until such time as the conditions are removed or lapse.

 
Derivative Financial Instruments

Derivative Financial Instruments

 

The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For share-based derivative financial instruments, the Company used the Monte Carlo simulation model, the Black Scholes model and a binomial model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the consolidated balance sheet as current or non-current based on whether or not net-cash settlement of the instrument could be required within 12 months after the balance sheet date.

 

 
Net Income (Loss) per Share

Net Income (Loss) per Share

 

Basic net income or loss per common share is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, restricted stock units and other potential common stock outstanding during the period. In the case of a net loss, the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table below sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share:

 

   As of January 31, 
   2022   2021 
Warrants   30,225,397    8,014,220 
Series D convertible redeemable preferred stock   20,000,000    - 
Stock options   888,058    1,047,377 
Restricted stock units   -    5,556 
Total   51,113,455    9,067,153 

 
Recent Accounting Standards

Recent Accounting Standards

 

In December 2019, the FASB issued ASU 2019-12, Simplification of Income Taxes (Topic 740) Income Taxes (“ASU 2019-12”). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for public companies for annual periods beginning after December 15, 2020, including interim periods within those fiscal years. The Company adopted this standard effective November 1, 2021 and it is not material to the financial results of the Company.

 

In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain convertible instruments, amends guidance on derivative scope exceptions for contracts in an entity’s own equity, and modifies the guidance on diluted earnings per share (“EPS”) calculations as a result of these changes. The standard will be effective for the Company for fiscal years beginning after December 15, 2023 and can be applied on either a fully retrospective or modified retrospective basis. Early adoption is permitted for fiscal years beginning after December 15, 2020. The Company adopted this standard effective November 1, 2021 and it is not material to the financial results of the Company.

 

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed consolidated financial statements.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Tables)
 3 Months Ended
Jan. 31, 2022
Accounting Policies [Abstract]  
SCHEDULE OF ANTI -DILUTED SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE

 

   As of January 31, 
   2022   2021 
Warrants   30,225,397    8,014,220 
Series D convertible redeemable preferred stock   20,000,000    - 
Stock options   888,058    1,047,377 
Restricted stock units   -    5,556 
Total   51,113,455    9,067,153 
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.0.1
PROPERTY AND EQUIPMENT (Tables)
 3 Months Ended
Jan. 31, 2022
Property, Plant and Equipment [Abstract]  
SCHEDULE OF PROPERTY AND EQUIPMENT

Property and equipment, net consisted of the following (in thousands):

 

   January 31, 2022   October 31, 2021 
Laboratory equipment  $179   $179 
Computer equipment   241    241 
Total property and equipment   420    420 
Accumulated depreciation and amortization   (320)   (302)
Net property and equipment  $100   $118 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.0.1
INTANGIBLE ASSETS (Tables)
 3 Months Ended
Jan. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
SUMMARY OF INTANGIBLE ASSETS

Intangible assets, net consisted of the following (in thousands):

 

   January 31, 2022   October 31, 2021 
         
Patents  $4,769   $4,836 
Licenses   777    777 
Software   98    98 
Total intangibles   5,644    5,711 
Accumulated amortization   (2,406)   (2,357)
Intangible assets  $3,238   $3,354 
SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS

As of January 31, 2022, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):

 

   Fiscal year ending
October 31,		 
     
2022 (Remaining)  $211 
2023   282 
2024   282 
2025   282 
2026   282 
Thereafter   1,899 
Total  $3,238 
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.0.1
ACCRUED EXPENSES (Tables)
 3 Months Ended
Jan. 31, 2022
Payables and Accruals [Abstract]  
SUMMARY OF ACCRUED EXPENSES

The following table summarizes accrued expenses included in the condensed consolidated balance sheets (in thousands):

 

   January 31, 2022   October 31, 2021 
         
Salaries and other compensation  $170   $55 
Vendors   1,524    1,968 
Professional fees   237    613 
Other   200    200 
Total accrued expenses  $2,131   $2,836 

 

 
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.0.1
LEASES (Tables)
 3 Months Ended
Jan. 31, 2022
Leases  
SCHEDULE OF SUPPLEMENTAL BALANCE SHEET RELATED TO LEASES

Supplemental balance sheet information related to leases was as follows (in thousands):

 

   January 31, 2022   October 31, 2021 
Operating leases:           
Operating lease right-of-use assets  $33   $40 
           
Operating lease liability  $29   $28 
Operating lease liability, net of current portion   5    12 
Total operating lease liabilities  $34   $40 
SCHEDULE OF LEASE EXPENSES

Supplemental lease expense related to leases was as follows (in thousands):

 

Lease Cost (in thousands)   Statements of Operations Classification   For the Three
Months Ended
January 31, 2022		     For the Three
Months Ended
January 31, 2021		  
Operating lease cost   General and administrative     7       290  
Variable lease cost   General and administrative   $ 9       437  
Total lease expense       $ 16       727  
SCHEDULE OF OTHER INFORMATION RELATED TO LEASES

Other information related to leases where the Company is the lessee is as follows:

 

   January 31, 2022   October 31, 2021 
Weighted-average remaining lease term   1.2 years    1.4 years 
Weighted-average discount rate   3.79%   3.79%
SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES

Supplemental cash flow information related to operating leases was as follows:

 

   For the Three
Months Ended
January 31, 2022		   For the Three
Months Ended
January 31, 2021		 
Cash paid for operating lease liabilities  $7   $324 
SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELLABLE LEASES

Future minimum lease payments under non-cancellable leases as of January 31, 2022 were as follows:

 

Fiscal Year ending October 31,    
2022 (Remaining)  $22 
2023   13 
Total minimum lease payments   35 
Less: Imputed interest   (1)
Total  $34 

 
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.0.1
COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Tables)
 3 Months Ended
Jan. 31, 2022
Subsidiary, Sale of Stock [Line Items]  
COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY

 

Exercise
Price		   Number of Shares
Underlying Warrants		   Expiration Date  Type of Financing
$281.25    25   N/A  Other warrants
$0.25    70,297   July 2024  September 2018 Public Offering
$2.80    327,338   September 2024  July 2019 Public Offering
$0.35    4,578,400   November 2025  November 2020 Public Offering
$0.70    11,244,135   April 2026  April 2021 Registered Direct Offering (Accompanying Warrants)
$0.70    14,005,202   5 years after the date such warrants become exercisable, if ever  April 2021 Private Placement (Private Placement Warrants)
 Grand Total    30,225,397       
SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY

In measuring the warrant liability for the September 2018 Public Offering warrants at January 31, 2022 and October 31, 2021, the Company used the following inputs in its Monte Carlo simulation model:

 

   January 31, 2022   October 31, 2021 
Exercise Price  $0.25   $0.30 
Stock Price  $0.136   $0.485 
Expected Term   2.61 years     2.87 years  
Volatility %   118%   123%
Risk Free Rate   1.29%   0.77%
Private Placement [Member]  
Subsidiary, Sale of Stock [Line Items]  
SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY

In measuring the warrant liability for the warrants issued in the April 2021 Private Placement at January 31, 2022 and October 31, 2021, the Company used the following inputs in its Black Scholes model:

 

   January 31, 2022   October 31, 2021 
Exercise Price  $0.70   $0.70 
Stock Price  $0.136   $0.485 
Expected Term    5.00 years      5.00 years  
Volatility %   108%   106%
Risk Free Rate   1.62%   1.18%
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.0.1
TEMPORARY EQUITY (Tables)
 3 Months Ended
Jan. 31, 2022
Temporary Equity  
SCHEDULE OF PREFERRED STOCK REDEMPTION LIABILITY

In measuring the preferred stock redemption liability at January 31, 2022 (issuance date), the Company used the following inputs in its binomial model:

 

   January 31, 2022 
Exercise Price  $0.25 
Stock Price  $0.136 
Volatility %   105%
Risk Free Rate   1.00%
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.0.1
STOCKHOLDERS’ EQUITY (Tables)
 3 Months Ended
Jan. 31, 2022
Equity [Abstract]  
SUMMARY OF STOCKHOLDERS EQUITY

A summary of the changes in stockholders’ equity for the three months ended January 31, 2022 and 2021 is presented below (in thousands, except share data):

 

   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
   Preferred Stock   Common Stock   Additional Paid-In   Accumulated   Total Shareholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
Balance at November 1, 2020      -   $     -    78,074,023   $78   $440,840   $(410,738)  $30,180 
Stock-based compensation   -    -    -    -    236    -    236 
Advaxis public offerings, net of offering costs   -    -    30,666,665    31    8,519    -    8,550 
Warrant exercises   -    -    7,390,000    7    2,579    -    2,586 
Net Loss   -    -    -    -    -    (3,977)   (3,977)
Balance at January 31, 2021   -   $-    116,130,688   $116   $452,174   $(414,715)  $37,575 

 

   Preferred Stock   Common Stock   Additional
Paid-In		   Accumulated   Total
Shareholders’		 
   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
Balance at November 1, 2021       -   $       -    145,638,459   $146   $467,342   $(428,600)  $38,888 
Stock-based compensation   -    -    -    -    26    -    26 
Net Loss   -    -    -    -    -    (365)   (365)
Balance at January 31, 2022   -   $-    145,638,459   $146   $467,368   $(428,965)  $38,549 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.0.1
SHARE BASED COMPENSATION (Tables)
 3 Months Ended
Jan. 31, 2022
Share-based Payment Arrangement [Abstract]  
SUMMARY OF SHARE BASED COMPENSATION EXPENSE

The following table summarizes share-based compensation expense included in the condensed consolidated statements of operations (in thousands):

 

   Three Months Ended January 31, 
   2022   2021 
Research and development  $13   $57 
General and administrative   13    179 
Total  $26   $236 
SUMMARY OF CHANGES IN STOCK OPTION PLAN

A summary of changes in the stock option plan for the three months ended January 31, 2022 is as follows:

 

   Shares   Weighted
Average
Exercise Price		   Weighted
Average
Remaining
Contractual Life
In Years		   Aggregate
Intrinsic Value
(in thousands)		 
Outstanding as of October 31, 2021   893,946   $19.32    7.80   $         27 
Cancelled or expired   (5,888)   277.50           
Outstanding as of January 31, 2022   888,058   $17.61    7.55   $- 
Vested and exercisable at January 31, 2022   484,641   $31.80    6.89   $- 
SUMMARY OF OUTSTANDING AND EXERCISABLE OPTIONS

The following table summarizes information about the outstanding and exercisable options at January 31, 2022:

 

Options Outstanding     Options Exercisable  
            Weighted     Weighted           Weighted     Weighted  
            Average     Average           Average     Average  
Exercise     Number     Remaining     Exercise     Number     Remaining     Exercise  
Price Range     Outstanding     Contractual     Price     Exercisable     Contractual     Price  
$ .30-$1.00       672,500       8.29     $ 0.54       270,000       8.20     $ 0.50  
$ 1.01-$10.00       55,379       6.80     $ 7.47       54,462       6.79     $ 7.56  
$ 10.01-$100.00       90,432       5.97     $ 29.02       90,432       5.97     $ 29.02  
$ 100.01-$258.30       69,747       3.07     $ 175.51       69,747       3.07     $ 175.51  
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.0.1
FAIR VALUE (Tables)
 3 Months Ended
Jan. 31, 2022
Fair Value Disclosures [Abstract]  
SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of January 31, 2022 and October 31, 2021 (in thousands):

 

   Level 1   Level 2   Level 3   Total 
Fair value measured at January 31, 2022
   Level 1   Level 2   Level 3   Total 
Financial assets at fair value:                    
Cash equivalents (money market funds)  $17,154   $-   $-   $17,154 
Total Financial Assets at Fair Value  $17,154   $-   $-   $17,154 
                     
Financial liabilities at fair value:                    
Preferred stock redemption liability  $-   $-   $87   $87 
Common stock warrant liability, warrants exercisable at $0.25 through September 2024   -    -    7    7 
Common stock warrant liability, warrants exercisable at $0.70 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)   -    -    1,120    1,120 
Total financial liabilities at fair value  $-   $-   $1,214   $1,214 

 

   Level 1   Level 2   Level 3   Total 
Fair value measured at October 31, 2021
   Level 1   Level 2   Level 3   Total 
Financial assets at fair value:                    
Cash equivalents (money market funds)  $17,153   $-   $-   $17,153 
Total Financial Assets at Fair Value  $17,153   $-   $-   $17,153 
                     
Financial liabilities at fair value:                    
Common stock warrant liability, warrants exercisable at $0.30 through September 2024  $-   $-   $27   $27 
Common stock warrant liability, warrants exercisable at $0.70 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)   -    -    4,902    4,902 
Total financial liabilities at fair value  $-   $-   $4,929   $4,929 
SCHEDULE OF FAIR VALUE MEASURING UNOBSERVABLE INPUTS

The following table presents changes in Level 3 liabilities measured at fair value (in thousands) for the three months ended January 31, 2022. Unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category.

 

   Preferred Stock Redemption Liability   Warrant Liabilities   Total 
Fair value at October 31, 2021  $           -   $4,929   $4,929 
Additions   87    -    87 
Change in fair value   -    (3,802)   (3,802)
Fair value at January 31, 2022  $87   $1,127   $1,214 
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.0.1
NATURE OF OPERATIONS (Details Narrative) - USD ($)
$ in Thousands
Jan. 31, 2022
Oct. 31, 2021
Jan. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]      
Cash and cash equivalents, at carrying value $ 36,480 $ 41,614 $ 33,318
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.0.1
SCHEDULE OF ANTI -DILUTED SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details) - shares
 3 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 51,113,455 9,067,153
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 30,225,397 8,014,220
SeriesD Convertable Redeemable Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 20,000,000
Stock Options [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 888,058 1,047,377
Restricted Stock Units [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 5,556
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Details Narrative) - USD ($)
$ in Thousands
Jan. 31, 2022
Oct. 31, 2021
Jan. 31, 2021
Restricted cash $ 5,250
SeriesD Preferred Stock Redemption [Member]      
Restricted cash $ 5,250    
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.0.1
SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)
$ in Thousands
Jan. 31, 2022
Oct. 31, 2021
Property, Plant and Equipment [Abstract]    
Laboratory equipment $ 179 $ 179
Computer equipment 241 241
Total property and equipment 420 420
Accumulated depreciation and amortization (320) (302)
Net property and equipment $ 100 $ 118
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.0.1
PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)
$ in Thousands
 3 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Property, Plant and Equipment [Abstract]    
Depreciation expense $ 18 $ 192
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.0.1
SUMMARY OF INTANGIBLE ASSETS (Details) - USD ($)
$ in Thousands
Jan. 31, 2022
Oct. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]    
Patents $ 4,769 $ 4,836
Licenses 777 777
Software 98 98
Total intangibles 5,644 5,711
Accumulated amortization (2,406) (2,357)
Intangible assets $ 3,238 $ 3,354
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.0.1
SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS (Details) - USD ($)
$ in Thousands
Jan. 31, 2022
Oct. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]    
2022 (Remaining) $ 211  
2023 282  
2024 282  
2025 282  
2026 282  
Thereafter 1,899  
Total $ 3,238 $ 3,354
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.0.1
INTANGIBLE ASSETS (Details Narrative) - USD ($)
$ in Thousands
 3 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Goodwill [Line Items]    
Book value patent applications, net $ 104
Intangible asset amortization expense 70 67
General and Administrative Expense [Member]    
Goodwill [Line Items]    
Book value patent applications, net 104
Intangible asset amortization expense $ 70 $ 67
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.0.1
SUMMARY OF ACCRUED EXPENSES (Details) - USD ($)
$ in Thousands
Jan. 31, 2022
Oct. 31, 2021
Payables and Accruals [Abstract]    
Salaries and other compensation $ 170 $ 55
Vendors 1,524 1,968
Professional fees 237 613
Other 200 200
Total accrued expenses $ 2,131 $ 2,836
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.0.1
SCHEDULE OF SUPPLEMENTAL BALANCE SHEET RELATED TO LEASES (Details) - USD ($)
$ in Thousands
Jan. 31, 2022
Oct. 31, 2021
Mar. 26, 2021
Mar. 25, 2021
Leases        
Operating lease right-of-use assets $ 33 $ 40 $ 4,500 $ 43
Operating lease liability 29 28    
Operating lease liability, net of current portion 5 12    
Total operating lease liabilities $ 34 $ 40 $ 5,600 $ 43
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.22.0.1
SCHEDULE OF LEASE EXPENSES (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Leases    
Operating lease cost $ 7 $ 290
Variable lease cost 9 437
Total lease expense $ 16 $ 727
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.22.0.1
SCHEDULE OF OTHER INFORMATION RELATED TO LEASES (Details)
Jan. 31, 2022
Oct. 31, 2021
Leases    
Weighted-average remaining lease term 1 year 2 months 12 days 1 year 4 months 24 days
Weighted-average discount rate 3.79% 3.79%
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.22.0.1
SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Leases    
Cash paid for operating lease liabilities $ 7 $ 324
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.22.0.1
SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELLABLE LEASES (Details) - USD ($)
$ in Thousands
Jan. 31, 2022
Oct. 31, 2021
Mar. 26, 2021
Mar. 25, 2021
Leases        
2022 (Remaining) $ 22      
2023 13      
Total minimum lease payments 35      
Less: Imputed interest (1)      
Total $ 34 $ 40 $ 5,600 $ 43
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.22.0.1
LEASES (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended
Mar. 26, 2021
Mar. 25, 2021
Jan. 31, 2022
Oct. 31, 2021
Leases        
Lease expiration date     Nov. 30, 2025  
Lease termination $ 1,000,000      
Security deposit     $ 182,000  
Net payment for termination fee 818,000      
Operating lease, Right of use asset 4,500,000 $ 43,000 33,000 $ 40,000
Operating lease liability 5,600,000 $ 43,000 $ 34,000 $ 40,000
Net gain on leases 100,000      
Rent paid $ 29,000      
Lease expiration date   Mar. 25, 2022    
Lessee finance lease renewal term date   Mar. 25, 2023    
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.22.0.1
COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Details) - $ / shares
shares in Thousands
 3 Months Ended 12 Months Ended
Jan. 31, 2022
Oct. 31, 2021
Offsetting Assets [Line Items]    
Exercise Price $ 0.25 $ 0.30
Grand Total Number of Shares Underlying Warrants 30,225,397 30,225,397
Exercise Price Range One [Member]    
Offsetting Assets [Line Items]    
Exercise Price $ 281.25 $ 281.25
Grand Total Number of Shares Underlying Warrants 25 25
Type of Financing Other warrants Other warrants
Exercise Price Range Two [Member]    
Offsetting Assets [Line Items]    
Exercise Price $ 0.25 $ 0.25
Grand Total Number of Shares Underlying Warrants 70,297 70,297
Type of Financing September 2018 Public Offering September 2018 Public Offering
Expiration Date July 2024 July 2024
Exercise Price Range Three [Member]    
Offsetting Assets [Line Items]    
Exercise Price $ 2.80 $ 2.80
Grand Total Number of Shares Underlying Warrants 327,338 327,338
Type of Financing July 2019 Public Offering July 2019 Public Offering
Expiration Date September 2024 September 2024
Exercise Price Range Four [Member]    
Offsetting Assets [Line Items]    
Exercise Price $ 0.35 $ 0.35
Grand Total Number of Shares Underlying Warrants 4,578,400 4,578,400
Type of Financing November 2020 Public Offering November 2020 Public Offering
Expiration Date November 2025 November 2025
Exercise Price Range Five [Member]    
Offsetting Assets [Line Items]    
Exercise Price $ 0.70 $ 0.70
Grand Total Number of Shares Underlying Warrants 11,244,135 11,244,135
Type of Financing April 2021 Registered Direct Offering (Accompanying Warrants) April 2021 Registered Direct Offering (Accompanying Warrants)
Expiration Date April 2026 April 2026
Exercise Price Range Six [Member]    
Offsetting Assets [Line Items]    
Exercise Price $ 0.70 $ 0.70
Grand Total Number of Shares Underlying Warrants 14,005,202 14,005,202
Type of Financing April 2021 Private Placement (Private Placement Warrants) April 2021 Private Placement (Private Placement Warrants)
Expiration Date 5 years after the date such warrants become exercisable, if ever 5 years after the date such warrants become exercisable, if ever
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.22.0.1
SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY (Details)
Jan. 31, 2022
$ / shares
Oct. 31, 2021
$ / shares
Exercise Price $ 0.25 $ 0.30
Private Placement [Member]    
Exercise Price 0.70 0.70
Warrant Liability [Member]    
Exercise Price 0.25 0.30
Stock Price $ 0.136 $ 0.485
Warrant Liability [Member] | Measurement Input, Expected Term [Member]    
Expected Term 2 years 7 months 9 days 2 years 10 months 13 days
Warrant Liability [Member] | Measurement Input, Price Volatility [Member]    
Measurement input percentage 118 123
Warrant Liability [Member] | Measurement Input, Risk Free Interest Rate [Member]    
Measurement input percentage 1.29 0.77
Warrant Liability [Member] | Private Placement [Member]    
Exercise Price $ 0.70 $ 0.70
Stock Price $ 0.136 $ 0.485
Warrant Liability [Member] | Private Placement [Member] | Measurement Input, Expected Term [Member]    
Expected Term 5 years 5 years
Warrant Liability [Member] | Private Placement [Member] | Measurement Input, Price Volatility [Member]    
Measurement input percentage 108 106
Warrant Liability [Member] | Private Placement [Member] | Measurement Input, Risk Free Interest Rate [Member]    
Measurement input percentage 1.62 1.18
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.22.0.1
COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Details Narrative) - USD ($)
 3 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Oct. 31, 2021
Jun. 03, 2021
Number of warrants to purchase common stock 30,225,397,000   30,225,397,000  
Warrant exercise price per share $ 0.25   $ 0.30  
Common stock par or stated value per share $ 0.001   $ 0.001  
Common stock shares authorized 170,000,000   170,000,000  
Fair value of the warrant liability $ 1,127,000   $ 4,929,000  
Income on fair value of warrants $ 3,802,000 $ 27,000    
Private Placement [Member]        
Warrant exercise price per share $ 0.70   $ 0.70  
IPO [Member]        
Common stock shares authorized 300,000,000      
Minimum [Member]        
Common stock shares authorized       170,000,000
Maximum [Member]        
Common stock shares authorized       300,000,000
Warrant [Member]        
Warrants outstanding 30,225,397   30,225,397  
Number of warrants to purchase common stock 30,225,397   30,225,397  
Warrant [Member] | Minimum [Member]        
Warrant exercise price per share $ 0.30      
Warrant [Member] | Maximum [Member]        
Warrant exercise price per share $ 281.25      
Equity Warrants [Member]        
Warrants outstanding 30,225,397      
Number of warrants to purchase common stock     16,149,898  
Warrant Liability [Member]        
Warrant exercise price per share $ 0.25   $ 0.30  
Warrant Liability [Member] | Private Placement [Member]        
Warrants outstanding 30,225,397   30,225,397  
Number of warrants to purchase common stock 14,075,499   14,075,499  
Warrant exercise price per share $ 0.70   $ 0.70  
Warrant Liability [Member] | Minimum [Member]        
Warrant exercise price per share   $ 0.25    
Warrant Liability [Member] | Maximum [Member]        
Warrant exercise price per share   $ 22.50    
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.22.0.1
SCHEDULE OF PREFERRED STOCK REDEMPTION LIABILITY (Details)
Jan. 31, 2022
Measurement Input, Exercise Price [Member]  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Measurement input percentage 0.25
Measurement Input, Share Price [Member]  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Measurement input percentage 0.136
Measurement Input, Price Volatility [Member]  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Measurement input percentage 105
Measurement Input, Risk Free Interest Rate [Member]  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Measurement input percentage 1.00
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.22.0.1
TEMPORARY EQUITY (Details Narrative)
 1 Months Ended 3 Months Ended
Jan. 31, 2022
USD ($)
Integer
$ / shares
shares
Jan. 31, 2022
USD ($)
$ / shares
Jan. 31, 2021
USD ($)
Oct. 31, 2021
USD ($)
Subsidiary, Sale of Stock [Line Items]        
Stated value     $ 8,550,000  
Issue discount 5.00%      
Proceeds from issuance or estimated offering $ 4,312,000      
Number of votes per share | Integer 30,000      
Temporary equity stock stated value accumulated dividends   105.00%    
Temporary equity stock stated value accumulated dividends on extension   110.00%    
Payments for proceeds from escrow offering $ 4,750,000      
Escrow deposit 500,000 $ 500,000    
Temporary equity stock stated value accumulated dividends on extension   105.00%    
Temporary equity, carrying amount, attributable to parent 4,225,000 $ 4,225,000  
Preferred stock, redemption amount $ 87,000 $ 87,000    
Series D Preferred Stock [Member]        
Subsidiary, Sale of Stock [Line Items]        
Preferred stock conversion price | $ / shares $ 0.25 $ 0.25    
Private Placement [Member] | Institutional Investors [Member] | Series D Preferred Stock [Member]        
Subsidiary, Sale of Stock [Line Items]        
Shares issued | shares 1,000,000      
Stated value $ 5,000,000      
Share purchase price | $ / shares $ 4.75 $ 4.75    
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.22.0.1
SUMMARY OF STOCKHOLDERS EQUITY (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Beginning balance, value $ 38,888 $ 30,180
Stock-based compensation 26 236
Advaxis public offerings, net of offering costs   8,550
Warrant exercises   2,586
Net Loss (365) (3,977)
Ending balance, value 38,549 37,575
Preferred Stock [Member]    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Beginning balance, value
Beginning balance, shares
Stock-based compensation
Stock-based compensation, shares
Advaxis public offerings, net of offering costs  
Advaxis public offerings, net of offering costs, shares  
Warrant exercises  
Net Loss
Ending balance, value
Ending balance, shares
Common Stock [Member]    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Beginning balance, value $ 146 $ 78
Beginning balance, shares 145,638,459 78,074,023
Stock-based compensation
Stock-based compensation, shares  
Advaxis public offerings, net of offering costs   $ 31
Advaxis public offerings, net of offering costs, shares   30,666,665
Warrant exercises   $ 7
Warrant exercises, shares   7,390,000
Net Loss
Ending balance, value $ 146 $ 116
Ending balance, shares 145,638,459 116,130,688
Additional Paid-in Capital [Member]    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Beginning balance, value $ 467,342 $ 440,840
Stock-based compensation 26 236
Advaxis public offerings, net of offering costs   8,519
Warrant exercises   2,579
Net Loss
Ending balance, value 467,368 452,174
Retained Earnings [Member]    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Beginning balance, value (428,600) (410,738)
Stock-based compensation
Advaxis public offerings, net of offering costs  
Warrant exercises  
Net Loss (365) (3,977)
Ending balance, value $ (428,965) $ (414,715)
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.22.0.1
SUMMARY OF SHARE BASED COMPENSATION EXPENSE (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Share-based compensation expense $ 26 $ 236
Research and Development Expense [Member]    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Share-based compensation expense 13 57
General and Administrative Expense [Member]    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Share-based compensation expense $ 13 $ 179
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.22.0.1
SUMMARY OF CHANGES IN STOCK OPTION PLAN (Details)
$ / shares in Units, $ in Thousands
 3 Months Ended
Jan. 31, 2022
USD ($)
$ / shares
shares
Share-based Payment Arrangement [Abstract]  
Shares Outstanding, Beginning Balance | shares 893,946
Weighted Average Exercise Price, Outstanding, Beginning | $ / shares $ 19.32
Weighted Average Remaining Contractual Life In Years, Beginning 7 years 9 months 18 days
Aggregate Intrinsic Value, Beginning | $ $ 27
Shares, Cancelled or Expired | shares (5,888)
Weighted Average Exercise Price, Cancelled or Expired | $ / shares $ 277.50
Shares, Outstanding, Ending Balance | shares 888,058
Weighted Average Exercise Price, Outstanding, Ending | $ / shares $ 17.61
Weighted Average Remaining Contractual Life In Years, Ending Balance 7 years 6 months 18 days
Aggregate Intrinsic Value, Ending | $
Shares, Vested and Exercisable | shares 484,641
Weighted Average Exercise Price, Vested and Exercisable | $ / shares $ 31.80
Weighted Average Remaining Contractual Life In Years, Vested and Exercisable 6 years 10 months 20 days
Aggregate Intrinsic Value, Vested and Exercisable | $
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.22.0.1
SUMMARY OF OUTSTANDING AND EXERCISABLE OPTIONS (Details)
 3 Months Ended
Jan. 31, 2022
$ / shares
shares
Exercise Price Range One [Member]  
Offsetting Assets [Line Items]  
Exercise Price Range, lower limit $ 0.30
Exercise Price Range, upper limit $ 1.00
Number Outstanding, Options Outstanding | shares 672,500
Weighted Average Remaining Contractual, Options Outstanding 8 years 3 months 14 days
Weighted Average Exercise Price, Options Outstanding $ 0.54
Number Outstanding, Options Exercisable | shares 270,000
Weighted Average Remaining Contractual Term Exercisable, Options Exercisable 8 years 2 months 12 days
Weighted Average Exercise Price, Options Exercisable $ 0.50
Exercise Price Range Two [Member]  
Offsetting Assets [Line Items]  
Exercise Price Range, lower limit 1.01
Exercise Price Range, upper limit $ 10.00
Number Outstanding, Options Outstanding | shares 55,379
Weighted Average Remaining Contractual, Options Outstanding 6 years 9 months 18 days
Weighted Average Exercise Price, Options Outstanding $ 7.47
Number Outstanding, Options Exercisable | shares 54,462
Weighted Average Remaining Contractual Term Exercisable, Options Exercisable 6 years 9 months 14 days
Weighted Average Exercise Price, Options Exercisable $ 7.56
Exercise Price Range Three [Member]  
Offsetting Assets [Line Items]  
Exercise Price Range, lower limit 10.01
Exercise Price Range, upper limit $ 100.00
Number Outstanding, Options Outstanding | shares 90,432
Weighted Average Remaining Contractual, Options Outstanding 5 years 11 months 19 days
Weighted Average Exercise Price, Options Outstanding $ 29.02
Number Outstanding, Options Exercisable | shares 90,432
Weighted Average Remaining Contractual Term Exercisable, Options Exercisable 5 years 11 months 19 days
Weighted Average Exercise Price, Options Exercisable $ 29.02
Exercise Price Range Four [Member]  
Offsetting Assets [Line Items]  
Exercise Price Range, lower limit 100.01
Exercise Price Range, upper limit $ 258.30
Number Outstanding, Options Outstanding | shares 69,747
Weighted Average Remaining Contractual, Options Outstanding 3 years 25 days
Weighted Average Exercise Price, Options Outstanding $ 175.51
Number Outstanding, Options Exercisable | shares 69,747
Weighted Average Remaining Contractual Term Exercisable, Options Exercisable 3 years 25 days
Weighted Average Exercise Price, Options Exercisable $ 175.51
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.22.0.1
SHARE BASED COMPENSATION (Details Narrative)
$ in Millions
 3 Months Ended
Jan. 31, 2022
USD ($)
shares
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]  
Unrecognized compensation cost related to outstanding stock options | $ $ 125,000.0
Unrecognized compensation cost related to non-vested remaining weighted average vesting period 1 year 4 months 17 days
Chief Executive Officer [Member]  
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]  
Share-based compensation arrangement by share-based payment award, options, nonvested, number of shares | shares 73,777
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.22.0.1
LICENSING AGREEMENTS (Details Narrative) - USD ($)
 3 Months Ended
Apr. 30, 2020
Sep. 04, 2018
Jan. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Milestone achievement, description     the Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement
Development, License and Supply Agreement [Member] | OS Therapies [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue $ 25,000    
Funding milestone payment   $ 2,337,500  
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.22.0.1
SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) - USD ($)
$ / shares in Units, $ in Thousands
Jan. 31, 2022
Oct. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total Financial Assets at Fair Value $ 17,154 $ 17,153
Preferred stock redemption liability 87
Common stock warrant liability, warrants exercisable at $0.30 through September 2024 $ 1,127 $ 4,929
Warrant exercise price per share $ 0.25 $ 0.30
Total financial liabilities at fair value $ 1,214 $ 4,929
Private Placement [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Warrant exercise price per share $ 0.70 $ 0.70
Common stock warrant liability, warrants exercisable at $0.70 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants) $ 1,120 $ 4,902
Through September Two Thousand Twenty Four [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Common stock warrant liability, warrants exercisable at $0.30 through September 2024 7 27
Money Market Funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents (money market funds) 17,154 17,153
Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total Financial Assets at Fair Value 17,154 17,153
Preferred stock redemption liability  
Total financial liabilities at fair value
Fair Value, Inputs, Level 1 [Member] | Private Placement [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Common stock warrant liability, warrants exercisable at $0.70 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)
Fair Value, Inputs, Level 1 [Member] | Through September Two Thousand Twenty Four [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Common stock warrant liability, warrants exercisable at $0.30 through September 2024
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents (money market funds) 17,154 17,153
Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total Financial Assets at Fair Value
Preferred stock redemption liability  
Total financial liabilities at fair value
Fair Value, Inputs, Level 2 [Member] | Private Placement [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Common stock warrant liability, warrants exercisable at $0.70 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)
Fair Value, Inputs, Level 2 [Member] | Through September Two Thousand Twenty Four [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Common stock warrant liability, warrants exercisable at $0.30 through September 2024
Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents (money market funds)
Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total Financial Assets at Fair Value
Preferred stock redemption liability 87  
Total financial liabilities at fair value 1,214 4,929
Fair Value, Inputs, Level 3 [Member] | Private Placement [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Common stock warrant liability, warrants exercisable at $0.70 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants) 1,120 4,902
Fair Value, Inputs, Level 3 [Member] | Through September Two Thousand Twenty Four [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Common stock warrant liability, warrants exercisable at $0.30 through September 2024 7 27
Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents (money market funds)
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.22.0.1
SCHEDULE OF FAIR VALUE MEASURING UNOBSERVABLE INPUTS (Details)
$ in Thousands
 3 Months Ended
Jan. 31, 2022
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Fair Value, Measurement , Beginning Balance $ 4,929
Fair Value, Measurement, Additions 87
Fair Value, Measurement, Change in fair value (3,802)
Fair Value, Measurement , Ending Balance 1,214
Preferred Stock Redemption Liability [Member]  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Fair Value, Measurement , Beginning Balance
Fair Value, Measurement, Additions 87
Fair Value, Measurement, Change in fair value
Fair Value, Measurement , Ending Balance 87
Warrant Liability [Member]  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Fair Value, Measurement , Beginning Balance 4,929
Fair Value, Measurement, Additions
Fair Value, Measurement, Change in fair value (3,802)
Fair Value, Measurement , Ending Balance $ 1,127
XML 68 form10-q_htm.xml IDEA: XBRL DOCUMENT 0001100397 2021-11-01 2022-01-31 0001100397 2022-03-16 0001100397 2022-01-31 0001100397 2021-10-31 0001100397 ADXS:SeriesDConvertibleRedeemablePreferredStockMember 2022-01-31 0001100397 ADXS:SeriesDConvertibleRedeemablePreferredStockMember 2021-10-31 0001100397 2020-11-01 2021-01-31 0001100397 2020-10-31 0001100397 2021-01-31 0001100397 ADXS:SeriesDPreferredStockRedemptionMember 2022-01-31 0001100397 us-gaap:WarrantMember 2021-11-01 2022-01-31 0001100397 us-gaap:WarrantMember 2020-11-01 2021-01-31 0001100397 ADXS:SeriesDConvertableRedeemablePreferredStockMember 2021-11-01 2022-01-31 0001100397 ADXS:SeriesDConvertableRedeemablePreferredStockMember 2020-11-01 2021-01-31 0001100397 ADXS:StockOptionsMember 2021-11-01 2022-01-31 0001100397 ADXS:StockOptionsMember 2020-11-01 2021-01-31 0001100397 ADXS:RestrictedStockUnitsMember 2021-11-01 2022-01-31 0001100397 ADXS:RestrictedStockUnitsMember 2020-11-01 2021-01-31 0001100397 us-gaap:GeneralAndAdministrativeExpenseMember 2021-11-01 2022-01-31 0001100397 us-gaap:GeneralAndAdministrativeExpenseMember 2020-11-01 2021-01-31 0001100397 2021-03-01 2021-03-26 0001100397 2021-03-26 0001100397 2021-03-01 2021-03-25 0001100397 2021-03-25 0001100397 us-gaap:WarrantMember 2022-01-31 0001100397 us-gaap:WarrantMember 2021-10-31 0001100397 srt:MinimumMember us-gaap:WarrantMember 2022-01-31 0001100397 srt:MaximumMember us-gaap:WarrantMember 2022-01-31 0001100397 ADXS:EquityWarrantsMember 2021-10-31 0001100397 ADXS:EquityWarrantsMember 2022-01-31 0001100397 ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2022-01-31 0001100397 ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2021-10-31 0001100397 us-gaap:IPOMember 2022-01-31 0001100397 srt:MinimumMember 2021-06-03 0001100397 srt:MaximumMember 2021-06-03 0001100397 srt:MaximumMember ADXS:WarrantLiabilityMember 2021-01-31 0001100397 srt:MinimumMember ADXS:WarrantLiabilityMember 2021-01-31 0001100397 us-gaap:PrivatePlacementMember 2021-11-01 2022-01-31 0001100397 ADXS:ExercisePriceRangeOneMember 2021-10-31 0001100397 ADXS:ExercisePriceRangeOneMember 2022-01-31 0001100397 ADXS:ExercisePriceRangeOneMember 2020-11-01 2021-10-31 0001100397 ADXS:ExercisePriceRangeOneMember 2021-11-01 2022-01-31 0001100397 ADXS:ExercisePriceRangeTwoMember 2021-10-31 0001100397 ADXS:ExercisePriceRangeTwoMember 2022-01-31 0001100397 ADXS:ExercisePriceRangeTwoMember 2020-11-01 2021-10-31 0001100397 ADXS:ExercisePriceRangeTwoMember 2021-11-01 2022-01-31 0001100397 ADXS:ExercisePriceRangeThreeMember 2021-10-31 0001100397 ADXS:ExercisePriceRangeThreeMember 2022-01-31 0001100397 ADXS:ExercisePriceRangeThreeMember 2020-11-01 2021-10-31 0001100397 ADXS:ExercisePriceRangeThreeMember 2021-11-01 2022-01-31 0001100397 ADXS:ExercisePriceRangeFourMember 2021-10-31 0001100397 ADXS:ExercisePriceRangeFourMember 2022-01-31 0001100397 ADXS:ExercisePriceRangeFourMember 2020-11-01 2021-10-31 0001100397 ADXS:ExercisePriceRangeFourMember 2021-11-01 2022-01-31 0001100397 ADXS:ExercisePriceRangeFiveMember 2021-10-31 0001100397 ADXS:ExercisePriceRangeFiveMember 2022-01-31 0001100397 ADXS:ExercisePriceRangeFiveMember 2020-11-01 2021-10-31 0001100397 ADXS:ExercisePriceRangeFiveMember 2021-11-01 2022-01-31 0001100397 ADXS:ExercisePriceRangeSixMember 2021-10-31 0001100397 ADXS:ExercisePriceRangeSixMember 2022-01-31 0001100397 ADXS:ExercisePriceRangeSixMember 2020-11-01 2021-10-31 0001100397 ADXS:ExercisePriceRangeSixMember 2021-11-01 2022-01-31 0001100397 us-gaap:MeasurementInputExpectedTermMember ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2022-01-31 0001100397 us-gaap:MeasurementInputExpectedTermMember ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2021-10-31 0001100397 us-gaap:MeasurementInputPriceVolatilityMember ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2022-01-31 0001100397 us-gaap:MeasurementInputPriceVolatilityMember ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2021-10-31 0001100397 us-gaap:MeasurementInputRiskFreeInterestRateMember ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2022-01-31 0001100397 us-gaap:MeasurementInputRiskFreeInterestRateMember ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2021-10-31 0001100397 ADXS:WarrantLiabilityMember 2022-01-31 0001100397 ADXS:WarrantLiabilityMember 2021-10-31 0001100397 us-gaap:MeasurementInputExpectedTermMember ADXS:WarrantLiabilityMember 2022-01-31 0001100397 us-gaap:MeasurementInputExpectedTermMember ADXS:WarrantLiabilityMember 2021-10-31 0001100397 us-gaap:MeasurementInputPriceVolatilityMember ADXS:WarrantLiabilityMember 2022-01-31 0001100397 us-gaap:MeasurementInputPriceVolatilityMember ADXS:WarrantLiabilityMember 2021-10-31 0001100397 us-gaap:MeasurementInputRiskFreeInterestRateMember ADXS:WarrantLiabilityMember 2022-01-31 0001100397 us-gaap:MeasurementInputRiskFreeInterestRateMember ADXS:WarrantLiabilityMember 2021-10-31 0001100397 ADXS:InstitutionalInvestorsMember us-gaap:SeriesDPreferredStockMember us-gaap:PrivatePlacementMember 2022-01-01 2022-01-31 0001100397 ADXS:InstitutionalInvestorsMember us-gaap:SeriesDPreferredStockMember us-gaap:PrivatePlacementMember 2022-01-31 0001100397 2022-01-01 2022-01-31 0001100397 us-gaap:SeriesDPreferredStockMember 2022-01-31 0001100397 us-gaap:MeasurementInputExercisePriceMember 2022-01-31 0001100397 us-gaap:MeasurementInputSharePriceMember 2022-01-31 0001100397 us-gaap:MeasurementInputPriceVolatilityMember 2022-01-31 0001100397 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-01-31 0001100397 us-gaap:PreferredStockMember 2020-10-31 0001100397 us-gaap:CommonStockMember 2020-10-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2020-10-31 0001100397 us-gaap:RetainedEarningsMember 2020-10-31 0001100397 us-gaap:PreferredStockMember 2020-11-01 2021-01-31 0001100397 us-gaap:CommonStockMember 2020-11-01 2021-01-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2020-11-01 2021-01-31 0001100397 us-gaap:RetainedEarningsMember 2020-11-01 2021-01-31 0001100397 us-gaap:PreferredStockMember 2021-01-31 0001100397 us-gaap:CommonStockMember 2021-01-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2021-01-31 0001100397 us-gaap:RetainedEarningsMember 2021-01-31 0001100397 us-gaap:PreferredStockMember 2021-10-31 0001100397 us-gaap:CommonStockMember 2021-10-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2021-10-31 0001100397 us-gaap:RetainedEarningsMember 2021-10-31 0001100397 us-gaap:PreferredStockMember 2021-11-01 2022-01-31 0001100397 us-gaap:CommonStockMember 2021-11-01 2022-01-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2021-11-01 2022-01-31 0001100397 us-gaap:RetainedEarningsMember 2021-11-01 2022-01-31 0001100397 us-gaap:PreferredStockMember 2022-01-31 0001100397 us-gaap:CommonStockMember 2022-01-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2022-01-31 0001100397 us-gaap:RetainedEarningsMember 2022-01-31 0001100397 us-gaap:ResearchAndDevelopmentExpenseMember 2021-11-01 2022-01-31 0001100397 us-gaap:ResearchAndDevelopmentExpenseMember 2020-11-01 2021-01-31 0001100397 srt:ChiefExecutiveOfficerMember 2022-01-31 0001100397 ADXS:OSTherapiesMember ADXS:DevelopmentLicenseAndSupplyAgreementMember 2020-04-29 2020-04-30 0001100397 ADXS:OSTherapiesMember ADXS:DevelopmentLicenseAndSupplyAgreementMember 2018-09-03 2018-09-04 0001100397 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2022-01-31 0001100397 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2022-01-31 0001100397 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2022-01-31 0001100397 us-gaap:MoneyMarketFundsMember 2022-01-31 0001100397 us-gaap:FairValueInputsLevel1Member 2022-01-31 0001100397 us-gaap:FairValueInputsLevel2Member 2022-01-31 0001100397 us-gaap:FairValueInputsLevel3Member 2022-01-31 0001100397 ADXS:ThroughSeptemberTwoThousandTwentyFourMember us-gaap:FairValueInputsLevel1Member 2022-01-31 0001100397 ADXS:ThroughSeptemberTwoThousandTwentyFourMember us-gaap:FairValueInputsLevel2Member 2022-01-31 0001100397 ADXS:ThroughSeptemberTwoThousandTwentyFourMember us-gaap:FairValueInputsLevel3Member 2022-01-31 0001100397 ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2022-01-31 0001100397 us-gaap:FairValueInputsLevel1Member us-gaap:PrivatePlacementMember 2022-01-31 0001100397 us-gaap:FairValueInputsLevel2Member us-gaap:PrivatePlacementMember 2022-01-31 0001100397 us-gaap:FairValueInputsLevel3Member us-gaap:PrivatePlacementMember 2022-01-31 0001100397 us-gaap:PrivatePlacementMember 2022-01-31 0001100397 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2021-10-31 0001100397 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2021-10-31 0001100397 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2021-10-31 0001100397 us-gaap:MoneyMarketFundsMember 2021-10-31 0001100397 us-gaap:FairValueInputsLevel1Member 2021-10-31 0001100397 us-gaap:FairValueInputsLevel2Member 2021-10-31 0001100397 us-gaap:FairValueInputsLevel3Member 2021-10-31 0001100397 ADXS:ThroughSeptemberTwoThousandTwentyFourMember us-gaap:FairValueInputsLevel1Member 2021-10-31 0001100397 ADXS:ThroughSeptemberTwoThousandTwentyFourMember us-gaap:FairValueInputsLevel2Member 2021-10-31 0001100397 ADXS:ThroughSeptemberTwoThousandTwentyFourMember us-gaap:FairValueInputsLevel3Member 2021-10-31 0001100397 ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2021-10-31 0001100397 us-gaap:FairValueInputsLevel1Member us-gaap:PrivatePlacementMember 2021-10-31 0001100397 us-gaap:FairValueInputsLevel2Member us-gaap:PrivatePlacementMember 2021-10-31 0001100397 us-gaap:FairValueInputsLevel3Member us-gaap:PrivatePlacementMember 2021-10-31 0001100397 us-gaap:PrivatePlacementMember 2021-10-31 0001100397 ADXS:PreferredStockRedemptionLiabilityMember 2021-10-31 0001100397 ADXS:WarrantLiabilityMember 2021-10-31 0001100397 ADXS:PreferredStockRedemptionLiabilityMember 2021-11-01 2022-01-31 0001100397 ADXS:WarrantLiabilityMember 2021-11-01 2022-01-31 0001100397 ADXS:PreferredStockRedemptionLiabilityMember 2022-01-31 0001100397 ADXS:WarrantLiabilityMember 2022-01-31 iso4217:USD shares iso4217:USD shares pure ADXS:Integer 0001100397 false --10-31 2022 Q1 2025-11-30 10-Q true 2022-01-31 false 001-36138 ADVAXIS, INC. DE 02-0563870 9 Deer Park Drive Suite K-1 Monmouth Junction NJ 08852 (609) 452-9813 Common Stock ADXS Yes Yes Non-accelerated Filer true false false 145638459 36480000 41614000 5250000 1386000 1643000 43116000 43257000 100000 118000 3238000 3354000 33000 40000 11000 11000 46498000 46780000 345000 87000 2131000 2836000 29000 28000 87000 1127000 4929000 3719000 7880000 5000 12000 3724000 7892000 0.001 0.001 1000000 1000000 5250000 4225000 0.001 0.001 4000000 5000000 0 0 0 0 0.001 0.001 170000000 170000000 145638459 145638459 145638459 145638459 146000 146000 467368000 467342000 -428965000 -428600000 38549000 38888000 46498000 46780000 1615000 1654000 2570000 2510000 3008000 4164000 5578000 -4164000 -3963000 1000 1000 3802000 -27000 -4000 12000 -365000 -3977000 -365000 -3977000 -0.00 -0.05 145638459 83943982 -365000 -3977000 26000 236000 3802000 -27000 -12000 104000 18000 192000 70000 67000 7000 195000 -257000 -463000 -447000 394000 -165000 -6000 -230000 -4138000 -2786000 58000 210000 -58000 -210000 4312000 8550000 2586000 4312000 11136000 116000 8140000 41614000 25178000 41730000 33318000 36480000 33318000 5250000 41730000 33318000 <p id="xdx_800_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zyXm2NCRbgI6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span id="xdx_824_zJAu1COA74Fa">NATURE OF OPERATIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advaxis, Inc. (“Advaxis” or the “Company”) is a clinical-stage biotechnology company focused on the development and commercialization of proprietary <i>Listeria monocytogenes</i> (“<i>Lm</i>”)-based antigen delivery products. The Company is using its <i>Lm </i>platform directed against tumor-specific targets in order to engage the patient’s immune system to destroy tumor cells. Through a license from the University of Pennsylvania, Advaxis has exclusive access to this proprietary formulation of attenuated <i>Lm</i> called <i>Lm</i> Technology<sup>TM</sup>. Advaxis’ proprietary approach is designed to deploy a unique mechanism of action that redirects the immune system to attack cancer in three distinct ways:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alerting and training the immune system by activating multiple pathways in Antigen-Presenting Cells (“APCs”) with the equivalent of multiple adjuvants;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attacking the tumor by generating a strong, cancer-specific T cell response; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Breaking down tumor protection through suppression of the protective cells in the tumor microenvironment (“TME”) that shields the tumor from the immune system. This enables the activated T cells to begin working to attack the tumor cells.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advaxis’ proprietary <i>Lm</i> platform technology has demonstrated clinical activity in several of its programs and has been dosed in over 470 patients across multiple clinical trials and in various tumor types. The Company believes that <i>Lm</i> Technology immunotherapies can complement and address significant unmet needs in the current oncology treatment landscape. Specifically, its product candidates have the potential to work synergistically with other immunotherapies, including checkpoint inhibitors, while having a generally well-tolerated safety profile.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity and Capital Resources</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity and Management’s Plans</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similar to other development stage biotechnology companies, the Company’s products that are being developed have not generated significant revenue. As a result, the Company has suffered recurring losses and requires significant cash resources to execute its business plans. These losses are expected to continue for the foreseeable future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of January 31, 2022, the Company had approximately $<span id="xdx_909_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20220131_zm8h4EiuGup1" title="Cash and cash equivalents, at carrying value">36.5</span> million in cash and cash equivalents. Although the Company expects to have sufficient capital to fund its obligations, as they become due, in the ordinary course of business until at least one year from the issuance of these consolidated financial statements, the actual amount of cash that it will need to operate is subject to many factors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes it will need to raise additional capital in order to continue to execute its business plan in the future. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to further scale back its operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 36500000 <p id="xdx_80D_eus-gaap--SignificantAccountingPoliciesTextBlock_zjhL97sK2Hg1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. <span id="xdx_826_z9NkMKhOXxz">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zSQ0WYRxI812" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zWkFpzYJd4m2">Basis of Presentation/Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) with respect to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and the accompanying unaudited interim condensed consolidated balance sheet as of January 31, 2022 has been derived from the Company’s October 31, 2021 audited financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements furnished include all adjustments (consisting of normal recurring accruals) necessary for a fair statement of the results for the interim periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating results for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates include the timelines associated with revenue recognition on upfront payments received, fair value and recoverability of the carrying value of property and equipment and intangible assets, fair value of warrant liability, grant date fair value of options, deferred tax assets and any related valuation allowance and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These unaudited interim condensed consolidated financial statements should be read in conjunction with the financial statements of the Company as of and for the fiscal year ended October 31, 2021 and notes thereto contained in the Company’s 2021 Annual Report on Form 10-K, as filed with the SEC on February 14, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_84E_eus-gaap--ConsolidationPolicyTextBlock_zJ7AQZ43jxTf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_z9Fz7IxZYb74">Principles of Consolidation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_843_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_z63MIAGZM1Kh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zOTE0TZGRdD1">Restricted Cash</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 31, 2022, the Company transferred $<span id="xdx_90E_eus-gaap--RestrictedCash_iI_pn3n3_c20220131__us-gaap--StatementClassOfStockAxis__custom--SeriesDPreferredStockRedemptionMember_zfPvbKAKHfzg" title="Restricted cash">5,250</span>,000 into an escrow fund to fund a potential Series D preferred stock redemption.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_846_ecustom--ConvertablePreferredStockPoliyTextBlock_zKVRgaIVqhl3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_z391TVFrYJgl">Convertible Preferred Stock</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control, as temporary equity (“mezzanine”) until such time as the conditions are removed or lapse.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_84E_eus-gaap--DerivativesReportingOfDerivativeActivity_zKwOl5IU2Q52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zw6p2AnICXKb">Derivative Financial Instruments</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For share-based derivative financial instruments, the Company used the Monte Carlo simulation model, the Black Scholes model and a binomial model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the consolidated balance sheet as current or non-current based on whether or not net-cash settlement of the instrument could be required within 12 months after the balance sheet date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zoBC6qc33L8f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zu6VrHJeTH9e">Net Income (Loss) per Share</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net income or loss per common share is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, restricted stock units and other potential common stock outstanding during the period. In the case of a net loss, the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table below sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share:</span></p> <p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zwQduRSOinga" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zDgVR58YTxC3" style="display: none">SCHEDULE OF ANTI -DILUTED SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">As of January 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20211101__20220131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zh2sNm9a0K9h" style="width: 16%; text-align: right" title="Total">30,225,397</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20201101__20210131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zk6H4g0Bv5v4" style="width: 16%; text-align: right" title="Total">8,014,220</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series D convertible redeemable preferred stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20211101__20220131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesDConvertableRedeemablePreferredStockMember_zHXLsg5XqDKi" style="text-align: right" title="Total">20,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20201101__20210131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesDConvertableRedeemablePreferredStockMember_zCr1aG5uUPu" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0330">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Stock options</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20211101__20220131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zaH47zNHreAc" style="text-align: right" title="Total">888,058</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20201101__20210131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zYoIZEwhpLI2" style="text-align: right" title="Total">1,047,377</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Restricted stock units</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20211101__20220131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsMember_zOMpXBOfDp8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0336">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20201101__20210131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsMember_zly2hU3qU1Qk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">5,556</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20211101__20220131_zSgXIZirSci7" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">51,113,455</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20201101__20210131_zM8xAyO51RI2" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">9,067,153</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zjdokjYa6Uv7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z3YzU8GwobPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zLVAUpvuERD3">Recent Accounting Standards</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, the FASB issued ASU 2019-12, Simplification of Income Taxes (Topic 740) Income Taxes (“ASU 2019-12”). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for public companies for annual periods beginning after December 15, 2020, including interim periods within those fiscal years. The Company adopted this standard effective November 1, 2021 and it is not material to the financial results of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain convertible instruments, amends guidance on derivative scope exceptions for contracts in an entity’s own equity, and modifies the guidance on diluted earnings per share (“EPS”) calculations as a result of these changes. The standard will be effective for the Company for fiscal years beginning after December 15, 2023 and can be applied on either a fully retrospective or modified retrospective basis. Early adoption is permitted for fiscal years beginning after December 15, 2020. The Company adopted this standard effective November 1, 2021 and it is not material to the financial results of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed consolidated financial statements.</span></p> <p id="xdx_857_z5ndTY9AgZT" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zSQ0WYRxI812" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zWkFpzYJd4m2">Basis of Presentation/Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) with respect to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and the accompanying unaudited interim condensed consolidated balance sheet as of January 31, 2022 has been derived from the Company’s October 31, 2021 audited financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements furnished include all adjustments (consisting of normal recurring accruals) necessary for a fair statement of the results for the interim periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating results for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates include the timelines associated with revenue recognition on upfront payments received, fair value and recoverability of the carrying value of property and equipment and intangible assets, fair value of warrant liability, grant date fair value of options, deferred tax assets and any related valuation allowance and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These unaudited interim condensed consolidated financial statements should be read in conjunction with the financial statements of the Company as of and for the fiscal year ended October 31, 2021 and notes thereto contained in the Company’s 2021 Annual Report on Form 10-K, as filed with the SEC on February 14, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_84E_eus-gaap--ConsolidationPolicyTextBlock_zJ7AQZ43jxTf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_z9Fz7IxZYb74">Principles of Consolidation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_843_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_z63MIAGZM1Kh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zOTE0TZGRdD1">Restricted Cash</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 31, 2022, the Company transferred $<span id="xdx_90E_eus-gaap--RestrictedCash_iI_pn3n3_c20220131__us-gaap--StatementClassOfStockAxis__custom--SeriesDPreferredStockRedemptionMember_zfPvbKAKHfzg" title="Restricted cash">5,250</span>,000 into an escrow fund to fund a potential Series D preferred stock redemption.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> 5250000 <p id="xdx_846_ecustom--ConvertablePreferredStockPoliyTextBlock_zKVRgaIVqhl3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_z391TVFrYJgl">Convertible Preferred Stock</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control, as temporary equity (“mezzanine”) until such time as the conditions are removed or lapse.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_84E_eus-gaap--DerivativesReportingOfDerivativeActivity_zKwOl5IU2Q52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zw6p2AnICXKb">Derivative Financial Instruments</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For share-based derivative financial instruments, the Company used the Monte Carlo simulation model, the Black Scholes model and a binomial model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the consolidated balance sheet as current or non-current based on whether or not net-cash settlement of the instrument could be required within 12 months after the balance sheet date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zoBC6qc33L8f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zu6VrHJeTH9e">Net Income (Loss) per Share</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net income or loss per common share is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, restricted stock units and other potential common stock outstanding during the period. In the case of a net loss, the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table below sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share:</span></p> <p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zwQduRSOinga" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zDgVR58YTxC3" style="display: none">SCHEDULE OF ANTI -DILUTED SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">As of January 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20211101__20220131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zh2sNm9a0K9h" style="width: 16%; text-align: right" title="Total">30,225,397</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20201101__20210131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zk6H4g0Bv5v4" style="width: 16%; text-align: right" title="Total">8,014,220</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series D convertible redeemable preferred stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20211101__20220131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesDConvertableRedeemablePreferredStockMember_zHXLsg5XqDKi" style="text-align: right" title="Total">20,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20201101__20210131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesDConvertableRedeemablePreferredStockMember_zCr1aG5uUPu" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0330">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Stock options</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20211101__20220131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zaH47zNHreAc" style="text-align: right" title="Total">888,058</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20201101__20210131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zYoIZEwhpLI2" style="text-align: right" title="Total">1,047,377</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Restricted stock units</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20211101__20220131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsMember_zOMpXBOfDp8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0336">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20201101__20210131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsMember_zly2hU3qU1Qk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">5,556</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20211101__20220131_zSgXIZirSci7" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">51,113,455</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20201101__20210131_zM8xAyO51RI2" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">9,067,153</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zjdokjYa6Uv7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zwQduRSOinga" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zDgVR58YTxC3" style="display: none">SCHEDULE OF ANTI -DILUTED SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">As of January 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20211101__20220131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zh2sNm9a0K9h" style="width: 16%; text-align: right" title="Total">30,225,397</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20201101__20210131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zk6H4g0Bv5v4" style="width: 16%; text-align: right" title="Total">8,014,220</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series D convertible redeemable preferred stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20211101__20220131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesDConvertableRedeemablePreferredStockMember_zHXLsg5XqDKi" style="text-align: right" title="Total">20,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20201101__20210131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesDConvertableRedeemablePreferredStockMember_zCr1aG5uUPu" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0330">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Stock options</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20211101__20220131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zaH47zNHreAc" style="text-align: right" title="Total">888,058</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20201101__20210131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zYoIZEwhpLI2" style="text-align: right" title="Total">1,047,377</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Restricted stock units</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20211101__20220131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsMember_zOMpXBOfDp8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0336">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20201101__20210131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsMember_zly2hU3qU1Qk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">5,556</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20211101__20220131_zSgXIZirSci7" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">51,113,455</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20201101__20210131_zM8xAyO51RI2" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">9,067,153</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 30225397 8014220 20000000 888058 1047377 5556 51113455 9067153 <p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z3YzU8GwobPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zLVAUpvuERD3">Recent Accounting Standards</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, the FASB issued ASU 2019-12, Simplification of Income Taxes (Topic 740) Income Taxes (“ASU 2019-12”). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for public companies for annual periods beginning after December 15, 2020, including interim periods within those fiscal years. The Company adopted this standard effective November 1, 2021 and it is not material to the financial results of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain convertible instruments, amends guidance on derivative scope exceptions for contracts in an entity’s own equity, and modifies the guidance on diluted earnings per share (“EPS”) calculations as a result of these changes. The standard will be effective for the Company for fiscal years beginning after December 15, 2023 and can be applied on either a fully retrospective or modified retrospective basis. Early adoption is permitted for fiscal years beginning after December 15, 2020. The Company adopted this standard effective November 1, 2021 and it is not material to the financial results of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed consolidated financial statements.</span></p> <p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zaKkrcO0DUbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3. <span id="xdx_822_zINcBeAfCPb9">PROPERTY AND EQUIPMENT</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--PropertyPlantAndEquipmentTextBlock_zCEyz3TW3qJk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net consisted of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zIJgY1rVc6id" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" id="xdx_492_20220131_zPydmVVA55qf" style="border-bottom: Black 1.5pt solid; text-align: center">January 31, 2022</td><td> </td><td> </td> <td colspan="2" id="xdx_49A_20211031_zOiJwked7Anc" style="border-bottom: Black 1.5pt solid; text-align: center">October 31, 2021</td><td> </td></tr> <tr id="xdx_408_eus-gaap--MachineryAndEquipmentGross_iI_pn3n3_maPPAEGzkmD_z5SdAeYCVRJh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Laboratory equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">179</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">179</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn3n3_maPPAEGzkmD_z7D53T4uhOs3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Computer equipment</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">241</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">241</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3n3_mtPPAEGzkmD_maPPAENzKAl_ztfXbKlp58B4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total property and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">420</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">420</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzKAl_z3GyK5EWRjji" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accumulated depreciation and amortization</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(320</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(302</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzKAl_z8uzoTEhJ3sg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net property and equipment</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">100</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">118</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AA_zgPOPUObqY3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation expense for the three months ended January 31, 2022 and 2021 was approximately $<span id="xdx_90B_eus-gaap--Depreciation_pn3n3_c20211101__20220131_zF0Obi8U3Uhg" title="Depreciation expense">18</span>,000 and $<span id="xdx_904_eus-gaap--Depreciation_pn3n3_c20201101__20210131_znO5L4F6Tw7j" title="Depreciation expense">192</span>,000, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_89B_eus-gaap--PropertyPlantAndEquipmentTextBlock_zCEyz3TW3qJk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net consisted of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zIJgY1rVc6id" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" id="xdx_492_20220131_zPydmVVA55qf" style="border-bottom: Black 1.5pt solid; text-align: center">January 31, 2022</td><td> </td><td> </td> <td colspan="2" id="xdx_49A_20211031_zOiJwked7Anc" style="border-bottom: Black 1.5pt solid; text-align: center">October 31, 2021</td><td> </td></tr> <tr id="xdx_408_eus-gaap--MachineryAndEquipmentGross_iI_pn3n3_maPPAEGzkmD_z5SdAeYCVRJh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Laboratory equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">179</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">179</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn3n3_maPPAEGzkmD_z7D53T4uhOs3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Computer equipment</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">241</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">241</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3n3_mtPPAEGzkmD_maPPAENzKAl_ztfXbKlp58B4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total property and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">420</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">420</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzKAl_z3GyK5EWRjji" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accumulated depreciation and amortization</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(320</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(302</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzKAl_z8uzoTEhJ3sg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net property and equipment</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">100</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">118</td><td style="text-align: left"> </td></tr> </table> 179000 179000 241000 241000 420000 420000 320000 302000 100000 118000 18000 192000 <p id="xdx_802_eus-gaap--IntangibleAssetsDisclosureTextBlock_zNS2qBC0e0N1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4. <span id="xdx_821_zLURfqWaM2vh">INTANGIBLE ASSETS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zs8r1bl7Di83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets, net consisted of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_zWIxW6pRxdS7" style="display: none">SUMMARY OF INTANGIBLE ASSETS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20220131_zj9t0MIfVw" style="border-bottom: Black 1.5pt solid; text-align: center">January 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20211031_zPjhQjLzUnc9" style="border-bottom: Black 1.5pt solid; text-align: center">October 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedPatentsGross_iI_pn3n3_maFLIAGzVwq_zz5nEQ3NXRkl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Patents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,769</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,836</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedLicenseAgreementsGross_iI_pn3n3_maFLIAGzVwq_zrSNGicy7i38" style="vertical-align: bottom; background-color: White"> <td>Licenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">777</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">777</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--FiniteLivedSoftwareGross_iI_pn3n3_maFLIAGzVwq_zw0NJ54lIuk7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Software</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">98</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">98</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsGross_iTI_pn3n3_mtFLIAGzVwq_maIANEGzsX7_zX4RyYshtOUd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total intangibles</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,644</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,711</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pn3n3_di_msIANEGzsX7_ze482UeGAXAb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,406</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,357</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtIANEGzsX7_zyhbILf9MtT6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,238</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,354</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_zN70j2eHSAMi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expiration dates of the existing patents range from 2021 to 2039 but the expiration dates can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to further pursue the application. Patent applications having a net book value of approximately $<span id="xdx_908_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pn3n3_c20211101__20220131__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zkFSV7eqxAs3" title="Book value patent applications, net">104</span>,000 and $<span id="xdx_901_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pn3n3_dxL_c20201101__20210131__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zShlfWnsZ17l" title="Book value patent applications, net::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0393">0</span></span> were abandoned and were charged to general and administrative expenses in the statement of operations for each of the three months ended January 31, 2022 and 2021, respectively. Amortization expense for intangible assets that was charged to general and administrative expense in the statement of operations aggregated approximately $<span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20211101__20220131__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zjgT7HQ5kS9h" title="Intangible asset amortization expense">70</span>,000 and $<span id="xdx_904_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20201101__20210131__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zLq4EUehu8bk" title="Intangible asset amortization expense">67</span>,000 for the three months ended January 31, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management has reviewed its long-lived assets for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. Net assets are recorded on the balance sheet for patents and licenses related to axalimogene filolisbac (AXAL), ADXS-HOT, ADXS-PSA and other products that are in development. However, if a competitor were to gain FDA approval for a similar treatment before the Company or if future clinical trials fail to meet the targeted endpoints, the Company will likely record an impairment related to these assets. In addition, if an application is rejected or fails to be issued, the Company would record an impairment of its estimated book value. Lastly, if the Company is unable to raise enough capital to continue funding its studies and developing its intellectual property, the Company would likely record an impairment to these assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z2P5WjHpXKkk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of January 31, 2022, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zI9hScxDP7sl" style="display: none">SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20220131_zaPHQDW5dik5" style="border-bottom: Black 1.5pt solid; text-align: center">Fiscal year ending <br/> October 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_z5QZ3GU8w5A4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">2022 (Remaining)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">211</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zXY6TBDv3bEj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">282</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_ztwDXdVZwPd8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">282</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zQTN8vIPKiIk" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">282</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zgkiqdvOQt46" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">282</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zBTI1f42Usa2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,899</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zBUc3WAyd3Ll" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,238</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zq9pVfW1Fo72" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zs8r1bl7Di83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets, net consisted of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_zWIxW6pRxdS7" style="display: none">SUMMARY OF INTANGIBLE ASSETS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20220131_zj9t0MIfVw" style="border-bottom: Black 1.5pt solid; text-align: center">January 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20211031_zPjhQjLzUnc9" style="border-bottom: Black 1.5pt solid; text-align: center">October 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedPatentsGross_iI_pn3n3_maFLIAGzVwq_zz5nEQ3NXRkl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Patents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,769</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,836</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedLicenseAgreementsGross_iI_pn3n3_maFLIAGzVwq_zrSNGicy7i38" style="vertical-align: bottom; background-color: White"> <td>Licenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">777</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">777</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--FiniteLivedSoftwareGross_iI_pn3n3_maFLIAGzVwq_zw0NJ54lIuk7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Software</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">98</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">98</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsGross_iTI_pn3n3_mtFLIAGzVwq_maIANEGzsX7_zX4RyYshtOUd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total intangibles</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,644</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,711</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pn3n3_di_msIANEGzsX7_ze482UeGAXAb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,406</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,357</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtIANEGzsX7_zyhbILf9MtT6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,238</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,354</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 4769000 4836000 777000 777000 98000 98000 5644000 5711000 2406000 2357000 3238000 3354000 104000 70000 67000 <p id="xdx_89A_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z2P5WjHpXKkk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of January 31, 2022, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zI9hScxDP7sl" style="display: none">SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20220131_zaPHQDW5dik5" style="border-bottom: Black 1.5pt solid; text-align: center">Fiscal year ending <br/> October 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_z5QZ3GU8w5A4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">2022 (Remaining)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">211</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zXY6TBDv3bEj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">282</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_ztwDXdVZwPd8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">282</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zQTN8vIPKiIk" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">282</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zgkiqdvOQt46" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">282</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zBTI1f42Usa2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,899</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zBUc3WAyd3Ll" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,238</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 211000 282000 282000 282000 282000 1899000 3238000 <p id="xdx_805_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zlC12rk7Yev4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5. <span id="xdx_826_zn4xJCqCa2T8">ACCRUED EXPENSES</span>:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zgvHMAbBePdl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes accrued expenses included in the condensed consolidated balance sheets (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_ziphVnKnREv6" style="display: none">SUMMARY OF ACCRUED EXPENSES</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20220131_zuyWj92Pm4Vj" style="border-bottom: Black 1.5pt solid; text-align: center">January 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20211031_znueKrzVYIzi" style="border-bottom: Black 1.5pt solid; text-align: center">October 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_40B_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzolp_zCUgpkuk9xLf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Salaries and other compensation</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">170</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">55</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pn3n3_maALCzolp_zDFhf7LrLlT9" style="vertical-align: bottom; background-color: White"> <td>Vendors</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,524</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,968</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzolp_zlgsdpuoB00d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">237</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">613</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzolp_zq6HzYk11Q75" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">200</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">200</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzolp_ztzPBAT9zMhd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,131</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,836</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_89F_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zgvHMAbBePdl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes accrued expenses included in the condensed consolidated balance sheets (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_ziphVnKnREv6" style="display: none">SUMMARY OF ACCRUED EXPENSES</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20220131_zuyWj92Pm4Vj" style="border-bottom: Black 1.5pt solid; text-align: center">January 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20211031_znueKrzVYIzi" style="border-bottom: Black 1.5pt solid; text-align: center">October 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_40B_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzolp_zCUgpkuk9xLf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Salaries and other compensation</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">170</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">55</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pn3n3_maALCzolp_zDFhf7LrLlT9" style="vertical-align: bottom; background-color: White"> <td>Vendors</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,524</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,968</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzolp_zlgsdpuoB00d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">237</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">613</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzolp_zq6HzYk11Q75" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">200</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">200</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzolp_ztzPBAT9zMhd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,131</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,836</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 170000 55000 1524000 1968000 237000 613000 200000 200000 2131000 2836000 <p id="xdx_803_eus-gaap--LesseeOperatingLeasesTextBlock_zEhihXRDcqZ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6. <span id="xdx_82B_zOMK7jH2OgG4">LEASES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating Leases</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company previously leased a corporate office and manufacturing facility in Princeton, New Jersey under an operating lease that was set to expire in <span id="xdx_90C_eus-gaap--LeaseExpirationDate1_dxL_c20211101__20220131_zvbfHSjbQ6Sf" title="Lease expiration date::XDX::2025-11-30"><span style="-sec-ix-hidden: xdx2ixbrl0436">November 2025</span></span>. On March 26, 2021, the Company entered into a Lease Termination and Surrender Agreement with respect to this lease agreement. The Lease Termination and Surrender Agreement provides for the early termination of the lease, which became effective on March 31, 2021. In connection with the early termination of the lease, the Company was required to pay a $<span id="xdx_902_eus-gaap--GainLossOnTerminationOfLease_c20210301__20210326_zPBCaNKf9uZf" title="Lease termination">1,000,000</span> termination payment. The unapplied security deposit totaling approximately $<span id="xdx_90A_eus-gaap--SecurityDeposit_iI_pp0p0_c20220131_zjoBznSsgPb4" title="Security deposit">182,000</span> was credited against the termination fee for a net payment of approximately $<span id="xdx_906_eus-gaap--GainLossOnDispositionOfAssets1_c20210301__20210326_zhMr4Tr21Yqh" title="Net payment for termination fee">818,000</span>. The Company wrote off of the remaining right-of-use asset of approximately $<span id="xdx_90A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn5n6_c20210326_zgnmCJRZdhb3" title="Operating lease, right of use asset">4.5</span> million and lease liability of approximately $<span id="xdx_90E_eus-gaap--OperatingLeaseLiability_iI_pn5n6_c20210326_z1afpjv0GIf2">5.6</span> million. After consideration of the termination payment and write off of remaining right-of-use asset and lease liability, the Company recorded a net gain of approximately $<span id="xdx_90F_eus-gaap--ReceivablesNetCurrent_iI_pn5n6_c20210326_zOXwI3i9OjBl" title="Net gain on leases">0.1</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 25, 2021, the Company entered into a new lease agreement for its corporate office/lab with base rent of approximately $<span id="xdx_906_ecustom--PaymentOfRent_iI_c20210326_ze3rs2Plzo22" title="Rent paid">29,000</span> per year, plus other expenses. The lease expires on <span id="xdx_90D_ecustom--LesseeFinanceLeasesTermOfContract_dd_c20210301__20210325_zvo5CXTcBEu9" title="Lease expiration date">March 25, 2022</span> and the Company has the option to renew the lease for one additional successive one-year term upon six months written notice to the landlord. This new lease was accounted for as a short-term lease at inception, and the Company elected not to recognize a right-of-use asset and lease liability. In September 2021, the Company exercised its option to renew the lease, extending the lease term until <span id="xdx_908_ecustom--LesseeFinanceLeasesRenewalTerm_dd_c20210301__20210325_zbN5tWDSozSi" title="Lessee finance lease renewal term date">March 25, 2023</span>. Since the renewed lease term exceeds one-year, the lease no longer qualifies for the short-term lease exception, resulting in the recognition of a right-of-use asset and operating lease liability of approximately $<span id="xdx_909_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20210325_zQP6TJHJmuE8" title="Operating lease, Right of use asset"><span id="xdx_908_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20210325_zON6BmGznxF1" title="Operating lease liability">43</span></span>,000.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_ecustom--ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_zzxbqbQvrH86" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental balance sheet information related to leases was as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B0_z5fHiLChpQ4i" style="display: none">SCHEDULE OF SUPPLEMENTAL BALANCE SHEET RELATED TO LEASES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20220131_z0hLLC57thv7" style="border-bottom: Black 1.5pt solid; text-align: center">January 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20211031_z6JyUYnfgWPc" style="border-bottom: Black 1.5pt solid; text-align: center">October 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Operating leases: </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify; padding-bottom: 1.5pt">Operating lease right-of-use assets</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">33</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">40</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_maOLLzSE5_z9S02qz3e1Qb" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Operating lease liability</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">29</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">28</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_maOLLzSE5_zSUND9fmFdWh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Operating lease liability, net of current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">12</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzSE5_zJVpxX3RBXRe" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Total operating lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">34</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zICgK1AtKEne" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--LeaseCostTableTextBlock_zlNPG55yc9g8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental lease expense related to leases was as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BB_ziDOhFPtCpYl" style="display: none">SCHEDULE OF LEASE EXPENSES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease Cost (in thousands)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements of Operations Classification</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_491_20211101__20220131_z94zmz93YGV3" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Three <br/> Months Ended <br/> January 31, 2022</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_495_20201101__20210131_zDn8pp3bHSy2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Three <br/> Months Ended <br/> January 31, 2021</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseCost_pn3n3_maLCzh2P_z1mYwMar5igc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease cost</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 23%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">290</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--VariableLeaseCost_pn3n3_maLCzh2P_zlUZI3IncMj8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Variable lease cost</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">437</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--LeaseCost_iT_pn3n3_mtLCzh2P_zJ7joOFREez6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total lease expense</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">727</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A1_z4OG07q1HbX7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_ecustom--ScheduleOfOtherInformationTableTextBlock_zl8lF6yuocOc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other information related to leases where the Company is the lessee is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B7_zfu8vDR88j2b" style="display: none">SCHEDULE OF OTHER INFORMATION RELATED TO LEASES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">January 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">October 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Weighted-average remaining lease term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220131_zIyI8pVoGGl5" title="Weighted-average remaining lease term">1.2</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211031_z6Jn4Oh9czNk" title="Weighted-average remaining lease term">1.4</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify">Weighted-average discount rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20220131_z4ZeKoIucnq9" title="Weighted-average discount rate">3.79</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20211031_zHBN9nKN0OX6" title="Weighted-average discount rate">3.79</span></td><td style="width: 1%; text-align: left">%</td></tr> </table> <p id="xdx_8AF_zCBjoOqpVnE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zbzHVYEyQu6c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental cash flow information related to operating leases was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B2_zcCf9LOkVvfb" style="display: none">SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20211101__20220131_znM7KcFyuqdj" style="border-bottom: Black 1.5pt solid; text-align: center">For the Three <br/> Months Ended <br/> January 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20201101__20210131_zHJDwSSYldj8" style="border-bottom: Black 1.5pt solid; text-align: center">For the Three <br/> Months Ended <br/> January 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseLeaseIncomeLeasePayments_zVYvgdPHzz3c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify; padding-bottom: 1.5pt">Cash paid for operating lease liabilities</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">7</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">324</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_z35bn9lZ9g8k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zMe9pBYX84db" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future minimum lease payments under non-cancellable leases as of January 31, 2022 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B5_zv10eQKlq7T8" style="display: none">SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELLABLE LEASES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: justify">Fiscal Year ending October 31,</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20220131_z2zmZPEmCEpa" style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzpLw_zPMthlXvE5ij" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">2022 (Remaining)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">22</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzpLw_zmKg3cDnABy5" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzpLw_zcKjxjmqlcA6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 10pt">Total minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_z8Pbkun3iHE8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zsV1Ipb9j3rf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">34</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1000000 182000 818000 4500000 5600000 100000 29000 2022-03-25 2023-03-25 43000 43000 <p id="xdx_894_ecustom--ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_zzxbqbQvrH86" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental balance sheet information related to leases was as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B0_z5fHiLChpQ4i" style="display: none">SCHEDULE OF SUPPLEMENTAL BALANCE SHEET RELATED TO LEASES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20220131_z0hLLC57thv7" style="border-bottom: Black 1.5pt solid; text-align: center">January 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20211031_z6JyUYnfgWPc" style="border-bottom: Black 1.5pt solid; text-align: center">October 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Operating leases: </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify; padding-bottom: 1.5pt">Operating lease right-of-use assets</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">33</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">40</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_maOLLzSE5_z9S02qz3e1Qb" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Operating lease liability</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">29</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">28</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_maOLLzSE5_zSUND9fmFdWh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Operating lease liability, net of current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">12</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzSE5_zJVpxX3RBXRe" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Total operating lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">34</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 33000 40000 29000 28000 5000 12000 34000 40000 <p id="xdx_898_eus-gaap--LeaseCostTableTextBlock_zlNPG55yc9g8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental lease expense related to leases was as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BB_ziDOhFPtCpYl" style="display: none">SCHEDULE OF LEASE EXPENSES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease Cost (in thousands)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements of Operations Classification</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_491_20211101__20220131_z94zmz93YGV3" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Three <br/> Months Ended <br/> January 31, 2022</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_495_20201101__20210131_zDn8pp3bHSy2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Three <br/> Months Ended <br/> January 31, 2021</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseCost_pn3n3_maLCzh2P_z1mYwMar5igc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease cost</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 23%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">290</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--VariableLeaseCost_pn3n3_maLCzh2P_zlUZI3IncMj8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Variable lease cost</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">437</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--LeaseCost_iT_pn3n3_mtLCzh2P_zJ7joOFREez6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total lease expense</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">727</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 7000 290000 9000 437000 16000 727000 <p id="xdx_89F_ecustom--ScheduleOfOtherInformationTableTextBlock_zl8lF6yuocOc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other information related to leases where the Company is the lessee is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B7_zfu8vDR88j2b" style="display: none">SCHEDULE OF OTHER INFORMATION RELATED TO LEASES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">January 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">October 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Weighted-average remaining lease term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220131_zIyI8pVoGGl5" title="Weighted-average remaining lease term">1.2</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211031_z6Jn4Oh9czNk" title="Weighted-average remaining lease term">1.4</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify">Weighted-average discount rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20220131_z4ZeKoIucnq9" title="Weighted-average discount rate">3.79</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20211031_zHBN9nKN0OX6" title="Weighted-average discount rate">3.79</span></td><td style="width: 1%; text-align: left">%</td></tr> </table> P1Y2M12D P1Y4M24D 0.0379 0.0379 <p id="xdx_892_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zbzHVYEyQu6c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental cash flow information related to operating leases was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B2_zcCf9LOkVvfb" style="display: none">SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20211101__20220131_znM7KcFyuqdj" style="border-bottom: Black 1.5pt solid; text-align: center">For the Three <br/> Months Ended <br/> January 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20201101__20210131_zHJDwSSYldj8" style="border-bottom: Black 1.5pt solid; text-align: center">For the Three <br/> Months Ended <br/> January 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseLeaseIncomeLeasePayments_zVYvgdPHzz3c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify; padding-bottom: 1.5pt">Cash paid for operating lease liabilities</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">7</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">324</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 7000 324000 <p id="xdx_898_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zMe9pBYX84db" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future minimum lease payments under non-cancellable leases as of January 31, 2022 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B5_zv10eQKlq7T8" style="display: none">SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELLABLE LEASES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: justify">Fiscal Year ending October 31,</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20220131_z2zmZPEmCEpa" style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzpLw_zPMthlXvE5ij" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">2022 (Remaining)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">22</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzpLw_zmKg3cDnABy5" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzpLw_zcKjxjmqlcA6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 10pt">Total minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_z8Pbkun3iHE8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zsV1Ipb9j3rf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">34</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 22000 13000 35000 1000 34000 <p id="xdx_807_ecustom--CommonStockPurchaseWarrantsAndWarrantLiabilityTextBlock_zNj9rlsRq0F5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7. <span id="xdx_82F_zUA6MyEZBe3h">COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of January 31, 2022 and October 31, 2021, there were outstanding and exercisable warrants to purchase <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPdLpSRkkIt5" title="Warrants outstanding"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zC97zOyGWN3c" title="Number of warrants to purchase common stock"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20211031__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z66EUxyRn0ud" title="Number of warrants to purchase common stock"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211031__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5IGnvr0lkvf" title="Warrants outstanding">30,225,397</span></span></span></span> shares of our common stock with exercise prices ranging from $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zqKtAQ7lIPKl" title="Warrant exercise price per share"><span title="Warrant exercise price per share">0.30</span></span> to $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zkI4jkKqIGQ8" title="Warrant exercise price per share"><span title="Warrant exercise price per share">281.25</span></span> per share. Information on the outstanding warrants is as follows:</span></p> <p id="xdx_89B_ecustom--ScheduleOfOutstandingWarrantsTableTextBlock_z5NvHymWeelj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8BC_zYQvWFUFkHw2" style="display: none">COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercise <br/> Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Shares <br/> Underlying Warrants</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Expiration Date</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Type of Financing</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zwc5f1ef5y5e" title="Exercise Price"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zcEqzN4ZA7ug" title="Exercise Price">281.25</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 17%; text-align: right"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zBU98lME6za1" title="Number of Shares Underlying Warrants"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_z5kNToqtIdwg" title="Number of Shares Underlying Warrants">25</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 25%">N/A</td><td style="width: 2%"> </td> <td style="width: 31%; text-align: left"><span id="xdx_90B_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zQ1D61EFj5g9" title="Type of Financing"><span id="xdx_903_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zb7uix0igZse" title="Type of Financing">Other warrants</span></span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zDjeGaTgERtd" title="Exercise Price"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zDja9ZAo79Nl" title="Exercise Price">0.25</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_znSz0R466nB8" title="Number of Shares Underlying Warrants"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_z71I4tbOQ54j" title="Number of Shares Underlying Warrants">70,297</span></span></td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_904_ecustom--WarrantsExpirationDescription_dd_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zpWG4yYOSWr6" title="Expiration Date"><span id="xdx_908_ecustom--WarrantsExpirationDescription_dd_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zFDmyNU3NhX1" title="Expiration Date">July 2024</span></span></td><td> </td> <td><span id="xdx_908_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zTjMW24mkBnl" title="Type of Financing"><span id="xdx_902_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zYlfTk8n2y16" title="Type of Financing">September 2018 Public Offering</span></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zyKaQTAx0GW9" title="Exercise Price"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zCbjEO20EXeb" title="Exercise Price">2.80</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_z4Ilsl4hIfPf" title="Number of Shares Underlying Warrants"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zC6jbvBU6M9i" title="Number of Shares Underlying Warrants">327,338</span></span></td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_900_ecustom--WarrantsExpirationDescription_dd_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zNIzFWhfjjXl" title="Expiration Date"><span id="xdx_909_ecustom--WarrantsExpirationDescription_dd_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zka1PP6gFCTj" title="Expiration Date">September 2024</span></span></td><td> </td> <td><span id="xdx_900_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zk4CXNfzo4o8" title="Type of Financing"><span id="xdx_907_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zMNNdWE7UWI2" title="Type of Financing">July 2019 Public Offering</span></span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_zviU5JMVUEE2" title="Exercise Price"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_zNNN85JwUHii" title="Exercise Price">0.35</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_zlGlhTQgsVI3" title="Number of Shares Underlying Warrants"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_zoxyLKr8PFkj" title="Number of Shares Underlying Warrants">4,578,400</span></span></td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_900_ecustom--WarrantsExpirationDescription_dd_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_zEZfi5dyUMog" title="Expiration Date"><span id="xdx_907_ecustom--WarrantsExpirationDescription_dd_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_ztyL0oTNYl18" title="Expiration Date">November 2025</span></span></td><td> </td> <td><span id="xdx_90F_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_z8rRgUc6LiE7" title="Type of Financing"><span id="xdx_90F_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_zCVtKawGGu69" title="Type of Financing">November 2020 Public Offering</span></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFiveMember_zASoRqB5166d" title="Exercise Price"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFiveMember_zeCkUO7ypR63" title="Exercise Price">0.70</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFiveMember_zQ3Nf3b27s3f" title="Number of Shares Underlying Warrants"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFiveMember_zeb9RoxbwIL4" title="Number of Shares Underlying Warrants">11,244,135</span></span></td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_901_ecustom--WarrantsExpirationDescription_dd_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFiveMember_zdJEeWxgw1Gl" title="Expiration Date"><span id="xdx_90E_ecustom--WarrantsExpirationDescription_dd_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFiveMember_zLPl9wFSGF93" title="Expiration Date">April 2026</span></span></td><td> </td> <td style="text-align: left"><span id="xdx_906_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFiveMember_zma4tkCx7KC" title="Type of Financing"><span id="xdx_904_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFiveMember_zcytYqSO0J5k" title="Type of Financing">April 2021 Registered Direct Offering (Accompanying Warrants)</span></span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeSixMember_zFMz6uGIhhBb" title="Exercise Price"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeSixMember_zQB23y0WReAe" title="Exercise Price">0.70</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeSixMember_z5SAQl8uTG4g" title="Number of Shares Underlying Warrants"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeSixMember_zJBfJtqzqPq5" title="Number of Shares Underlying Warrants">14,005,202</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left; padding-bottom: 1.5pt"><span id="xdx_90C_ecustom--WarrantsExpirationDescription_dd_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeSixMember_zQ18d9ORA2N3" title="Expiration Date"><span id="xdx_908_ecustom--WarrantsExpirationDescription_dd_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeSixMember_zQfzv1lv4kth" title="Expiration Date">5 years after the date such warrants become exercisable, if ever</span></span></td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left; padding-bottom: 1.5pt"><span id="xdx_900_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeSixMember_zzJQP3pKok7f" title="Type of Financing"><span id="xdx_906_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeSixMember_zvvSh8CSNXG1" title="Type of Financing">April 2021 Private Placement (Private Placement Warrants)</span></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Grand Total</b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20211031_z7myIuiaSYRj" title="Grand Total Number of Shares Underlying Warrants"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220131_zyXMJM6oTIfb" title="Grand Total Number of Shares Underlying Warrants">30,225,397</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> <p id="xdx_8AC_z5adTDCHrsl8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of January 31, 2022 and October 31, 2021, the Company had <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20211031__us-gaap--StatementEquityComponentsAxis__custom--EquityWarrantsMember_zlUvPGpbyzh1">16,149,898 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of its total <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220131__us-gaap--StatementEquityComponentsAxis__custom--EquityWarrantsMember_zR6EMjsE3MYb">30,225,397 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">outstanding warrants classified as equity (equity warrants).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant Liability</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of January 31, 2022 and October 31, 2021, the Company had <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220131__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zsTDDHo8eAX9" title="Number of warrants to purchase common stock"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20211031__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z8Nmv9H4o2Q3" title="Number of warrants to purchase common stock">14,075,499</span></span> of its total <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211031__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zoaMeJTPr2ze" title="Warrants outstanding"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220131__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zb0VWEGDcZk" title="Warrants outstanding">30,225,397</span></span> outstanding warrants from an April 2021 private offering of common stock and warrants (the “April 2021 Private Placement”) and a September 2018 public offering of common stock and warrants (the “September 2018 Public Offering”) classified as liabilities (liability warrants).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The warrants issued in the April 2021 Private Placement will become exercisable only on such day, if ever, that is 14 days after the Company files an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock, $<span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220131_z4W9T7NvfVVg" title="Common stock par or stated value per share">0.001</span> par value per share from <span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20220131_zrCkEaeF8yEl" title="Common stock shares authorized">170,000,000</span> shares to <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_c20220131__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zM4qCLIrQZah" title="Common stock shares authorized">300,000,000</span> shares. These warrants expire five years after the date they become exercisable. As of January 31, 2022, the Company did not have sufficient authorized common stock to allow for the issuance of common stock underlying these warrants. The Company did not receive stockholder authorization to increase the authorized shares from <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_c20210603__srt--RangeAxis__srt--MinimumMember_zMi6eUOa6dz7" title="Common stock shares authorized">170,000,000</span> to <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_c20210603__srt--RangeAxis__srt--MaximumMember_zsse2RFHoV13" title="Common stock shares authorized">300,000,000</span> shares at the stockholder’s meeting commenced on June 3, 2021. The Company was subsequently required to file a proxy to seek an increase in the number of authorized shares and did not file such a proxy but rather elected to seek a reverse stock split to, among other things, increase the shares available. Accordingly, based on certain indemnification provisions of the securities purchase agreement, the Company concluded that liability classification is warranted. The Company utilized the Black Scholes model to calculate the fair value of these warrants at issuance and at each subsequent reporting date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_hus-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zZ3EPn6bwGc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In measuring the warrant liability for the warrants issued in the April 2021 Private Placement at January 31, 2022 and October 31, 2021, the Company used the following inputs in its Black Scholes model:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B6_ztfL1iHWwzJ6" style="display: none">SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">January 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">October 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Exercise Price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220131__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zJ4J3MfPLtce" style="width: 16%; text-align: right" title="Exercise Price">0.70</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zd36Rg1bkIJl" style="width: 16%; text-align: right" title="Exercise Price">0.70</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Stock Price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharePrice_iI_pid_c20220131__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zO30UOBDf53k" style="text-align: right" title="Stock Price">0.136</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--SharePrice_iI_pid_c20211031__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zbLnLAj8jLUl" style="text-align: right" title="Stock Price">0.485</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zHCywyRUSSY5" title="Expected Term">5</span>.00 years </span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zHXrbBHEiJG4" title="Expected Term">5</span>.00 years </span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility %</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zTRwAW2LblT4" title="Measurement input percentage">108</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zh9T8NSouba3" title="Measurement input percentage">106</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk Free Rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zDjKt2L6Xmf" title="Measurement input percentage">1.62</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z3wY3ojQo8U3" title="Measurement input percentage">1.18</span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8AC_zhXUhUyNcTp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The September 2018 Public Offering warrants contain a down round feature, except for exempt issuances as defined in the warrant agreement, in which the exercise price would immediately be reduced to match a dilutive issuance of common stock, options, convertible securities and changes in option price or rate of conversion. As of January 31, 2021, the down round feature was triggered four times and the exercise price of the warrants were reduced from $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210131__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__srt--RangeAxis__srt--MaximumMember_zuAMoZRJeqLh" title="Warrant exercise price per share">22.50</span> to $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210131__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__srt--RangeAxis__srt--MinimumMember_zFxL168nlmr9" title="Warrant exercise price per share">0.25</span>. The warrants require liability classification as the warrant agreement requires the Company to maintain an effective registration statement and does not specify any circumstances under which settlement in other than cash would be permitted or required. As a result, net cash settlement is assumed and liability classification is warranted. For these liability warrants, the Company utilized the Monte Carlo simulation model to calculate the fair value of these warrants at issuance and at each subsequent reporting date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zWcGYSZnGPpc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In measuring the warrant liability for the September 2018 Public Offering warrants at January 31, 2022 and October 31, 2021, the Company used the following inputs in its Monte Carlo simulation model:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B0_zjVfFAiTL5hl" style="display: none">SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">January 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">October 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Exercise Price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220131__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_zAwset6nizpk" style="width: 16%; text-align: right" title="Exercise Price">0.25</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_zYcGqbh4yfR8" style="width: 16%; text-align: right" title="Exercise Price">0.30</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Stock Price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--SharePrice_iI_pid_c20220131__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_z8JJMR3w8cw6" style="text-align: right" title="Stock Price">0.136</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20211031__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_zdQukssCjnzb" style="text-align: right" title="Stock Price">0.485</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_zW0Ya4pI9klg" title="Expected Term">2.61</span> years </span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_zpsnqi3v4cga" title="Expected Term">2.87</span> years </span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility %</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_zsUVW05C3Tz7" title="Measurement input percentage">118</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_zA96TBMLJSW3" title="Measurement input percentage">123</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk Free Rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_z3jwSGolOkc6" title="Measurement input percentage">1.29</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_zcx9igyuTCA6" title="Measurement input percentage">0.77</span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8AB_zksn83yvvM0h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">At January 31, 2022 and October 31, 2021, the fair value of the warrant liability was approximately $<span id="xdx_90A_ecustom--FairValueOfWarrantLiability_iI_c20220131_zL22Jl3mU13f" title="Fair value of the warrant liability">1,127,000</span> and $<span id="xdx_907_ecustom--FairValueOfWarrantLiability_iI_c20211031_zlUdGopYVYmj" title="Fair value of the warrant liability">4,929,000</span>, respectively. For the three months ended January 31, 2022 and 2021, the Company reported income of approximately $<span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_c20211101__20220131_zo5mSgvmp3r8" title="Income on fair value of warrants">3,802,000</span> and expense of $<span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_c20201101__20210131_zbFFs7HKt0ic" title="Income on fair value of warrants">27,000</span>, respectively, due to changes in the fair value of the warrant liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 30225397 30225397 30225397 30225397 0.30 281.25 <p id="xdx_89B_ecustom--ScheduleOfOutstandingWarrantsTableTextBlock_z5NvHymWeelj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8BC_zYQvWFUFkHw2" style="display: none">COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercise <br/> Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Shares <br/> Underlying Warrants</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Expiration Date</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Type of Financing</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zwc5f1ef5y5e" title="Exercise Price"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zcEqzN4ZA7ug" title="Exercise Price">281.25</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 17%; text-align: right"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zBU98lME6za1" title="Number of Shares Underlying Warrants"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_z5kNToqtIdwg" title="Number of Shares Underlying Warrants">25</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 25%">N/A</td><td style="width: 2%"> </td> <td style="width: 31%; text-align: left"><span id="xdx_90B_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zQ1D61EFj5g9" title="Type of Financing"><span id="xdx_903_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zb7uix0igZse" title="Type of Financing">Other warrants</span></span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zDjeGaTgERtd" title="Exercise Price"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zDja9ZAo79Nl" title="Exercise Price">0.25</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_znSz0R466nB8" title="Number of Shares Underlying Warrants"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_z71I4tbOQ54j" title="Number of Shares Underlying Warrants">70,297</span></span></td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_904_ecustom--WarrantsExpirationDescription_dd_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zpWG4yYOSWr6" title="Expiration Date"><span id="xdx_908_ecustom--WarrantsExpirationDescription_dd_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zFDmyNU3NhX1" title="Expiration Date">July 2024</span></span></td><td> </td> <td><span id="xdx_908_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zTjMW24mkBnl" title="Type of Financing"><span id="xdx_902_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zYlfTk8n2y16" title="Type of Financing">September 2018 Public Offering</span></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zyKaQTAx0GW9" title="Exercise Price"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zCbjEO20EXeb" title="Exercise Price">2.80</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_z4Ilsl4hIfPf" title="Number of Shares Underlying Warrants"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zC6jbvBU6M9i" title="Number of Shares Underlying Warrants">327,338</span></span></td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_900_ecustom--WarrantsExpirationDescription_dd_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zNIzFWhfjjXl" title="Expiration Date"><span id="xdx_909_ecustom--WarrantsExpirationDescription_dd_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zka1PP6gFCTj" title="Expiration Date">September 2024</span></span></td><td> </td> <td><span id="xdx_900_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zk4CXNfzo4o8" title="Type of Financing"><span id="xdx_907_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zMNNdWE7UWI2" title="Type of Financing">July 2019 Public Offering</span></span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_zviU5JMVUEE2" title="Exercise Price"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_zNNN85JwUHii" title="Exercise Price">0.35</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_zlGlhTQgsVI3" title="Number of Shares Underlying Warrants"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_zoxyLKr8PFkj" title="Number of Shares Underlying Warrants">4,578,400</span></span></td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_900_ecustom--WarrantsExpirationDescription_dd_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_zEZfi5dyUMog" title="Expiration Date"><span id="xdx_907_ecustom--WarrantsExpirationDescription_dd_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_ztyL0oTNYl18" title="Expiration Date">November 2025</span></span></td><td> </td> <td><span id="xdx_90F_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_z8rRgUc6LiE7" title="Type of Financing"><span id="xdx_90F_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_zCVtKawGGu69" title="Type of Financing">November 2020 Public Offering</span></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFiveMember_zASoRqB5166d" title="Exercise Price"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFiveMember_zeCkUO7ypR63" title="Exercise Price">0.70</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFiveMember_zQ3Nf3b27s3f" title="Number of Shares Underlying Warrants"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFiveMember_zeb9RoxbwIL4" title="Number of Shares Underlying Warrants">11,244,135</span></span></td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_901_ecustom--WarrantsExpirationDescription_dd_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFiveMember_zdJEeWxgw1Gl" title="Expiration Date"><span id="xdx_90E_ecustom--WarrantsExpirationDescription_dd_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFiveMember_zLPl9wFSGF93" title="Expiration Date">April 2026</span></span></td><td> </td> <td style="text-align: left"><span id="xdx_906_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFiveMember_zma4tkCx7KC" title="Type of Financing"><span id="xdx_904_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFiveMember_zcytYqSO0J5k" title="Type of Financing">April 2021 Registered Direct Offering (Accompanying Warrants)</span></span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeSixMember_zFMz6uGIhhBb" title="Exercise Price"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeSixMember_zQB23y0WReAe" title="Exercise Price">0.70</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeSixMember_z5SAQl8uTG4g" title="Number of Shares Underlying Warrants"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeSixMember_zJBfJtqzqPq5" title="Number of Shares Underlying Warrants">14,005,202</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left; padding-bottom: 1.5pt"><span id="xdx_90C_ecustom--WarrantsExpirationDescription_dd_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeSixMember_zQ18d9ORA2N3" title="Expiration Date"><span id="xdx_908_ecustom--WarrantsExpirationDescription_dd_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeSixMember_zQfzv1lv4kth" title="Expiration Date">5 years after the date such warrants become exercisable, if ever</span></span></td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left; padding-bottom: 1.5pt"><span id="xdx_900_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeSixMember_zzJQP3pKok7f" title="Type of Financing"><span id="xdx_906_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeSixMember_zvvSh8CSNXG1" title="Type of Financing">April 2021 Private Placement (Private Placement Warrants)</span></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Grand Total</b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20211031_z7myIuiaSYRj" title="Grand Total Number of Shares Underlying Warrants"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220131_zyXMJM6oTIfb" title="Grand Total Number of Shares Underlying Warrants">30,225,397</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> 281.25 281.25 25000 25000 Other warrants Other warrants 0.25 0.25 70297000 70297000 July 2024 July 2024 September 2018 Public Offering September 2018 Public Offering 2.80 2.80 327338000 327338000 September 2024 September 2024 July 2019 Public Offering July 2019 Public Offering 0.35 0.35 4578400000 4578400000 November 2025 November 2025 November 2020 Public Offering November 2020 Public Offering 0.70 0.70 11244135000 11244135000 April 2026 April 2026 April 2021 Registered Direct Offering (Accompanying Warrants) April 2021 Registered Direct Offering (Accompanying Warrants) 0.70 0.70 14005202000 14005202000 5 years after the date such warrants become exercisable, if ever 5 years after the date such warrants become exercisable, if ever April 2021 Private Placement (Private Placement Warrants) April 2021 Private Placement (Private Placement Warrants) 30225397000 30225397000 16149898 30225397 14075499 14075499 30225397 30225397 0.001 170000000 300000000 170000000 300000000 <p id="xdx_894_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_hus-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zZ3EPn6bwGc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In measuring the warrant liability for the warrants issued in the April 2021 Private Placement at January 31, 2022 and October 31, 2021, the Company used the following inputs in its Black Scholes model:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B6_ztfL1iHWwzJ6" style="display: none">SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">January 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">October 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Exercise Price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220131__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zJ4J3MfPLtce" style="width: 16%; text-align: right" title="Exercise Price">0.70</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zd36Rg1bkIJl" style="width: 16%; text-align: right" title="Exercise Price">0.70</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Stock Price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharePrice_iI_pid_c20220131__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zO30UOBDf53k" style="text-align: right" title="Stock Price">0.136</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--SharePrice_iI_pid_c20211031__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zbLnLAj8jLUl" style="text-align: right" title="Stock Price">0.485</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zHCywyRUSSY5" title="Expected Term">5</span>.00 years </span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zHXrbBHEiJG4" title="Expected Term">5</span>.00 years </span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility %</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zTRwAW2LblT4" title="Measurement input percentage">108</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zh9T8NSouba3" title="Measurement input percentage">106</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk Free Rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zDjKt2L6Xmf" title="Measurement input percentage">1.62</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z3wY3ojQo8U3" title="Measurement input percentage">1.18</span></td><td style="text-align: left">%</td></tr> </table> 0.70 0.70 0.136 0.485 P5Y P5Y 108 106 1.62 1.18 22.50 0.25 <p id="xdx_897_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zWcGYSZnGPpc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In measuring the warrant liability for the September 2018 Public Offering warrants at January 31, 2022 and October 31, 2021, the Company used the following inputs in its Monte Carlo simulation model:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B0_zjVfFAiTL5hl" style="display: none">SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">January 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">October 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Exercise Price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220131__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_zAwset6nizpk" style="width: 16%; text-align: right" title="Exercise Price">0.25</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_zYcGqbh4yfR8" style="width: 16%; text-align: right" title="Exercise Price">0.30</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Stock Price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--SharePrice_iI_pid_c20220131__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_z8JJMR3w8cw6" style="text-align: right" title="Stock Price">0.136</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20211031__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_zdQukssCjnzb" style="text-align: right" title="Stock Price">0.485</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_zW0Ya4pI9klg" title="Expected Term">2.61</span> years </span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_zpsnqi3v4cga" title="Expected Term">2.87</span> years </span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility %</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_zsUVW05C3Tz7" title="Measurement input percentage">118</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_zA96TBMLJSW3" title="Measurement input percentage">123</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk Free Rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_z3jwSGolOkc6" title="Measurement input percentage">1.29</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_zcx9igyuTCA6" title="Measurement input percentage">0.77</span></td><td style="text-align: left">%</td></tr> </table> 0.25 0.30 0.136 0.485 P2Y7M9D P2Y10M13D 118 123 1.29 0.77 1127000 4929000 3802000 27000 <p id="xdx_80E_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zMHoKPuBO0d6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8. <span id="xdx_829_z1LPcU9rYPXi">COMMITMENTS AND CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Atachbarian</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 15, 2021, a purported stockholder of the Company commenced an action against the Company and certain of its directors in the U.S. District Court for the District of New Jersey, entitled Atachbarian v. Advaxis, Inc., et al., No. 3:21-cv-20006. The plaintiff alleges that the defendants breached their fiduciary duties and violated Section 14(a) and Rule 20(a) of the Securities Exchange Act of 1934 and Rule 14a-9 promulgated thereunder by allegedly failing to disclose certain matters in its Registration Statement on Form S-4 (Commission File No. 333-259065 (the “Registration Statement”) filed in connection with a proposed merger with Biosight Ltd. (the “Previously Proposed Merger”). On December 15, 2021, pursuant to an understanding reached with the plaintiff, the Company made certain other additional disclosures that mooted the demands asserted in the complaint. On December 17, 2021, the plaintiff filed a notice of voluntary dismissal with prejudice. On February 7, 2022, the Company and the plaintiff reached a settlement agreement, which is recorded in accrued expenses in the consolidated balance statement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Purported Stockholder Claims Related to Biosight Transaction</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between September 16, 2021, and November 4, 2021, the Company received demand letters on behalf of six purported stockholders of the Company, alleging that the Company failed to disclose certain matters in the Registration Statement, and demanding that the Company disclose such information in a supplemental disclosure filed with the SEC. On October 14, 2021, the Company filed an amendment to the Registration Statement and on November 8, 2021, the Company made certain other additional disclosures that mooted the demands asserted in the above-referenced letters. The six plaintiffs have made a settlement demand. The Company believes it has adequately accrued for a settlement, which is recorded in accrued expenses in the consolidated balance sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, the Company received certain additional demands from stockholders asserting that the proxy materials filed by the Company in connection with the Previously Proposed Merger contained alleged material misstatements and/or omissions in violation of federal law. In response to these demands, the Company agreed to make, and did make, certain supplemental disclosures to the proxy materials. At this time, the Company is unable to predict the likelihood of an unfavorable outcome.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_80B_ecustom--TemporaryEquityDisclosureTextBlock_zIUGJ4JmbVyg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9. <span id="xdx_829_zB3MVSrYiZnb">TEMPORARY EQUITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series D Convertible Preferred Stock Offering</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 31, 2022, the Company closed on an offering with certain institutional investors for the private placement of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220131__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InstitutionalInvestorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zYBGElywxm49" title="Shares issued">1,000,000</span> shares of Series D convertible redeemable preferred stock (“Series D preferred stock”). The shares to be sold have an aggregate stated value of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220131__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InstitutionalInvestorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_z1Qva1jiGKcj" title="Stated value">5,000,000</span>. Each share of the Series D preferred stock has a purchase price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InstitutionalInvestorsMember_zVo8CEJzHVTk" title="Share purchase price">4.75</span>, representing an original issue discount of <span id="xdx_903_ecustom--PreferredStockDiscountRatePercentage_dp_uPure_c20220101__20220131_z49DALCwR8Re" title="Issue discount">5</span>% of the stated value. Total net proceeds from the offering, after deducting the financial advisor’s fees and other estimated offering expenses, were approximately $<span id="xdx_907_ecustom--ProceedsFromIssuanceOrEstimatedOffering_c20220101__20220131_zHlSldZuIxG8" title="Proceeds from issuance or estimated offering">4,312,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has called a special meeting of stockholders to consider an amendment (the “Amendment”) to the Company’s Amended and Restated Certificate of Incorporation, to effect a reverse stock split of the outstanding shares of common stock by a ratio to be determined by the Board of Directors of the Company within a range to be specified in the proposal put to the stockholders for approval of the Amendment. The investors have agreed in the Purchase Agreement to not transfer, offer, sell, contract to sell, hypothecate, pledge or otherwise dispose of the shares of the Series D preferred stock until the reverse stock split and to vote the shares of the Series D preferred stock purchased in the offering in a manner that “mirrors” the proportions on which the shares of common stock (excluding any shares of common stock that are not voted) are voted on the reverse stock split and the Amendment. The Amendment requires the approval of the majority of the votes associated with the Company’s outstanding stock entitled to vote on the proposal. The certificate of designation provides that the Series D preferred stock will have no voting rights, other than the right to vote as a class on certain specified matters, except that each share of Series D preferred stock will have the right to cast <span id="xdx_909_ecustom--NumberofVotesPerShare_pid_uInteger_c20220101__20220131_zSBJxhF0tAub" title="Number of votes per share">30,000</span> votes per share of Series D preferred stock on the reverse stock split.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Series D preferred stock can be converted at the option of the holder at any time after the Company has received stockholder approval for a reverse stock split and filed the requisite amendment with the Delaware Secretary of State’s office to effectuate the reverse stock split, subject to beneficial ownership limitations. The Company will be permitted to compel conversion of the Series D preferred stock after the fulfillment of certain conditions and subject to certain limitations. The Series D preferred stock is convertible into shares of Common Stock at a rate of $<span id="xdx_905_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20220131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zc4jDT85COpa" title="Preferred stock conversion price">0.25</span> per share for the Series D preferred stock. In addition, on or after the reverse stock split date, and subject to the satisfaction of certain conditions, the Company can cause the holder of the Series D Preferred Stock to convert their shares of Series D Preferred Stock, subject to such beneficial ownership limitations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Series D preferred stock has a liquidation preference over the common stock, and may be redeemed by the investors. Each holder of the Series D preferred stock has the right to cause the Company to redeem all or part of their shares of the Series D preferred stock from the earlier of receipt of stockholder approval of the reverse stock split or 90 days following the original issue date until 120 days following the original issue date (the “Redemption Date”) in cash at a redemption price equal to <span id="xdx_90B_ecustom--TemporaryEquityStockStatedValueAccumulatedDividends_dp_uPure_c20211101__20220131_z6BUH97lg1Ji" title="Temporary equity stock stated value accumulated dividends">105</span>% of the stated value plus an amount equal to accumulated but unpaid dividends, if any, on such shares (whether or not earned or declared, but excluding interest on such dividends) up to, but excluding, the Redemption Date. Under certain circumstances, the commencement of the period during which the Series D preferred stock may be redeemed may be extended from 90 days following the original issue date to 135 days following the original issue date, in which case the Redemption Date would be extended to 165 days following the original issue date. Should such extension occur, the redemption price would be increased to an amount equal to <span id="xdx_909_ecustom--TemporaryEquityStockStatedValueAccumulatedDividendsOnExtension_dp_c20211101__20220131_z5cAwQa5rXV9" title="Temporary equity stock stated value accumulated dividends on extension">110</span>% of the stated value plus an amount equal to accumulated but unpaid dividends, if any, on such shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The holders of Series D preferred stock will be entitled to dividends, on an as-if converted basis, equal to dividends actually paid, if any, on shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The $<span id="xdx_90D_ecustom--PaymentsForProceedsFromEscrowOffering_pn4n6_c20220101__20220131_zqlTUark1Ot5" title="Payments for proceeds from escrow offering">4.75</span> million in gross proceeds of the offering are held in an escrow account, along with an additional $<span id="xdx_90D_eus-gaap--EscrowDeposit_iI_c20220131_zPPnso3FGYd2" title="Escrow deposit">500,000</span> deposited by the Company to cover the aggregate original issue discount as well as the additional amount that would be necessary to fund the <span id="xdx_900_ecustom--TemporaryEquityStockStatedValueAccumulatedDividendsOnExpiration_dp_c20211101__20220131_zDRXAWFgMEi9" title="Temporary equity stock stated value accumulated dividends on extension">105</span>% redemption price until the expiration of the redemption period for the Series D Preferred Stock, as applicable, subject to the earlier payment to redeeming holders. Upon expiration of the redemption period, any proceeds remaining in escrow will be disbursed to the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the Offering, the Company and the investors entered into a registration rights agreement, pursuant to which the Company is required to file a registration statement with the Securities and Exchange Commission to register for resale the shares that are issued upon the conversion of shares of Series D preferred stock. The registration statement will be filed with the Securities and Exchange Commission on or before the 60th calendar day following the first date on which shares are issued upon the conversion of shares of Series D preferred stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since the Series D preferred stock has a redemption feature at the option of the holder, it is classified as temporary equity. At the January 31, 2022 issuance date, the Series D preferred stock was recorded on the balance sheet at approximately $<span id="xdx_90A_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_pn3n3_c20220131_zK6Gwbch2FP4" title="Temporary equity, carrying amount, attributable to parent">4,225</span>,000, which is the $<span id="xdx_905_ecustom--ProceedsFromIssuanceOrEstimatedOffering_c20220101__20220131_zW2LzfZAA805" title="Proceeds from issuance or estimated offering">4,312,000</span> net proceeds less the $<span id="xdx_90F_eus-gaap--PreferredStockRedemptionAmount_iI_c20220131_z8G1gURRs78i" title="Preferred stock, redemption amount">87,000</span> value of the bifurcated preferred stock redemption liability (see below).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preferred Stock Redemption Liability</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluated the preferred stock redemption feature under ASC 815. Since the preferred stock redemption feature is not considered to be clearly and closely related to the preferred stock host and the redemption feature meets the four characteristics of a derivative under ASC 815, the preferred stock redemption feature is required to be bifurcated from the preferred stock host and valued as a liability. The Company utilized a binomial model to calculate the fair value of the preferred stock redemption feature at issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_ecustom--PreferredStockRedemptionLiabilityTableTextBlock_zukvnZyejRu6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In measuring the preferred stock redemption liability at January 31, 2022 (issuance date), the Company used the following inputs in its binomial model:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8BD_zFgCQv8MwmK9" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">SCHEDULE OF PREFERRED STOCK REDEMPTION LIABILITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">January 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Exercise Price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20220131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zazwW8WUU0ec" style="width: 16%; text-align: right" title="Exercise Price">0.25</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Stock Price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20220131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z61588canNWd" style="text-align: right" title="Stock Price">0.136</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility %</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20220131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zzwySFReYbVa" title="Measurement input percentage">105</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk Free Rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20220131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zIR085zJANoi" title="Measurement input percentage">1.00</span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A3_zdlK6rJ6TS0g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">At January 31, 2022, the fair value of </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the preferred stock redemption liability <span style="background-color: white">was approximately $<span id="xdx_906_eus-gaap--PreferredStockRedemptionAmount_iI_c20220131_zjiJWUbT1kri" title="Preferred stock, redemption amount">87,000</span>.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 1000000 5000000 4.75 0.05 4312000 30000 0.25 1.05 1.10 4750000 500000 1.05 4225000 4312000 87000 <p id="xdx_895_ecustom--PreferredStockRedemptionLiabilityTableTextBlock_zukvnZyejRu6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In measuring the preferred stock redemption liability at January 31, 2022 (issuance date), the Company used the following inputs in its binomial model:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8BD_zFgCQv8MwmK9" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">SCHEDULE OF PREFERRED STOCK REDEMPTION LIABILITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">January 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Exercise Price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20220131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zazwW8WUU0ec" style="width: 16%; text-align: right" title="Exercise Price">0.25</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Stock Price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20220131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z61588canNWd" style="text-align: right" title="Stock Price">0.136</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility %</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20220131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zzwySFReYbVa" title="Measurement input percentage">105</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk Free Rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20220131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zIR085zJANoi" title="Measurement input percentage">1.00</span></td><td style="text-align: left">%</td></tr> </table> 0.25 0.136 105 1.00 87000 <p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zMMDp3ar8n54" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10. <span id="xdx_825_zINLvkso575e">STOCKHOLDERS’ EQUITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_z5rcIfvHdCxd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the changes in stockholders’ equity for the three months ended January 31, 2022 and 2021 is presented below (in thousands, except share data):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8BA_z2KmVIbkOv86" style="display: none">SUMMARY OF STOCKHOLDERS EQUITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zpOta7dKpw3l" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zYH6tAhiQjh7" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zrghyx4HtgIe" style="border-bottom: Black 1.5pt solid; text-align: center">Capital</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zNuINDaj3Nn2" style="border-bottom: Black 1.5pt solid; text-align: center">Deficit</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4BF_ztAhzDZBnnFf" style="border-bottom: Black 1.5pt solid; text-align: center">Equity</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Preferred Stock</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Additional Paid-In</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Accumulated</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Total Shareholders’</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Capital</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Deficit</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Equity</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_43C_c20201101__20210131_eus-gaap--StockholdersEquity_iS_znsV1WS18fO7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 30%">Balance at November 1, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zavE1O4BXv81" style="width: 6%; text-align: right" title="Beginning balance, shares">  <span style="-sec-ix-hidden: xdx2ixbrl0755"> </span>-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">    <span style="-sec-ix-hidden: xdx2ixbrl0749"> </span>-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z03csIsIHhm5" style="width: 6%; text-align: right" title="Beginning balance, shares">78,074,023</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">78</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">440,840</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(410,738</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">30,180</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_43E_c20201101__20210131_eus-gaap--StockholdersEquity_iS_zxC6zWdyY3u5" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Beginning balance, value</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zDEQuj1bUOqk" style="text-align: right" title="Beginning balance, shares">  <span style="-sec-ix-hidden: xdx2ixbrl0765"> </span>-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">    <span style="-sec-ix-hidden: xdx2ixbrl0759"> </span>-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zN565Ghw5CGf" style="text-align: right" title="Beginning balance, shares">78,074,023</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">78</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">440,840</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(410,738</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">30,180</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_z004sZGiQVj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationGross_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zgwdBgDeUcqj" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0774">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0769"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0770"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">236</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0772"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">236</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zSZbsEqFJFXd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Advaxis public offerings, net of offering costs</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zHJSzSJOey74" style="text-align: right" title="Advaxis public offerings, net of offering costs, shares"><span style="-sec-ix-hidden: xdx2ixbrl0782">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0776"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4CGowlY6KT2" style="text-align: right" title="Advaxis public offerings, net of offering costs, shares">30,666,665</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,519</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0779"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,550</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--StockIssuedDuringPeriodValueWarrantsExercised_ziU9JnDRk9w6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant exercises</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0786"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3ysinyKRf21" style="text-align: right" title="Warrant exercises, shares">7,390,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,579</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0789"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,586</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--NetIncomeLoss_zvrAsoIHlbyi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Net Loss</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0794"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0795"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0796"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,977</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,977</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_43E_c20201101__20210131_eus-gaap--StockholdersEquity_iE_zzHRjUcAzfCg" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at January 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zWujIExgXbDa" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, shares"><span style="-sec-ix-hidden: xdx2ixbrl0806">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0800">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqO3Sqs93Bx1" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, shares">116,130,688</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">116</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">452,174</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(414,715</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">37,575</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_438_c20201101__20210131_eus-gaap--StockholdersEquity_iE_zhhv42Eaq1L1" style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Ending balance , value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zi49wgNGRjVd" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, shares"><span style="-sec-ix-hidden: xdx2ixbrl0816">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0810">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_za6od5z4qKY5" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, shares">116,130,688</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">116</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">452,174</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(414,715</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">37,575</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Preferred Stock</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Additional <br/> Paid-In</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Accumulated</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Total <br/> Shareholders’</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Capital</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Deficit</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Equity</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_43C_c20211101__20220131_eus-gaap--StockholdersEquity_iS_zFuxzmaPIyXi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 30%">Balance at November 1, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_pid_c20211101__20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zCz0wg9NtIv3" style="width: 6%; text-align: right" title="Beginning balance, shares">   <span style="-sec-ix-hidden: xdx2ixbrl0826"> </span>-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">      <span style="-sec-ix-hidden: xdx2ixbrl0820"> </span>-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20211101__20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvwXoDs4bKXk" style="width: 6%; text-align: right" title="Beginning balance, shares">145,638,459</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">146</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">467,342</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(428,600</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">38,888</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_434_c20211101__20220131_eus-gaap--StockholdersEquity_iS_zoWk2Sh0yYy5" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Beginning balance, value</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20211101__20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zxkJDDuGLX4k" style="text-align: right" title="Beginning balance, shares">   <span style="-sec-ix-hidden: xdx2ixbrl0836"> </span>-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">      <span style="-sec-ix-hidden: xdx2ixbrl0830"> </span>-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20211101__20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbhtiKZ894Dk" style="text-align: right" title="Beginning balance, shares">145,638,459</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">146</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">467,342</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(428,600</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">38,888</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_z27wfd0uEWA4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationGross_pid_c20211101__20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zgQjjmHkDB7f" style="text-align: right" title="Stock-based compensation, shares"><span style="-sec-ix-hidden: xdx2ixbrl0846">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0840"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationGross_pid_c20211101__20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5cdFrwGySAf" style="text-align: right" title="Stock-based compensation, shares"><span style="-sec-ix-hidden: xdx2ixbrl0848">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0841"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0843"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--NetIncomeLoss_zXYx8gZgqitd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Net Loss</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0850"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0851"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0852"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(365</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(365</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_436_c20211101__20220131_eus-gaap--StockholdersEquity_iE_z1JgeivaJaR8" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at January 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pid_c20211101__20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zDRwCMVL4ehd" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, shares"><span style="-sec-ix-hidden: xdx2ixbrl0862">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0856">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_pid_c20211101__20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znWpMGcrNVW" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, shares">145,638,459</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">146</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">467,368</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(428,965</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">38,549</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_431_c20211101__20220131_eus-gaap--StockholdersEquity_iE_zdEzoOWZnjJg" style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Ending balance, value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_pid_c20211101__20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zenPAJSYrHOh" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, shares"><span style="-sec-ix-hidden: xdx2ixbrl0872">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0866">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_pid_c20211101__20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH6dXOdiClPi" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, shares">145,638,459</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">146</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">467,368</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(428,965</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">38,549</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zecSGHtCOY79" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_z5rcIfvHdCxd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the changes in stockholders’ equity for the three months ended January 31, 2022 and 2021 is presented below (in thousands, except share data):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8BA_z2KmVIbkOv86" style="display: none">SUMMARY OF STOCKHOLDERS EQUITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zpOta7dKpw3l" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zYH6tAhiQjh7" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zrghyx4HtgIe" style="border-bottom: Black 1.5pt solid; text-align: center">Capital</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zNuINDaj3Nn2" style="border-bottom: Black 1.5pt solid; text-align: center">Deficit</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4BF_ztAhzDZBnnFf" style="border-bottom: Black 1.5pt solid; text-align: center">Equity</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Preferred Stock</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Additional Paid-In</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Accumulated</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Total Shareholders’</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Capital</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Deficit</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Equity</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_43C_c20201101__20210131_eus-gaap--StockholdersEquity_iS_znsV1WS18fO7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 30%">Balance at November 1, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zavE1O4BXv81" style="width: 6%; text-align: right" title="Beginning balance, shares">  <span style="-sec-ix-hidden: xdx2ixbrl0755"> </span>-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">    <span style="-sec-ix-hidden: xdx2ixbrl0749"> </span>-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z03csIsIHhm5" style="width: 6%; text-align: right" title="Beginning balance, shares">78,074,023</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">78</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">440,840</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(410,738</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">30,180</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_43E_c20201101__20210131_eus-gaap--StockholdersEquity_iS_zxC6zWdyY3u5" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Beginning balance, value</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zDEQuj1bUOqk" style="text-align: right" title="Beginning balance, shares">  <span style="-sec-ix-hidden: xdx2ixbrl0765"> </span>-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">    <span style="-sec-ix-hidden: xdx2ixbrl0759"> </span>-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zN565Ghw5CGf" style="text-align: right" title="Beginning balance, shares">78,074,023</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">78</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">440,840</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(410,738</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">30,180</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_z004sZGiQVj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationGross_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zgwdBgDeUcqj" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0774">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0769"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0770"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">236</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0772"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">236</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zSZbsEqFJFXd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Advaxis public offerings, net of offering costs</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zHJSzSJOey74" style="text-align: right" title="Advaxis public offerings, net of offering costs, shares"><span style="-sec-ix-hidden: xdx2ixbrl0782">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0776"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4CGowlY6KT2" style="text-align: right" title="Advaxis public offerings, net of offering costs, shares">30,666,665</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,519</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0779"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,550</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--StockIssuedDuringPeriodValueWarrantsExercised_ziU9JnDRk9w6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant exercises</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0786"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3ysinyKRf21" style="text-align: right" title="Warrant exercises, shares">7,390,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,579</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0789"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,586</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--NetIncomeLoss_zvrAsoIHlbyi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Net Loss</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0794"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0795"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0796"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,977</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,977</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_43E_c20201101__20210131_eus-gaap--StockholdersEquity_iE_zzHRjUcAzfCg" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at January 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zWujIExgXbDa" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, shares"><span style="-sec-ix-hidden: xdx2ixbrl0806">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0800">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqO3Sqs93Bx1" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, shares">116,130,688</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">116</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">452,174</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(414,715</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">37,575</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_438_c20201101__20210131_eus-gaap--StockholdersEquity_iE_zhhv42Eaq1L1" style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Ending balance , value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zi49wgNGRjVd" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, shares"><span style="-sec-ix-hidden: xdx2ixbrl0816">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0810">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_za6od5z4qKY5" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, shares">116,130,688</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">116</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">452,174</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(414,715</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">37,575</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Preferred Stock</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Additional <br/> Paid-In</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Accumulated</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Total <br/> Shareholders’</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Capital</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Deficit</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Equity</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_43C_c20211101__20220131_eus-gaap--StockholdersEquity_iS_zFuxzmaPIyXi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 30%">Balance at November 1, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_pid_c20211101__20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zCz0wg9NtIv3" style="width: 6%; text-align: right" title="Beginning balance, shares">   <span style="-sec-ix-hidden: xdx2ixbrl0826"> </span>-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">      <span style="-sec-ix-hidden: xdx2ixbrl0820"> </span>-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20211101__20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvwXoDs4bKXk" style="width: 6%; text-align: right" title="Beginning balance, shares">145,638,459</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">146</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">467,342</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(428,600</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">38,888</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_434_c20211101__20220131_eus-gaap--StockholdersEquity_iS_zoWk2Sh0yYy5" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Beginning balance, value</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20211101__20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zxkJDDuGLX4k" style="text-align: right" title="Beginning balance, shares">   <span style="-sec-ix-hidden: xdx2ixbrl0836"> </span>-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">      <span style="-sec-ix-hidden: xdx2ixbrl0830"> </span>-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20211101__20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbhtiKZ894Dk" style="text-align: right" title="Beginning balance, shares">145,638,459</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">146</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">467,342</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(428,600</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">38,888</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_z27wfd0uEWA4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationGross_pid_c20211101__20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zgQjjmHkDB7f" style="text-align: right" title="Stock-based compensation, shares"><span style="-sec-ix-hidden: xdx2ixbrl0846">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0840"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationGross_pid_c20211101__20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5cdFrwGySAf" style="text-align: right" title="Stock-based compensation, shares"><span style="-sec-ix-hidden: xdx2ixbrl0848">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0841"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0843"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--NetIncomeLoss_zXYx8gZgqitd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Net Loss</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0850"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0851"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0852"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(365</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(365</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_436_c20211101__20220131_eus-gaap--StockholdersEquity_iE_z1JgeivaJaR8" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at January 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pid_c20211101__20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zDRwCMVL4ehd" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, shares"><span style="-sec-ix-hidden: xdx2ixbrl0862">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0856">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_pid_c20211101__20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znWpMGcrNVW" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, shares">145,638,459</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">146</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">467,368</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(428,965</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">38,549</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_431_c20211101__20220131_eus-gaap--StockholdersEquity_iE_zdEzoOWZnjJg" style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Ending balance, value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_pid_c20211101__20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zenPAJSYrHOh" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, shares"><span style="-sec-ix-hidden: xdx2ixbrl0872">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0866">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_pid_c20211101__20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH6dXOdiClPi" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, shares">145,638,459</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">146</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">467,368</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(428,965</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">38,549</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 78074023 78000 440840000 -410738000 30180000 78074023 78000 440840000 -410738000 30180000 236000 236000 30666665 31000 8519000 8550000 7390000 7000 2579000 2586000 -3977000 -3977000 116130688 116000 452174000 -414715000 37575000 116130688 116000 452174000 -414715000 37575000 145638459 146000 467342000 -428600000 38888000 145638459 146000 467342000 -428600000 38888000 26000 26000 -365000 -365000 145638459 146000 467368000 -428965000 38549000 145638459 146000 467368000 -428965000 38549000 <p id="xdx_809_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zVLfF363jwC6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11. <span id="xdx_823_zbeG3sr1Xx2j">SHARE BASED COMPENSATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zrFfIPISw2O3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes share-based compensation expense included in the condensed consolidated statements of operations (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zgFImC5Tdw42" style="display: none">SUMMARY OF SHARE BASED COMPENSATION EXPENSE </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three Months Ended January 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Research and development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20211101__20220131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zpqZNmAActca" style="width: 16%; text-align: right" title="Share-based compensation expense">13</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensation_pn3n3_c20201101__20210131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zIOaqKkQmVpa" style="width: 16%; text-align: right" title="Share-based compensation expense">57</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensation_pn3n3_c20211101__20220131__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zdilteUBP6A5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Share-based compensation expense">13</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_pn3n3_c20201101__20210131__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zl5Xp8epgnNk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Share-based compensation expense">179</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20211101__20220131_zIaBQYPMoLP3" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based compensation expense">26</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20201101__20210131_zWnJUVH6VNRh" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based compensation expense">236</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_znRw9WppRD3i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock Options</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zj4jxfHQhVe7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of changes in the stock option plan for the three months ended January 31, 2022 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BE_z99pMk2NuW38" style="display: none">SUMMARY OF CHANGES IN STOCK OPTION PLAN</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted <br/> Average <br/> Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted <br/> Average <br/> Remaining <br/> Contractual Life <br/> In Years</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Aggregate <br/> Intrinsic Value <br/> (in thousands)</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding as of October 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20211101__20220131_zuQSzQS5KzWk" style="width: 11%; text-align: right" title="Shares Outstanding, Beginning Balance">893,946</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20211101__20220131_zm6Hi1Mx093h" style="width: 11%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning">19.32</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211101__20220131_z7jLSJBHDW28" title="Weighted Average Remaining Contractual Life In Years, Beginning">7.80</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20211101__20220131_zX1zsgSdPwja" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value, Beginning">         27</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Cancelled or expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20211101__20220131_zVYt49PhlPSg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares, Cancelled or Expired">(5,888</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20211101__20220131_zCA8lbEINeG" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Cancelled or Expired">277.50</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding as of January 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20211101__20220131_zJuexT7ewIra" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares, Outstanding, Ending Balance">888,058</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20211101__20220131_zT26ku5szK7d" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding, Ending">17.61</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20211101__20220131_z2DxqBOvIVj4" title="Weighted Average Remaining Contractual Life In Years, Ending Balance">7.55</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20211101__20220131_zChlZql0Z45g" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Ending"><span style="-sec-ix-hidden: xdx2ixbrl0912">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Vested and exercisable at January 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20220131_zwvedPPZy2c2" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares, Vested and Exercisable">484,641</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220131_zehBFp1T84N8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Vested and Exercisable">31.80</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20211101__20220131_zFJzPZz8TVKe" title="Weighted Average Remaining Contractual Life In Years, Vested and Exercisable">6.89</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20220131_zK7o7I6X0DH8" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl0920">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zbrLCK1WFCyg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zzBNaIV5jqm6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes information about the outstanding and exercisable options at January 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B5_zUtUYZ8B3Mfk" style="display: none">SUMMARY OF OUTSTANDING AND EXERCISABLE OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="14" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options Outstanding</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="10" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options Exercisable</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price Range</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contractual</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contractual</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zolmvzEhLOjk" title="Exercise Price Range, lower limit">.30</span>-$<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zkwC19Cg0kNf" title="Exercise Price Range, upper limit">1.00</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_z8nHhMa9Pjyj" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number Outstanding, Options Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">672,500</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zPwQWfzKwcFh" title="Weighted Average Remaining Contractual, Options Outstanding">8.29</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zI6W3ne99bql" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Weighted Average Exercise Price, Options Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.54</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zLiConPGeTL5" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number Outstanding, Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">270,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zDYZyX5noD2l" title="Weighted Average Remaining Contractual Term Exercisable, Options Exercisable">8.20</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zdbVUpmrsr6d" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Weighted Average Exercise Price, Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.50</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_znVSlXaqzTe8" title="Exercise Price Range, lower limit">1.01</span>-$<span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zuXA9V4KC1ik" title="Exercise Price Range, upper limit">10.00</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zxC5TZHmPo4l" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number Outstanding, Options Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55,379</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zvF497BOIemk" title="Weighted Average Remaining Contractual, Options Outstanding">6.80</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_z269UZeeZ094" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.47</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zHP1vXfsNyM9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number Outstanding, Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54,462</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zpWJEuln1Bva" title="Weighted Average Remaining Contractual Term Exercisable, Options Exercisable">6.79</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zQkMOtnr5Tv3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.56</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_ziJ3peCZOzc8" title="Exercise Price Range, lower limit">10.01</span>-$<span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zQHgqK3h3RR8" title="Exercise Price Range, upper limit">100.00</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zIEQkYWSruj4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number Outstanding, Options Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90,432</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_z8HCpXYQXKvl" title="Weighted Average Remaining Contractual, Options Outstanding">5.97</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zR5Kwv06HJj6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29.02</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zXfnu69Y6p87" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number Outstanding, Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90,432</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zJdRsoftSIzl" title="Weighted Average Remaining Contractual Term Exercisable, Options Exercisable">5.97</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_ztdu2FcGU4u3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29.02</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_zXDOV7AYtJI9" title="Exercise Price Range, lower limit">100.01</span>-$<span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_zHstNM8sRhLe" title="Exercise Price Range, upper limit">258.30</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_z97XGMtl4b14" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number Outstanding, Options Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69,747</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_zgCT0xnNU9q1" title="Weighted Average Remaining Contractual, Options Outstanding">3.07</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_z71tU48ApLa5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">175.51</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_z6Oq7hrQciTd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number Outstanding, Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69,747</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_zQHZYzAR0nAi" title="Weighted Average Remaining Contractual Term Exercisable, Options Exercisable">3.07</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_z1zwp7TZGAQj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">175.51</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AF_zyoSlqEhO1vd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of January 31, 2022, there was approximately $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20220131_z3PI6ZE7cDzi" title="Unrecognized compensation cost related to outstanding stock options">125,000</span> of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining weighted average vesting period of <span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20211101__20220131_za3JRJtgvf1k" title="Unrecognized compensation cost related to non-vested remaining weighted average vesting period">1.38</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Potential Acceleration of Stock Options</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the event of a merger transaction, similar to the Previously Proposed Merger Agreement, all of the Chief Executive Officer’s <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20220131__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z59F2Oc61pY6" title="Share-based compensation arrangement by share-based payment award, options, nonvested, number of shares">73,777</span> unvested stock options, pursuant to his employment agreement, would accelerate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_89C_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zrFfIPISw2O3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes share-based compensation expense included in the condensed consolidated statements of operations (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zgFImC5Tdw42" style="display: none">SUMMARY OF SHARE BASED COMPENSATION EXPENSE </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three Months Ended January 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Research and development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20211101__20220131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zpqZNmAActca" style="width: 16%; text-align: right" title="Share-based compensation expense">13</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensation_pn3n3_c20201101__20210131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zIOaqKkQmVpa" style="width: 16%; text-align: right" title="Share-based compensation expense">57</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensation_pn3n3_c20211101__20220131__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zdilteUBP6A5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Share-based compensation expense">13</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_pn3n3_c20201101__20210131__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zl5Xp8epgnNk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Share-based compensation expense">179</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20211101__20220131_zIaBQYPMoLP3" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based compensation expense">26</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20201101__20210131_zWnJUVH6VNRh" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based compensation expense">236</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 13000 57000 13000 179000 26000 236000 <p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zj4jxfHQhVe7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of changes in the stock option plan for the three months ended January 31, 2022 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BE_z99pMk2NuW38" style="display: none">SUMMARY OF CHANGES IN STOCK OPTION PLAN</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted <br/> Average <br/> Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted <br/> Average <br/> Remaining <br/> Contractual Life <br/> In Years</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Aggregate <br/> Intrinsic Value <br/> (in thousands)</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding as of October 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20211101__20220131_zuQSzQS5KzWk" style="width: 11%; text-align: right" title="Shares Outstanding, Beginning Balance">893,946</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20211101__20220131_zm6Hi1Mx093h" style="width: 11%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning">19.32</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211101__20220131_z7jLSJBHDW28" title="Weighted Average Remaining Contractual Life In Years, Beginning">7.80</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20211101__20220131_zX1zsgSdPwja" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value, Beginning">         27</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Cancelled or expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20211101__20220131_zVYt49PhlPSg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares, Cancelled or Expired">(5,888</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20211101__20220131_zCA8lbEINeG" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Cancelled or Expired">277.50</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding as of January 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20211101__20220131_zJuexT7ewIra" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares, Outstanding, Ending Balance">888,058</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20211101__20220131_zT26ku5szK7d" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding, Ending">17.61</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20211101__20220131_z2DxqBOvIVj4" title="Weighted Average Remaining Contractual Life In Years, Ending Balance">7.55</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20211101__20220131_zChlZql0Z45g" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Ending"><span style="-sec-ix-hidden: xdx2ixbrl0912">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Vested and exercisable at January 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20220131_zwvedPPZy2c2" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares, Vested and Exercisable">484,641</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220131_zehBFp1T84N8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Vested and Exercisable">31.80</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20211101__20220131_zFJzPZz8TVKe" title="Weighted Average Remaining Contractual Life In Years, Vested and Exercisable">6.89</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20220131_zK7o7I6X0DH8" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl0920">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 893946 19.32 P7Y9M18D 27000 5888 277.50 888058 17.61 P7Y6M18D 484641 31.80 P6Y10M20D <p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zzBNaIV5jqm6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes information about the outstanding and exercisable options at January 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B5_zUtUYZ8B3Mfk" style="display: none">SUMMARY OF OUTSTANDING AND EXERCISABLE OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="14" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options Outstanding</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="10" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options Exercisable</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price Range</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contractual</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contractual</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zolmvzEhLOjk" title="Exercise Price Range, lower limit">.30</span>-$<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zkwC19Cg0kNf" title="Exercise Price Range, upper limit">1.00</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_z8nHhMa9Pjyj" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number Outstanding, Options Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">672,500</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zPwQWfzKwcFh" title="Weighted Average Remaining Contractual, Options Outstanding">8.29</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zI6W3ne99bql" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Weighted Average Exercise Price, Options Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.54</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zLiConPGeTL5" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number Outstanding, Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">270,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zDYZyX5noD2l" title="Weighted Average Remaining Contractual Term Exercisable, Options Exercisable">8.20</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zdbVUpmrsr6d" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Weighted Average Exercise Price, Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.50</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_znVSlXaqzTe8" title="Exercise Price Range, lower limit">1.01</span>-$<span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zuXA9V4KC1ik" title="Exercise Price Range, upper limit">10.00</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zxC5TZHmPo4l" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number Outstanding, Options Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55,379</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zvF497BOIemk" title="Weighted Average Remaining Contractual, Options Outstanding">6.80</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_z269UZeeZ094" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.47</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zHP1vXfsNyM9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number Outstanding, Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54,462</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zpWJEuln1Bva" title="Weighted Average Remaining Contractual Term Exercisable, Options Exercisable">6.79</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zQkMOtnr5Tv3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.56</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_ziJ3peCZOzc8" title="Exercise Price Range, lower limit">10.01</span>-$<span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zQHgqK3h3RR8" title="Exercise Price Range, upper limit">100.00</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zIEQkYWSruj4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number Outstanding, Options Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90,432</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_z8HCpXYQXKvl" title="Weighted Average Remaining Contractual, Options Outstanding">5.97</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zR5Kwv06HJj6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29.02</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zXfnu69Y6p87" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number Outstanding, Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90,432</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zJdRsoftSIzl" title="Weighted Average Remaining Contractual Term Exercisable, Options Exercisable">5.97</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_ztdu2FcGU4u3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29.02</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_zXDOV7AYtJI9" title="Exercise Price Range, lower limit">100.01</span>-$<span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_zHstNM8sRhLe" title="Exercise Price Range, upper limit">258.30</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_z97XGMtl4b14" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number Outstanding, Options Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69,747</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_zgCT0xnNU9q1" title="Weighted Average Remaining Contractual, Options Outstanding">3.07</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_z71tU48ApLa5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">175.51</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_z6Oq7hrQciTd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number Outstanding, Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69,747</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211101__20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_zQHZYzAR0nAi" title="Weighted Average Remaining Contractual Term Exercisable, Options Exercisable">3.07</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220131__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_z1zwp7TZGAQj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">175.51</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 0.30 1.00 672500 P8Y3M14D 0.54 270000 P8Y2M12D 0.50 1.01 10.00 55379 P6Y9M18D 7.47 54462 P6Y9M14D 7.56 10.01 100.00 90432 P5Y11M19D 29.02 90432 P5Y11M19D 29.02 100.01 258.30 69747 P3Y25D 175.51 69747 P3Y25D 175.51 125000000000 P1Y4M17D 73777 <p id="xdx_800_ecustom--LicensingAgreementsDisclosuresTextBlock_zhsUojY3Tbbk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12. <span id="xdx_826_z5ANTkjunUv6">LICENSING AGREEMENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>OS Therapies LLC</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 4, 2018, the Company entered into a development, license and supply agreement with OS Therapies (“OST”) for the use of ADXS31-164, also known as ADXS-HER2, for evaluation in the treatment of osteosarcoma in humans. Under the terms of the license agreement, as amended, OST will be responsible for the conduct and funding of a clinical study evaluating ADXS-HER2 in recurrent, completely resected osteosarcoma. Under the most recent amendment to the licensing agreement, OST agreed to pay Advaxis $<span id="xdx_90D_eus-gaap--Revenues_pp0p0_c20200429__20200430__us-gaap--TypeOfArrangementAxis__custom--DevelopmentLicenseAndSupplyAgreementMember__srt--StatementScenarioAxis__custom--OSTherapiesMember_z6yxeRv31qtk" title="Revenue">25,000</span> per month (“Monthly Payment”) starting on April 30, 2020 until it achieved its funding milestone of $<span id="xdx_90C_ecustom--FundingMilestonePayment_pp0p0_c20180903__20180904__us-gaap--TypeOfArrangementAxis__custom--DevelopmentLicenseAndSupplyAgreementMember__srt--StatementScenarioAxis__custom--OSTherapiesMember_zfAmJOZk0E3" title="Funding milestone payment">2,337,500</span>. Upon receipt of the first Monthly Payment, Advaxis initiated the transfer of the intellectual property and licensing rights of ADXS31-164, which were licensed pursuant to the Penn Agreement, back to the University of Pennsylvania. Contemporaneously, OST will enter negotiations with the University of Pennsylvania to establish a licensing agreement for ADXS31-164 to OST for clinical and commercial development of the ADXS31-164 technology.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended January 31, 2021, <span id="xdx_90C_ecustom--MilestoneAchievementDescription_c20211101__20220131_z0WG7b8LYIUa" title="Milestone achievement, description">the Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement</span>. The Company therefore transferred and OST took full ownership of the IND application for ADXS31-164 in its entirety along with agreements and promises contained therein, as well as all obligations associated with this IND or any HER2 product/program development.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> 25000 2337500 the Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement <p id="xdx_80D_eus-gaap--FairValueDisclosuresTextBlock_zY8pOxcx70y3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13. <span id="xdx_82C_zlWz8JXosDii">FAIR VALUE</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● Level 1 — Quoted prices in active markets for identical assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● Level 2— Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zvyGyQmYP1xf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of January 31, 2022 and October 31, 2021 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zecfTW6vxaNk" style="display: none">SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20220131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zgvL8d1wXwJd" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20220131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zYR8ouOGfYt" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20220131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zKDJjg26ciBc" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20220131_zfQTHsvR3I68" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="17" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value measured at January 31, 2022</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: justify">Financial assets at fair value:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_hus-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_z3VcEsxVeO9g" style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Cash equivalents (money market funds)</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">17,154</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1007">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1008">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">17,154</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AssetsFairValueDisclosure_iI_ze91twA4dk2i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total Financial Assets at Fair Value</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">17,154</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1012">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1013">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">17,154</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: justify">Financial liabilities at fair value:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--PreferredStockRedemptionLiability_iI_pn3n3_zaP7vMwWGimc" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Preferred stock redemption liability</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1016">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1017">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">87</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">87</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--CommonStockWarrantLiability_iI_pn3n3_hus-gaap--AwardTypeAxis__custom--ThroughSeptemberTwoThousandTwentyFourMember_zYbJKCZlFye9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Common stock warrant liability, warrants exercisable at $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220131_zak8RIIGlURb" title="Warrant exercise price per share">0.25</span> through September 2024</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1021"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1022"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--CommonStockWarrantLiability1_iI_pn3n3_hus-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zMMETkpsryai" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Common stock warrant liability, warrants exercisable at $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220131__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zoFsaf0mQaT1" title="Warrant exercise price per share">0.70</span> through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1028"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1029"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,120</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,120</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zWCDSJlwy88e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total financial liabilities at fair value</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1035">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1036">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,214</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,214</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20211031__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_ztURdGHzghg7" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20211031__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zSriQ5ENbVBc" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20211031__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zbx5bQvncZff" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20211031_zh7gIhuggfX3" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="17" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value measured at October 31, 2021</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: justify">Financial assets at fair value:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_hus-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_ztiDiwvXgPRe" style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Cash equivalents (money market funds)</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">17,153</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1041">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1042">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">17,153</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AssetsFairValueDisclosure_iI_zwdTJsArt2F6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total Financial Assets at Fair Value</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">17,153</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1046">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1047">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">17,153</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: justify">Financial liabilities at fair value:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--CommonStockWarrantLiability_iI_pn3n3_hus-gaap--AwardTypeAxis__custom--ThroughSeptemberTwoThousandTwentyFourMember_zno2ZVU32Wxd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Common stock warrant liability, warrants exercisable at $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031_zEdgZa3l5Ar2" title="Warrant exercise price per share">0.30</span> through September 2024</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1050">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1051">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">27</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">27</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--CommonStockWarrantLiability1_iI_pn3n3_hus-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zO0Hluqlt3dc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Common stock warrant liability, warrants exercisable at $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zsEr3IxQdd88" title="Warrant exercise price per share">0.70</span> through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1057"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1058"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,902</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,902</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zbkysW8iJqQ3" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total financial liabilities at fair value</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1064">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1065">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">4,929</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">4,929</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zjOTM1z57IDf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zHvjcplpeTG1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents changes in Level 3 liabilities measured at fair value (in thousands) for the three months ended January 31, 2022. Unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_ztDle1h9dEU9" style="display: none">SCHEDULE OF FAIR VALUE MEASURING UNOBSERVABLE INPUTS</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Preferred Stock Redemption Liability</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrant Liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; font-weight: bold; text-align: justify">Fair value at October 31, 2021</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20211101__20220131__us-gaap--FairValueByLiabilityClassAxis__custom--PreferredStockRedemptionLiabilityMember_zTK0NgZDitLc" style="width: 14%; font-weight: bold; text-align: right">          <span style="-sec-ix-hidden: xdx2ixbrl1070"> </span>-</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20211101__20220131__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zlDnqxPRWLVf" style="width: 14%; font-weight: bold; text-align: right" title="Fair Value, Measurement , Beginning Balance">4,929</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20211101__20220131_zyM6XNH7crXh" style="width: 14%; font-weight: bold; text-align: right" title="Fair Value, Measurement , Beginning Balance">4,929</td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Additions</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_c20211101__20220131__us-gaap--FairValueByLiabilityClassAxis__custom--PreferredStockRedemptionLiabilityMember_zA8EsDzuYpUb" style="text-align: right" title="Fair Value, Measurement, Additions">87</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_c20211101__20220131__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zkbEq8OKnt25" style="text-align: right" title="Fair Value, Measurement, Additions"><span style="-sec-ix-hidden: xdx2ixbrl1078">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_c20211101__20220131_zkVqZ1ZJ86Tj" style="text-align: right" title="Fair Value, Measurement, Additions">87</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20211101__20220131__us-gaap--FairValueByLiabilityClassAxis__custom--PreferredStockRedemptionLiabilityMember_zQCZCtHQenT3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value, Measurement, Change in fair value"><span style="-sec-ix-hidden: xdx2ixbrl1082">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20211101__20220131__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_z2x7l3Lka89" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value, Measurement, Change in fair value">(3,802</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20211101__20220131_z3BfNo2AEW95" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value, Measurement, Change in fair value">(3,802</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Fair value at January 31, 2022</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20211101__20220131__us-gaap--FairValueByLiabilityClassAxis__custom--PreferredStockRedemptionLiabilityMember_zHvF5hNOE3Zj" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair Value, Measurement , Ending Balance">87</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20211101__20220131__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zbD7smzrkh6c" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair Value, Measurement , Ending Balance">1,127</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20211101__20220131_zzZH6nCZzdBa" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair Value, Measurement , Ending Balance">1,214</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zKpwynJlfzwj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_89B_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zvyGyQmYP1xf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of January 31, 2022 and October 31, 2021 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zecfTW6vxaNk" style="display: none">SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20220131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zgvL8d1wXwJd" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20220131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zYR8ouOGfYt" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20220131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zKDJjg26ciBc" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20220131_zfQTHsvR3I68" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="17" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value measured at January 31, 2022</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: justify">Financial assets at fair value:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_hus-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_z3VcEsxVeO9g" style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Cash equivalents (money market funds)</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">17,154</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1007">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1008">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">17,154</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AssetsFairValueDisclosure_iI_ze91twA4dk2i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total Financial Assets at Fair Value</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">17,154</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1012">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1013">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">17,154</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: justify">Financial liabilities at fair value:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--PreferredStockRedemptionLiability_iI_pn3n3_zaP7vMwWGimc" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Preferred stock redemption liability</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1016">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1017">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">87</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">87</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--CommonStockWarrantLiability_iI_pn3n3_hus-gaap--AwardTypeAxis__custom--ThroughSeptemberTwoThousandTwentyFourMember_zYbJKCZlFye9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Common stock warrant liability, warrants exercisable at $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220131_zak8RIIGlURb" title="Warrant exercise price per share">0.25</span> through September 2024</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1021"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1022"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--CommonStockWarrantLiability1_iI_pn3n3_hus-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zMMETkpsryai" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Common stock warrant liability, warrants exercisable at $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220131__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zoFsaf0mQaT1" title="Warrant exercise price per share">0.70</span> through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1028"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1029"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,120</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,120</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zWCDSJlwy88e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total financial liabilities at fair value</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1035">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1036">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,214</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,214</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20211031__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_ztURdGHzghg7" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20211031__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zSriQ5ENbVBc" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20211031__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zbx5bQvncZff" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20211031_zh7gIhuggfX3" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="17" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value measured at October 31, 2021</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: justify">Financial assets at fair value:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_hus-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_ztiDiwvXgPRe" style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Cash equivalents (money market funds)</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">17,153</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1041">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1042">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">17,153</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AssetsFairValueDisclosure_iI_zwdTJsArt2F6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total Financial Assets at Fair Value</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">17,153</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1046">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1047">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">17,153</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: justify">Financial liabilities at fair value:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--CommonStockWarrantLiability_iI_pn3n3_hus-gaap--AwardTypeAxis__custom--ThroughSeptemberTwoThousandTwentyFourMember_zno2ZVU32Wxd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Common stock warrant liability, warrants exercisable at $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031_zEdgZa3l5Ar2" title="Warrant exercise price per share">0.30</span> through September 2024</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1050">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1051">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">27</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">27</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--CommonStockWarrantLiability1_iI_pn3n3_hus-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zO0Hluqlt3dc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Common stock warrant liability, warrants exercisable at $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zsEr3IxQdd88" title="Warrant exercise price per share">0.70</span> through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1057"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1058"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,902</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,902</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zbkysW8iJqQ3" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total financial liabilities at fair value</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1064">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1065">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">4,929</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">4,929</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 17154000 17154000 17154000 17154000 87000 87000 0.25 7000 7000 0.70 1120000 1120000 1214000 1214000 17153000 17153000 17153000 17153000 0.30 27000 27000 0.70 4902000 4902000 4929000 4929000 <p id="xdx_895_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zHvjcplpeTG1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents changes in Level 3 liabilities measured at fair value (in thousands) for the three months ended January 31, 2022. Unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_ztDle1h9dEU9" style="display: none">SCHEDULE OF FAIR VALUE MEASURING UNOBSERVABLE INPUTS</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Preferred Stock Redemption Liability</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrant Liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; font-weight: bold; text-align: justify">Fair value at October 31, 2021</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20211101__20220131__us-gaap--FairValueByLiabilityClassAxis__custom--PreferredStockRedemptionLiabilityMember_zTK0NgZDitLc" style="width: 14%; font-weight: bold; text-align: right">          <span style="-sec-ix-hidden: xdx2ixbrl1070"> </span>-</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20211101__20220131__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zlDnqxPRWLVf" style="width: 14%; font-weight: bold; text-align: right" title="Fair Value, Measurement , Beginning Balance">4,929</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20211101__20220131_zyM6XNH7crXh" style="width: 14%; font-weight: bold; text-align: right" title="Fair Value, Measurement , Beginning Balance">4,929</td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Additions</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_c20211101__20220131__us-gaap--FairValueByLiabilityClassAxis__custom--PreferredStockRedemptionLiabilityMember_zA8EsDzuYpUb" style="text-align: right" title="Fair Value, Measurement, Additions">87</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_c20211101__20220131__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zkbEq8OKnt25" style="text-align: right" title="Fair Value, Measurement, Additions"><span style="-sec-ix-hidden: xdx2ixbrl1078">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_c20211101__20220131_zkVqZ1ZJ86Tj" style="text-align: right" title="Fair Value, Measurement, Additions">87</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20211101__20220131__us-gaap--FairValueByLiabilityClassAxis__custom--PreferredStockRedemptionLiabilityMember_zQCZCtHQenT3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value, Measurement, Change in fair value"><span style="-sec-ix-hidden: xdx2ixbrl1082">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20211101__20220131__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_z2x7l3Lka89" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value, Measurement, Change in fair value">(3,802</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_c20211101__20220131_z3BfNo2AEW95" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value, Measurement, Change in fair value">(3,802</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Fair value at January 31, 2022</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20211101__20220131__us-gaap--FairValueByLiabilityClassAxis__custom--PreferredStockRedemptionLiabilityMember_zHvF5hNOE3Zj" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair Value, Measurement , Ending Balance">87</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20211101__20220131__us-gaap--FairValueByLiabilityClassAxis__custom--WarrantLiabilityMember_zbD7smzrkh6c" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair Value, Measurement , Ending Balance">1,127</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20211101__20220131_zzZH6nCZzdBa" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair Value, Measurement , Ending Balance">1,214</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 4929000 4929000 87000 87000 -3802000 -3802000 87000 1127000 1214000 EXCEL 69 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 70 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 71 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 72 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 149 331 1 false 42 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://advaxis.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://advaxis.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://advaxis.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://advaxis.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://advaxis.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - NATURE OF OPERATIONS Sheet http://advaxis.com/role/NatureOfOperations NATURE OF OPERATIONS Notes 6 false false R7.htm 00000007 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION Sheet http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentation SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION Notes 7 false false R8.htm 00000008 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://advaxis.com/role/PropertyAndEquipment PROPERTY AND EQUIPMENT Notes 8 false false R9.htm 00000009 - Disclosure - INTANGIBLE ASSETS Sheet http://advaxis.com/role/IntangibleAssets INTANGIBLE ASSETS Notes 9 false false R10.htm 00000010 - Disclosure - ACCRUED EXPENSES Sheet http://advaxis.com/role/AccruedExpenses ACCRUED EXPENSES Notes 10 false false R11.htm 00000011 - Disclosure - LEASES Sheet http://advaxis.com/role/Leases LEASES Notes 11 false false R12.htm 00000012 - Disclosure - COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY Sheet http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiability COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY Notes 12 false false R13.htm 00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://advaxis.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 13 false false R14.htm 00000014 - Disclosure - TEMPORARY EQUITY Sheet http://advaxis.com/role/TemporaryEquity TEMPORARY EQUITY Notes 14 false false R15.htm 00000015 - Disclosure - STOCKHOLDERS??? EQUITY Sheet http://advaxis.com/role/StockholdersEquity STOCKHOLDERS??? EQUITY Notes 15 false false R16.htm 00000016 - Disclosure - SHARE BASED COMPENSATION Sheet http://advaxis.com/role/ShareBasedCompensation SHARE BASED COMPENSATION Notes 16 false false R17.htm 00000017 - Disclosure - LICENSING AGREEMENTS Sheet http://advaxis.com/role/LicensingAgreements LICENSING AGREEMENTS Notes 17 false false R18.htm 00000018 - Disclosure - FAIR VALUE Sheet http://advaxis.com/role/FairValue FAIR VALUE Notes 18 false false R19.htm 00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Policies) Sheet http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Policies) Policies 19 false false R20.htm 00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Tables) Sheet http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Tables) Tables http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentation 20 false false R21.htm 00000021 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://advaxis.com/role/PropertyAndEquipmentTables PROPERTY AND EQUIPMENT (Tables) Tables http://advaxis.com/role/PropertyAndEquipment 21 false false R22.htm 00000022 - Disclosure - INTANGIBLE ASSETS (Tables) Sheet http://advaxis.com/role/IntangibleAssetsTables INTANGIBLE ASSETS (Tables) Tables http://advaxis.com/role/IntangibleAssets 22 false false R23.htm 00000023 - Disclosure - ACCRUED EXPENSES (Tables) Sheet http://advaxis.com/role/AccruedExpensesTables ACCRUED EXPENSES (Tables) Tables http://advaxis.com/role/AccruedExpenses 23 false false R24.htm 00000024 - Disclosure - LEASES (Tables) Sheet http://advaxis.com/role/LeasesTables LEASES (Tables) Tables http://advaxis.com/role/Leases 24 false false R25.htm 00000025 - Disclosure - COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Tables) Sheet http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityTables COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Tables) Tables http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiability 25 false false R26.htm 00000026 - Disclosure - TEMPORARY EQUITY (Tables) Sheet http://advaxis.com/role/TemporaryEquityTables TEMPORARY EQUITY (Tables) Tables http://advaxis.com/role/TemporaryEquity 26 false false R27.htm 00000027 - Disclosure - STOCKHOLDERS??? EQUITY (Tables) Sheet http://advaxis.com/role/StockholdersEquityTables STOCKHOLDERS??? EQUITY (Tables) Tables http://advaxis.com/role/StockholdersEquity 27 false false R28.htm 00000028 - Disclosure - SHARE BASED COMPENSATION (Tables) Sheet http://advaxis.com/role/ShareBasedCompensationTables SHARE BASED COMPENSATION (Tables) Tables http://advaxis.com/role/ShareBasedCompensation 28 false false R29.htm 00000029 - Disclosure - FAIR VALUE (Tables) Sheet http://advaxis.com/role/FairValueTables FAIR VALUE (Tables) Tables http://advaxis.com/role/FairValue 29 false false R30.htm 00000030 - Disclosure - NATURE OF OPERATIONS (Details Narrative) Sheet http://advaxis.com/role/NatureOfOperationsDetailsNarrative NATURE OF OPERATIONS (Details Narrative) Details http://advaxis.com/role/NatureOfOperations 30 false false R31.htm 00000031 - Disclosure - SCHEDULE OF ANTI -DILUTED SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details) Sheet http://advaxis.com/role/ScheduleOfAnti-dilutedSecuritiesExcludedFromDilutedNetLossPerShareDetails SCHEDULE OF ANTI -DILUTED SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details) Details 31 false false R32.htm 00000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Details Narrative) Sheet http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Details Narrative) Details http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationTables 32 false false R33.htm 00000033 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details) Sheet http://advaxis.com/role/ScheduleOfPropertyAndEquipmentDetails SCHEDULE OF PROPERTY AND EQUIPMENT (Details) Details 33 false false R34.htm 00000034 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) Sheet http://advaxis.com/role/PropertyAndEquipmentDetailsNarrative PROPERTY AND EQUIPMENT (Details Narrative) Details http://advaxis.com/role/PropertyAndEquipmentTables 34 false false R35.htm 00000035 - Disclosure - SUMMARY OF INTANGIBLE ASSETS (Details) Sheet http://advaxis.com/role/SummaryOfIntangibleAssetsDetails SUMMARY OF INTANGIBLE ASSETS (Details) Details 35 false false R36.htm 00000036 - Disclosure - SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS (Details) Sheet http://advaxis.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS (Details) Details 36 false false R37.htm 00000037 - Disclosure - INTANGIBLE ASSETS (Details Narrative) Sheet http://advaxis.com/role/IntangibleAssetsDetailsNarrative INTANGIBLE ASSETS (Details Narrative) Details http://advaxis.com/role/IntangibleAssetsTables 37 false false R38.htm 00000038 - Disclosure - SUMMARY OF ACCRUED EXPENSES (Details) Sheet http://advaxis.com/role/SummaryOfAccruedExpensesDetails SUMMARY OF ACCRUED EXPENSES (Details) Details 38 false false R39.htm 00000039 - Disclosure - SCHEDULE OF SUPPLEMENTAL BALANCE SHEET RELATED TO LEASES (Details) Sheet http://advaxis.com/role/ScheduleOfSupplementalBalanceSheetRelatedToLeasesDetails SCHEDULE OF SUPPLEMENTAL BALANCE SHEET RELATED TO LEASES (Details) Details 39 false false R40.htm 00000040 - Disclosure - SCHEDULE OF LEASE EXPENSES (Details) Sheet http://advaxis.com/role/ScheduleOfLeaseExpensesDetails SCHEDULE OF LEASE EXPENSES (Details) Details 40 false false R41.htm 00000041 - Disclosure - SCHEDULE OF OTHER INFORMATION RELATED TO LEASES (Details) Sheet http://advaxis.com/role/ScheduleOfOtherInformationRelatedToLeasesDetails SCHEDULE OF OTHER INFORMATION RELATED TO LEASES (Details) Details 41 false false R42.htm 00000042 - Disclosure - SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES (Details) Sheet http://advaxis.com/role/ScheduleOfCashFlowInformationRelatedToLeasesDetails SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES (Details) Details 42 false false R43.htm 00000043 - Disclosure - SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELLABLE LEASES (Details) Sheet http://advaxis.com/role/ScheduleOfFutureMinimumLeasePaymentsUnderNon-cancellableLeasesDetails SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELLABLE LEASES (Details) Details 43 false false R44.htm 00000044 - Disclosure - LEASES (Details Narrative) Sheet http://advaxis.com/role/LeasesDetailsNarrative LEASES (Details Narrative) Details http://advaxis.com/role/LeasesTables 44 false false R45.htm 00000045 - Disclosure - COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Details) Sheet http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetails COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Details) Details http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityTables 45 false false R46.htm 00000046 - Disclosure - SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY (Details) Sheet http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY (Details) Details 46 false false R47.htm 00000047 - Disclosure - COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Details Narrative) Sheet http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Details Narrative) Details http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityTables 47 false false R48.htm 00000048 - Disclosure - SCHEDULE OF PREFERRED STOCK REDEMPTION LIABILITY (Details) Sheet http://advaxis.com/role/ScheduleOfPreferredStockRedemptionLiabilityDetails SCHEDULE OF PREFERRED STOCK REDEMPTION LIABILITY (Details) Details 48 false false R49.htm 00000049 - Disclosure - TEMPORARY EQUITY (Details Narrative) Sheet http://advaxis.com/role/TemporaryEquityDetailsNarrative TEMPORARY EQUITY (Details Narrative) Details http://advaxis.com/role/TemporaryEquityTables 49 false false R50.htm 00000050 - Disclosure - SUMMARY OF STOCKHOLDERS EQUITY (Details) Sheet http://advaxis.com/role/SummaryOfStockholdersEquityDetails SUMMARY OF STOCKHOLDERS EQUITY (Details) Details 50 false false R51.htm 00000051 - Disclosure - SUMMARY OF SHARE BASED COMPENSATION EXPENSE (Details) Sheet http://advaxis.com/role/SummaryOfShareBasedCompensationExpenseDetails SUMMARY OF SHARE BASED COMPENSATION EXPENSE (Details) Details 51 false false R52.htm 00000052 - Disclosure - SUMMARY OF CHANGES IN STOCK OPTION PLAN (Details) Sheet http://advaxis.com/role/SummaryOfChangesInStockOptionPlanDetails SUMMARY OF CHANGES IN STOCK OPTION PLAN (Details) Details 52 false false R53.htm 00000053 - Disclosure - SUMMARY OF OUTSTANDING AND EXERCISABLE OPTIONS (Details) Sheet http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails SUMMARY OF OUTSTANDING AND EXERCISABLE OPTIONS (Details) Details 53 false false R54.htm 00000054 - Disclosure - SHARE BASED COMPENSATION (Details Narrative) Sheet http://advaxis.com/role/ShareBasedCompensationDetailsNarrative SHARE BASED COMPENSATION (Details Narrative) Details http://advaxis.com/role/ShareBasedCompensationTables 54 false false R55.htm 00000055 - Disclosure - LICENSING AGREEMENTS (Details Narrative) Sheet http://advaxis.com/role/LicensingAgreementsDetailsNarrative LICENSING AGREEMENTS (Details Narrative) Details http://advaxis.com/role/LicensingAgreements 55 false false R56.htm 00000056 - Disclosure - SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) Sheet http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) Details 56 false false R57.htm 00000057 - Disclosure - SCHEDULE OF FAIR VALUE MEASURING UNOBSERVABLE INPUTS (Details) Sheet http://advaxis.com/role/ScheduleOfFairValueMeasuringUnobservableInputsDetails SCHEDULE OF FAIR VALUE MEASURING UNOBSERVABLE INPUTS (Details) Details 57 false false All Reports Book All Reports form10-q.htm adxs-20220131.xsd adxs-20220131_cal.xml adxs-20220131_def.xml adxs-20220131_lab.xml adxs-20220131_pre.xml ex31-1.htm ex31-2.htm ex32-1.htm ex32-2.htm http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 75 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-q.htm": { "axisCustom": 0, "axisStandard": 16, "contextCount": 149, "dts": { "calculationLink": { "local": [ "adxs-20220131_cal.xml" ] }, "definitionLink": { "local": [ "adxs-20220131_def.xml" ] }, "inline": { "local": [ "form10-q.htm" ] }, "labelLink": { "local": [ "adxs-20220131_lab.xml" ] }, "presentationLink": { "local": [ "adxs-20220131_pre.xml" ] }, "schema": { "local": [ "adxs-20220131.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 394, "entityCount": 1, "hidden": { "http://advaxis.com/20220131": 13, "http://fasb.org/us-gaap/2021-01-31": 73, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 91 }, "keyCustom": 31, "keyStandard": 300, "memberCustom": 18, "memberStandard": 22, "nsprefix": "ADXS", "nsuri": "http://advaxis.com/20220131", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://advaxis.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - ACCRUED EXPENSES", "role": "http://advaxis.com/role/AccruedExpenses", "shortName": "ACCRUED EXPENSES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - LEASES", "role": "http://advaxis.com/role/Leases", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "ADXS:CommonStockPurchaseWarrantsAndWarrantLiabilityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY", "role": "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiability", "shortName": "COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "ADXS:CommonStockPurchaseWarrantsAndWarrantLiabilityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://advaxis.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "ADXS:TemporaryEquityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - TEMPORARY EQUITY", "role": "http://advaxis.com/role/TemporaryEquity", "shortName": "TEMPORARY EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "ADXS:TemporaryEquityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - STOCKHOLDERS\u2019 EQUITY", "role": "http://advaxis.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS\u2019 EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - SHARE BASED COMPENSATION", "role": "http://advaxis.com/role/ShareBasedCompensation", "shortName": "SHARE BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "ADXS:LicensingAgreementsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - LICENSING AGREEMENTS", "role": "http://advaxis.com/role/LicensingAgreements", "shortName": "LICENSING AGREEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "ADXS:LicensingAgreementsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - FAIR VALUE", "role": "http://advaxis.com/role/FairValue", "shortName": "FAIR VALUE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Policies)", "role": "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://advaxis.com/role/BalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31", "decimals": "-3", "lang": null, "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Tables)", "role": "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - PROPERTY AND EQUIPMENT (Tables)", "role": "http://advaxis.com/role/PropertyAndEquipmentTables", "shortName": "PROPERTY AND EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - INTANGIBLE ASSETS (Tables)", "role": "http://advaxis.com/role/IntangibleAssetsTables", "shortName": "INTANGIBLE ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - ACCRUED EXPENSES (Tables)", "role": "http://advaxis.com/role/AccruedExpensesTables", "shortName": "ACCRUED EXPENSES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "ADXS:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - LEASES (Tables)", "role": "http://advaxis.com/role/LeasesTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "ADXS:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ADXS:CommonStockPurchaseWarrantsAndWarrantLiabilityTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "ADXS:ScheduleOfOutstandingWarrantsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Tables)", "role": "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityTables", "shortName": "COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ADXS:CommonStockPurchaseWarrantsAndWarrantLiabilityTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "ADXS:ScheduleOfOutstandingWarrantsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ADXS:TemporaryEquityDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "ADXS:PreferredStockRedemptionLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - TEMPORARY EQUITY (Tables)", "role": "http://advaxis.com/role/TemporaryEquityTables", "shortName": "TEMPORARY EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ADXS:TemporaryEquityDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "ADXS:PreferredStockRedemptionLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)", "role": "http://advaxis.com/role/StockholdersEquityTables", "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - SHARE BASED COMPENSATION (Tables)", "role": "http://advaxis.com/role/ShareBasedCompensationTables", "shortName": "SHARE BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - FAIR VALUE (Tables)", "role": "http://advaxis.com/role/FairValueTables", "shortName": "FAIR VALUE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PreferredStockLiquidationPreferenceValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://advaxis.com/role/BalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PreferredStockLiquidationPreferenceValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - NATURE OF OPERATIONS (Details Narrative)", "role": "http://advaxis.com/role/NatureOfOperationsDetailsNarrative", "shortName": "NATURE OF OPERATIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - SCHEDULE OF ANTI -DILUTED SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details)", "role": "http://advaxis.com/role/ScheduleOfAnti-dilutedSecuritiesExcludedFromDilutedNetLossPerShareDetails", "shortName": "SCHEDULE OF ANTI -DILUTED SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RestrictedCash", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Details Narrative)", "role": "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31_custom_SeriesDPreferredStockRedemptionMember", "decimals": "-3", "lang": null, "name": "us-gaap:RestrictedCash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:MachineryAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)", "role": "http://advaxis.com/role/ScheduleOfPropertyAndEquipmentDetails", "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:MachineryAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)", "role": "http://advaxis.com/role/PropertyAndEquipmentDetailsNarrative", "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedPatentsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - SUMMARY OF INTANGIBLE ASSETS (Details)", "role": "http://advaxis.com/role/SummaryOfIntangibleAssetsDetails", "shortName": "SUMMARY OF INTANGIBLE ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedPatentsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS (Details)", "role": "http://advaxis.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails", "shortName": "SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - INTANGIBLE ASSETS (Details Narrative)", "role": "http://advaxis.com/role/IntangibleAssetsDetailsNarrative", "shortName": "INTANGIBLE ASSETS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-012022-01-31_us-gaap_GeneralAndAdministrativeExpenseMember", "decimals": "-3", "lang": null, "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - SUMMARY OF ACCRUED EXPENSES (Details)", "role": "http://advaxis.com/role/SummaryOfAccruedExpensesDetails", "shortName": "SUMMARY OF ACCRUED EXPENSES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - SCHEDULE OF SUPPLEMENTAL BALANCE SHEET RELATED TO LEASES (Details)", "role": "http://advaxis.com/role/ScheduleOfSupplementalBalanceSheetRelatedToLeasesDetails", "shortName": "SCHEDULE OF SUPPLEMENTAL BALANCE SHEET RELATED TO LEASES (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-11-012021-01-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "role": "http://advaxis.com/role/StatementsOfOperations", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-11-012021-01-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - SCHEDULE OF LEASE EXPENSES (Details)", "role": "http://advaxis.com/role/ScheduleOfLeaseExpensesDetails", "shortName": "SCHEDULE OF LEASE EXPENSES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "ADXS:ScheduleOfOtherInformationTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - SCHEDULE OF OTHER INFORMATION RELATED TO LEASES (Details)", "role": "http://advaxis.com/role/ScheduleOfOtherInformationRelatedToLeasesDetails", "shortName": "SCHEDULE OF OTHER INFORMATION RELATED TO LEASES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "ADXS:ScheduleOfOtherInformationTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLeaseIncomeLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES (Details)", "role": "http://advaxis.com/role/ScheduleOfCashFlowInformationRelatedToLeasesDetails", "shortName": "SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLeaseIncomeLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELLABLE LEASES (Details)", "role": "http://advaxis.com/role/ScheduleOfFutureMinimumLeasePaymentsUnderNon-cancellableLeasesDetails", "shortName": "SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELLABLE LEASES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-03-012021-03-26", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GainLossOnTerminationOfLease", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - LEASES (Details Narrative)", "role": "http://advaxis.com/role/LeasesDetailsNarrative", "shortName": "LEASES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-03-012021-03-26", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GainLossOnTerminationOfLease", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Details)", "role": "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetails", "shortName": "COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "span", "span", "td", "tr", "table", "ADXS:ScheduleOfOutstandingWarrantsTableTextBlock", "ADXS:CommonStockPurchaseWarrantsAndWarrantLiabilityTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31_custom_ExercisePriceRangeOneMember", "decimals": "INF", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY (Details)", "role": "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails", "shortName": "SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ADXS:CommonStockPurchaseWarrantsAndWarrantLiabilityTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31_custom_WarrantLiabilityMember", "decimals": "INF", "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "span", "span", "td", "tr", "table", "ADXS:ScheduleOfOutstandingWarrantsTableTextBlock", "ADXS:CommonStockPurchaseWarrantsAndWarrantLiabilityTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Details Narrative)", "role": "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative", "shortName": "COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "ADXS:CommonStockPurchaseWarrantsAndWarrantLiabilityTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31", "decimals": "0", "lang": null, "name": "ADXS:FairValueOfWarrantLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ADXS:PreferredStockRedemptionLiabilityTableTextBlock", "ADXS:TemporaryEquityDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31_us-gaap_MeasurementInputExercisePriceMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesFvNiMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - SCHEDULE OF PREFERRED STOCK REDEMPTION LIABILITY (Details)", "role": "http://advaxis.com/role/ScheduleOfPreferredStockRedemptionLiabilityDetails", "shortName": "SCHEDULE OF PREFERRED STOCK REDEMPTION LIABILITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ADXS:PreferredStockRedemptionLiabilityTableTextBlock", "ADXS:TemporaryEquityDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31_us-gaap_MeasurementInputExercisePriceMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesFvNiMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-11-012021-01-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - TEMPORARY EQUITY (Details Narrative)", "role": "http://advaxis.com/role/TemporaryEquityDetailsNarrative", "shortName": "TEMPORARY EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "ADXS:TemporaryEquityDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-01-31", "decimals": "INF", "lang": null, "name": "ADXS:PreferredStockDiscountRatePercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://advaxis.com/role/StatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-11-012021-01-31", "decimals": "-3", "lang": null, "name": "us-gaap:GainLossOnSaleOfPropertyPlantEquipment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-10-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000050 - Disclosure - SUMMARY OF STOCKHOLDERS EQUITY (Details)", "role": "http://advaxis.com/role/SummaryOfStockholdersEquityDetails", "shortName": "SUMMARY OF STOCKHOLDERS EQUITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-10-31", "decimals": "-3", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000051 - Disclosure - SUMMARY OF SHARE BASED COMPENSATION EXPENSE (Details)", "role": "http://advaxis.com/role/SummaryOfShareBasedCompensationExpenseDetails", "shortName": "SUMMARY OF SHARE BASED COMPENSATION EXPENSE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-012022-01-31_us-gaap_ResearchAndDevelopmentExpenseMember", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-10-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000052 - Disclosure - SUMMARY OF CHANGES IN STOCK OPTION PLAN (Details)", "role": "http://advaxis.com/role/SummaryOfChangesInStockOptionPlanDetails", "shortName": "SUMMARY OF CHANGES IN STOCK OPTION PLAN (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-10-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-012022-01-31_custom_ExercisePriceRangeOneMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000053 - Disclosure - SUMMARY OF OUTSTANDING AND EXERCISABLE OPTIONS (Details)", "role": "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails", "shortName": "SUMMARY OF OUTSTANDING AND EXERCISABLE OPTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-012022-01-31_custom_ExercisePriceRangeOneMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000054 - Disclosure - SHARE BASED COMPENSATION (Details Narrative)", "role": "http://advaxis.com/role/ShareBasedCompensationDetailsNarrative", "shortName": "SHARE BASED COMPENSATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "p", "ADXS:LicensingAgreementsDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "ADXS:MilestoneAchievementDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000055 - Disclosure - LICENSING AGREEMENTS (Details Narrative)", "role": "http://advaxis.com/role/LicensingAgreementsDetailsNarrative", "shortName": "LICENSING AGREEMENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "ADXS:LicensingAgreementsDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "ADXS:MilestoneAchievementDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000056 - Disclosure - SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details)", "role": "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "shortName": "SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-10-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000057 - Disclosure - SCHEDULE OF FAIR VALUE MEASURING UNOBSERVABLE INPUTS (Details)", "role": "http://advaxis.com/role/ScheduleOfFairValueMeasuringUnobservableInputsDetails", "shortName": "SCHEDULE OF FAIR VALUE MEASURING UNOBSERVABLE INPUTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-10-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000006 - Disclosure - NATURE OF OPERATIONS", "role": "http://advaxis.com/role/NatureOfOperations", "shortName": "NATURE OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION", "role": "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentation", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - PROPERTY AND EQUIPMENT", "role": "http://advaxis.com/role/PropertyAndEquipment", "shortName": "PROPERTY AND EQUIPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - INTANGIBLE ASSETS", "role": "http://advaxis.com/role/IntangibleAssets", "shortName": "INTANGIBLE ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 42, "tag": { "ADXS_ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of Financing.", "label": "Type of Financing" } } }, "localname": "ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetails" ], "xbrltype": "stringItemType" }, "ADXS_CommonStockPurchaseWarrantsAndWarrantLiabilityTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock Purchase Warrants And Warrant Liability [Text Block]", "label": "COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY" } } }, "localname": "CommonStockPurchaseWarrantsAndWarrantLiabilityTextBlock", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiability" ], "xbrltype": "textBlockItemType" }, "ADXS_CommonStockWarrantLiability": { "auth_ref": [], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock warrant liability.", "label": "Common stock warrant liability", "verboseLabel": "Common stock warrant liability, warrants exercisable at $0.30 through September 2024" } } }, "localname": "CommonStockWarrantLiability", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/BalanceSheets", "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "ADXS_CommonStockWarrantLiability1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock warrant liability.", "label": "Common stock warrant liability, warrants exercisable at $0.70 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)" } } }, "localname": "CommonStockWarrantLiability1", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "ADXS_ConvertablePreferredStockPoliyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertable Preferred Stock [Poliy Text Block]", "label": "Convertible Preferred Stock" } } }, "localname": "ConvertablePreferredStockPoliyTextBlock", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "ADXS_DevelopmentLicenseAndSupplyAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Development, License and Supply Agreement [Member]", "label": "Development, License and Supply Agreement [Member]" } } }, "localname": "DevelopmentLicenseAndSupplyAgreementMember", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ADXS_DisclosureCommonStockPurchaseWarrantsAndWarrantLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Purchase Warrants And Warrant Liability" } } }, "localname": "DisclosureCommonStockPurchaseWarrantsAndWarrantLiabilityAbstract", "nsuri": "http://advaxis.com/20220131", "xbrltype": "stringItemType" }, "ADXS_DisclosureLeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases", "terseLabel": "Schedule Of Lease Expenses", "verboseLabel": "Schedule Of Supplemental Balance Sheet Related To Leases" } } }, "localname": "DisclosureLeasesAbstract", "nsuri": "http://advaxis.com/20220131", "xbrltype": "stringItemType" }, "ADXS_DisclosureLicensingAgreementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Licensing Agreements" } } }, "localname": "DisclosureLicensingAgreementsAbstract", "nsuri": "http://advaxis.com/20220131", "xbrltype": "stringItemType" }, "ADXS_DisclosureTemporaryEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Temporary Equity" } } }, "localname": "DisclosureTemporaryEquityAbstract", "nsuri": "http://advaxis.com/20220131", "xbrltype": "stringItemType" }, "ADXS_EquityWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Warrants [Member]", "label": "Equity Warrants [Member]" } } }, "localname": "EquityWarrantsMember", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "ADXS_ExercisePriceRangeFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Five [Member].", "label": "Exercise Price Range Five [Member]" } } }, "localname": "ExercisePriceRangeFiveMember", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetails" ], "xbrltype": "domainItemType" }, "ADXS_ExercisePriceRangeFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Four [Member]", "label": "Exercise Price Range Four [Member]" } } }, "localname": "ExercisePriceRangeFourMember", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetails", "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails" ], "xbrltype": "domainItemType" }, "ADXS_ExercisePriceRangeOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range One [Member]", "label": "Exercise Price Range One [Member]" } } }, "localname": "ExercisePriceRangeOneMember", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetails", "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails" ], "xbrltype": "domainItemType" }, "ADXS_ExercisePriceRangeSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Six [Member].", "label": "Exercise Price Range Six [Member]" } } }, "localname": "ExercisePriceRangeSixMember", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetails" ], "xbrltype": "domainItemType" }, "ADXS_ExercisePriceRangeThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Three [Member]", "label": "Exercise Price Range Three [Member]" } } }, "localname": "ExercisePriceRangeThreeMember", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetails", "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails" ], "xbrltype": "domainItemType" }, "ADXS_ExercisePriceRangeTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Two [Member]", "label": "Exercise Price Range Two [Member]" } } }, "localname": "ExercisePriceRangeTwoMember", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetails", "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails" ], "xbrltype": "domainItemType" }, "ADXS_FairValueOfWarrantLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of the warrant liability.", "label": "Fair value of the warrant liability" } } }, "localname": "FairValueOfWarrantLiability", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ADXS_FiniteLivedSoftwareGross": { "auth_ref": [], "calculation": { "http://advaxis.com/role/SummaryOfIntangibleAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finite-lived software, gross.", "label": "Software" } } }, "localname": "FiniteLivedSoftwareGross", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/SummaryOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ADXS_FundingMilestonePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Funding milestone payment.", "label": "Funding milestone payment" } } }, "localname": "FundingMilestonePayment", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ADXS_IncreaseDecreaseInOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in operating lease liabilities.", "label": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ADXS_InstitutionalInvestorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Institutional Investors [Member]", "label": "Institutional Investors [Member]" } } }, "localname": "InstitutionalInvestorsMember", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "ADXS_LesseeFinanceLeasesRenewalTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee finance lease renewal term.", "label": "Lessee finance lease renewal term date" } } }, "localname": "LesseeFinanceLeasesRenewalTerm", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/LeasesDetailsNarrative" ], "xbrltype": "dateItemType" }, "ADXS_LesseeFinanceLeasesTermOfContract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee finance lease term of contract.", "label": "Lease expiration date [Default Label]", "verboseLabel": "Lease expiration date" } } }, "localname": "LesseeFinanceLeasesTermOfContract", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/LeasesDetailsNarrative" ], "xbrltype": "dateItemType" }, "ADXS_LicensingAgreementsDisclosuresTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Licensing agreements disclosures [TextBlock]", "label": "LICENSING AGREEMENTS" } } }, "localname": "LicensingAgreementsDisclosuresTextBlock", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/LicensingAgreements" ], "xbrltype": "textBlockItemType" }, "ADXS_MilestoneAchievementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone achievement description", "label": "Milestone achievement, description" } } }, "localname": "MilestoneAchievementDescription", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "ADXS_NumberofVotesPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of votes per share", "label": "Number of votes per share" } } }, "localname": "NumberofVotesPerShare", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "integerItemType" }, "ADXS_OSTherapiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "OS Therapies [Member]", "label": "OS Therapies [Member]" } } }, "localname": "OSTherapiesMember", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ADXS_PaymentOfRent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payments for rent.", "label": "Rent paid" } } }, "localname": "PaymentOfRent", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ADXS_PaymentsForProceedsFromEscrowOffering": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments for proceeds from escrow offering", "label": "Payments for proceeds from escrow offering" } } }, "localname": "PaymentsForProceedsFromEscrowOffering", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ADXS_PreferredStockDiscountRatePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock discount rate percentage", "label": "Issue discount" } } }, "localname": "PreferredStockDiscountRatePercentage", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "ADXS_PreferredStockRedemptionLiability": { "auth_ref": [], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Preferred stock redemption liability.", "label": "Preferred stock redemption liability" } } }, "localname": "PreferredStockRedemptionLiability", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/BalanceSheets", "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "ADXS_PreferredStockRedemptionLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Stock Redemption Liability [Member]", "label": "Preferred Stock Redemption Liability [Member]" } } }, "localname": "PreferredStockRedemptionLiabilityMember", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueMeasuringUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "ADXS_PreferredStockRedemptionLiabilityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock redemption liability [Table Text Block]", "label": "SCHEDULE OF PREFERRED STOCK REDEMPTION LIABILITY" } } }, "localname": "PreferredStockRedemptionLiabilityTableTextBlock", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/TemporaryEquityTables" ], "xbrltype": "textBlockItemType" }, "ADXS_ProceedsFromIssuanceOrEstimatedOffering": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance or estimated offering", "label": "Proceeds from issuance or estimated offering" } } }, "localname": "ProceedsFromIssuanceOrEstimatedOffering", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ADXS_RestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Stock Units [Member]", "label": "Restricted Stock Units [Member]" } } }, "localname": "RestrictedStockUnitsMember", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/ScheduleOfAnti-dilutedSecuritiesExcludedFromDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "ADXS_ScheduleOfOtherInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Other Information [Table Text Block]", "label": "SCHEDULE OF OTHER INFORMATION RELATED TO LEASES" } } }, "localname": "ScheduleOfOtherInformationTableTextBlock", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "ADXS_ScheduleOfOutstandingWarrantsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Outstanding Warrants [Table Text Block]", "label": "Schedule Of Outstanding Warrants [Table Text Block]", "verboseLabel": "COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY" } } }, "localname": "ScheduleOfOutstandingWarrantsTableTextBlock", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityTables" ], "xbrltype": "textBlockItemType" }, "ADXS_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Supplemental Balance Sheet Information Related To Leases [Table Text Block]", "label": "SCHEDULE OF SUPPLEMENTAL BALANCE SHEET RELATED TO LEASES" } } }, "localname": "ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "ADXS_SeriesDConvertableRedeemablePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SeriesD Convertable Redeemable Preferred Stock [Member]", "label": "SeriesD Convertable Redeemable Preferred Stock [Member]" } } }, "localname": "SeriesDConvertableRedeemablePreferredStockMember", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/ScheduleOfAnti-dilutedSecuritiesExcludedFromDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "ADXS_SeriesDConvertibleRedeemablePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series D Convertible Redeemable Preferred Stock [Member]", "label": "Series D Convertible Redeemable Preferred Stock [Member]" } } }, "localname": "SeriesDConvertibleRedeemablePreferredStockMember", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "ADXS_SeriesDPreferredStockRedemptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SeriesD Preferred Stock Redemption [Member]", "label": "SeriesD Preferred Stock Redemption [Member]" } } }, "localname": "SeriesDPreferredStockRedemptionMember", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "domainItemType" }, "ADXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sharebased compensation arrangement by sharebased payment award options outstanding weighted average remaining contractual term ending.", "label": "Weighted Average Remaining Contractual Life In Years, Ending Balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermEnding", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/SummaryOfChangesInStockOptionPlanDetails" ], "xbrltype": "durationItemType" }, "ADXS_StockIssuedDuringPeriodSharesWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares warrants exercised.", "label": "Warrant exercises, shares" } } }, "localname": "StockIssuedDuringPeriodSharesWarrantsExercised", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "ADXS_StockIssuedDuringPeriodValueWarrantsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of warrants.", "label": "StockIssuedDuringPeriodValueWarrantsExercised", "verboseLabel": "Warrant exercises" } } }, "localname": "StockIssuedDuringPeriodValueWarrantsExercised", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "ADXS_StockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Options [Member]", "label": "Stock Options [Member]" } } }, "localname": "StockOptionsMember", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/ScheduleOfAnti-dilutedSecuritiesExcludedFromDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "ADXS_TemporaryEquityDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary Equity Disclosure [Text Block]", "label": "TEMPORARY EQUITY" } } }, "localname": "TemporaryEquityDisclosureTextBlock", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/TemporaryEquity" ], "xbrltype": "textBlockItemType" }, "ADXS_TemporaryEquityStockStatedValueAccumulatedDividends": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity stock stated value accumulated dividends.", "label": "Temporary equity stock stated value accumulated dividends" } } }, "localname": "TemporaryEquityStockStatedValueAccumulatedDividends", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "ADXS_TemporaryEquityStockStatedValueAccumulatedDividendsOnExpiration": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity stock stated value accumulated dividends on expiration.", "label": "TemporaryEquityStockStatedValueAccumulatedDividendsOnExpiration", "verboseLabel": "Temporary equity stock stated value accumulated dividends on extension" } } }, "localname": "TemporaryEquityStockStatedValueAccumulatedDividendsOnExpiration", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "ADXS_TemporaryEquityStockStatedValueAccumulatedDividendsOnExtension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity stock stated value accumulated dividends on extension.", "label": "Temporary equity stock stated value accumulated dividends on extension" } } }, "localname": "TemporaryEquityStockStatedValueAccumulatedDividendsOnExtension", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "ADXS_ThroughSeptemberTwoThousandTwentyFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Through September Two Thousand Twenty Four [Member]" } } }, "localname": "ThroughSeptemberTwoThousandTwentyFourMember", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "ADXS_WarrantLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant Liability [Member]", "label": "Warrant Liability [Member]" } } }, "localname": "WarrantLiabilityMember", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative", "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails", "http://advaxis.com/role/ScheduleOfFairValueMeasuringUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "ADXS_WarrantsExpirationDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expiration date description.", "label": "Expiration Date" } } }, "localname": "WarrantsExpirationDescription", "nsuri": "http://advaxis.com/20220131", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetails" ], "xbrltype": "stringItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r359", "r361", "r362" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://advaxis.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r158", "r168", "r199", "r201", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r332", "r333", "r345", "r346" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r158", "r168", "r199", "r201", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r332", "r333", "r345", "r346" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r158", "r168", "r188", "r199", "r201", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r332", "r333", "r345", "r346" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r158", "r168", "r188", "r199", "r201", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r332", "r333", "r345", "r346" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r82", "r86", "r200" ], "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://advaxis.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r82", "r86", "r145", "r200", "r284" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://advaxis.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r118", "r279" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://advaxis.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://advaxis.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "ACCRUED EXPENSES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/AccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r31", "r283" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrent": { "auth_ref": [ "r31", "r72", "r278", "r280" ], "calculation": { "http://advaxis.com/role/SummaryOfAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Vendors" } } }, "localname": "AccountsPayableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://advaxis.com/role/SummaryOfAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses", "totalLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheets", "http://advaxis.com/role/SummaryOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r7", "r8", "r34" ], "calculation": { "http://advaxis.com/role/SummaryOfAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r29", "r136" ], "calculation": { "http://advaxis.com/role/ScheduleOfPropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r46", "r47", "r258", "r259", "r260", "r261", "r262", "r263" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r19", "r223", "r283" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r74", "r75", "r76", "r220", "r221", "r222", "r245" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r60", "r125", "r130" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization expense of intangible assets", "verboseLabel": "Intangible asset amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/IntangibleAssetsDetailsNarrative", "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Total" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfAnti-dilutedSecuritiesExcludedFromDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfAnti-dilutedSecuritiesExcludedFromDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfAnti-dilutedSecuritiesExcludedFromDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfAnti-dilutedSecuritiesExcludedFromDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r70", "r104", "r107", "r113", "r120", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r233", "r236", "r256", "r281", "r283", "r314", "r322" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r5", "r40", "r70", "r120", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r233", "r236", "r256", "r281", "r283" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r247" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Total Financial Assets at Fair Value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r204", "r219" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation/Estimates" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalizedComputerSoftwareGross": { "auth_ref": [ "r347" ], "calculation": { "http://advaxis.com/role/ScheduleOfPropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.", "label": "Computer equipment" } } }, "localname": "CapitalizedComputerSoftwareGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r27", "r62" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents", "periodEndLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents, at carrying value" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheets", "http://advaxis.com/role/NatureOfOperationsDetailsNarrative", "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash equivalents (money market funds)" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r11", "r63", "r313" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r57", "r62", "r65" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Total cash, cash equivalents and restricted cash shown in condensed statements of cash flows", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed balance sheets that sum to the total of the same such amounts shown in the condensed statements of cash flows:" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r57", "r257" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r68", "r70", "r87", "r88", "r89", "r91", "r93", "r98", "r99", "r100", "r120", "r147", "r151", "r152", "r153", "r156", "r157", "r165", "r166", "r170", "r174", "r256", "r364" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical", "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative", "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r181" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Exercise Price", "verboseLabel": "Warrant exercise price per share" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetails", "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative", "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails", "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Grand Total Number of Shares Underlying Warrants", "verboseLabel": "Number of warrants to purchase common stock" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetails", "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Warrants outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r36", "r144", "r317", "r328" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Contingencies \u2013 Note 10" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r141", "r142", "r143", "r146", "r340" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r74", "r75", "r245" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value", "verboseLabel": "Common stock par or stated value per share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical", "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized", "verboseLabel": "Common stock shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical", "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r17", "r180" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r17", "r283" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock - $0.001 par value; 170,000,000 shares authorized, 145,638,459 shares issued and outstanding at January 31, 2022 and October 31, 2021." } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r67", "r235" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r60", "r134" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/PropertyAndEquipmentDetailsNarrative", "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetails", "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r241" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://advaxis.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Net changes in fair value of derivative liabilities", "negatedLabel": "(Gain) loss on change in value of warrants" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows", "http://advaxis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r43", "r240", "r242", "r243", "r244" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetails", "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesReportingOfDerivativeActivity": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for derivatives entered into for trading purposes and those entered into for purposes other than trading including where and when derivative financial instruments and derivative commodity instruments and their related gains or losses are reported in the entity's statements of financial position, cash flows, and results of operations.", "label": "Derivative Financial Instruments" } } }, "localname": "DerivativesReportingOfDerivativeActivity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "SHARE BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Net loss per common share, basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r94", "r95" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Net Income (Loss) per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://advaxis.com/role/SummaryOfAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Salaries and other compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Unrecognized compensation cost related to non-vested remaining weighted average vesting period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r218" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Unrecognized compensation cost related to outstanding stock options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r46", "r47", "r48", "r74", "r75", "r76", "r78", "r83", "r85", "r97", "r121", "r180", "r182", "r220", "r221", "r222", "r228", "r229", "r245", "r258", "r259", "r260", "r261", "r262", "r263", "r334", "r335", "r336", "r369" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative", "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails", "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNiMeasurementInput": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Measurement Input", "verboseLabel": "Measurement input percentage" } } }, "localname": "EquitySecuritiesFvNiMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfPreferredStockRedemptionLiabilityDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_EscrowDeposit": { "auth_ref": [ "r316", "r341" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.", "label": "Escrow deposit" } } }, "localname": "EscrowDeposit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r60", "r162" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Income on fair value of warrants" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r247", "r248", "r249", "r255" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfPreferredStockRedemptionLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfPreferredStockRedemptionLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r159", "r160", "r161", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r198", "r248", "r285", "r286", "r287" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r254", "r255" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueMeasuringUnobservableInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "FAIR VALUE" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/FairValue" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r159", "r189", "r190", "r195", "r198", "r248", "r285" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r159", "r160", "r161", "r189", "r190", "r195", "r198", "r248", "r286" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r159", "r160", "r161", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r198", "r248", "r287" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueMeasuringUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueMeasuringUnobservableInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r252", "r255" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueMeasuringUnobservableInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r252", "r255" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "SCHEDULE OF FAIR VALUE MEASURING UNOBSERVABLE INPUTS" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement, Change in fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueMeasuringUnobservableInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": { "auth_ref": [ "r253" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement, Additions" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueMeasuringUnobservableInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r252" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Fair Value, Measurement , Ending Balance", "periodStartLabel": "Fair Value, Measurement , Beginning Balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueMeasuringUnobservableInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r159", "r160", "r161", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r198", "r285", "r286", "r287" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetAssetLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of asset after deduction of liability.", "label": "Total financial liabilities at fair value" } } }, "localname": "FairValueNetAssetLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r129" ], "calculation": { "http://advaxis.com/role/SummaryOfIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r131" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "2022 (Remaining)" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r131" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r131" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r131" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r129", "r299" ], "calculation": { "http://advaxis.com/role/SummaryOfIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "totalLabel": "Total intangibles" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r129", "r298" ], "calculation": { "http://advaxis.com/role/SummaryOfIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Intangible assets", "verboseLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails", "http://advaxis.com/role/SummaryOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedLicenseAgreementsGross": { "auth_ref": [ "r129" ], "calculation": { "http://advaxis.com/role/SummaryOfIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross carrying amount as of the balance sheet date of certain rights acquired to exercise a certain privilege or pursue a particular business or occupation and which is deemed to have a finite economic life.", "label": "Licenses" } } }, "localname": "FiniteLivedLicenseAgreementsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedPatentsGross": { "auth_ref": [ "r129" ], "calculation": { "http://advaxis.com/role/SummaryOfIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.", "label": "Patents" } } }, "localname": "FiniteLivedPatentsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r60" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Net payment for termination fee" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r60" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Loss on disposal of property and equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnTerminationOfLease": { "auth_ref": [ "r264" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.", "label": "Lease termination" } } }, "localname": "GainLossOnTerminationOfLease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r53" ], "calculation": { "http://advaxis.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/IntangibleAssetsDetailsNarrative", "http://advaxis.com/role/SummaryOfShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r60", "r132" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "Abandonment of intangible assets", "verboseLabel": "Book value patent applications, net" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/IntangibleAssetsDetailsNarrative", "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r50", "r104", "r106", "r109", "r112", "r114", "r312", "r318", "r320", "r330" ], "calculation": { "http://advaxis.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Net loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r138", "r140" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/IntangibleAssetsDetailsNarrative", "http://advaxis.com/role/SummaryOfShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/IntangibleAssetsDetailsNarrative", "http://advaxis.com/role/SummaryOfShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r71", "r84", "r85", "r103", "r227", "r230", "r231", "r331" ], "calculation": { "http://advaxis.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r64" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Cash paid for taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r59" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r59", "r295" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Change in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r59" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses, other current assets and deferred expenses" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "INTANGIBLE ASSETS" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r124", "r127" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible assets (net of accumulated amortization)" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "calculation": { "http://advaxis.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest income, net" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r271", "r273" ], "calculation": { "http://advaxis.com/role/ScheduleOfLeaseExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease expense" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfLeaseExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "SCHEDULE OF LEASE EXPENSES" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.", "label": "Lease expiration date" } } }, "localname": "LeaseExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/LeasesDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELLABLE LEASES" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r272" ], "calculation": { "http://advaxis.com/role/ScheduleOfFutureMinimumLeasePaymentsUnderNon-cancellableLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfFutureMinimumLeasePaymentsUnderNon-cancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r272" ], "calculation": { "http://advaxis.com/role/ScheduleOfFutureMinimumLeasePaymentsUnderNon-cancellableLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "verboseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfFutureMinimumLeasePaymentsUnderNon-cancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r272" ], "calculation": { "http://advaxis.com/role/ScheduleOfFutureMinimumLeasePaymentsUnderNon-cancellableLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "verboseLabel": "2022 (Remaining)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfFutureMinimumLeasePaymentsUnderNon-cancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r272" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfFutureMinimumLeasePaymentsUnderNon-cancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "LEASES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r33", "r70", "r108", "r120", "r147", "r148", "r149", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r234", "r236", "r237", "r256", "r281", "r282" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r23", "r70", "r120", "r256", "r283", "r315", "r325" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r35", "r70", "r120", "r147", "r148", "r149", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r234", "r236", "r237", "r256", "r281", "r282", "r283" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_MachineryAndEquipmentGross": { "auth_ref": [ "r6", "r135" ], "calculation": { "http://advaxis.com/role/ScheduleOfPropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Laboratory equipment" } } }, "localname": "MachineryAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputExercisePriceMember": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using agreed upon price for exchange of underlying asset.", "label": "Measurement Input, Exercise Price [Member]" } } }, "localname": "MeasurementInputExercisePriceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfPreferredStockRedemptionLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails", "http://advaxis.com/role/ScheduleOfPreferredStockRedemptionLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails", "http://advaxis.com/role/ScheduleOfPreferredStockRedemptionLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Measurement Input, Share Price [Member]" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfPreferredStockRedemptionLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails", "http://advaxis.com/role/ScheduleOfPreferredStockRedemptionLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails", "http://advaxis.com/role/ScheduleOfPreferredStockRedemptionLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r57" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r57" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r57", "r58", "r61" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r44", "r45", "r48", "r51", "r61", "r70", "r77", "r79", "r80", "r81", "r82", "r84", "r85", "r90", "r104", "r106", "r109", "r112", "r114", "r120", "r147", "r148", "r149", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r246", "r256", "r319", "r329" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://advaxis.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net Loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows", "http://advaxis.com/role/StatementsOfOperations", "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Offsetting Assets [Line Items]" } } }, "localname": "OffsettingAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetails", "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingAssetsTable": { "auth_ref": [ "r41", "r42" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements.", "label": "Offsetting Assets [Table]" } } }, "localname": "OffsettingAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetails", "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://advaxis.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r104", "r106", "r109", "r112", "r114" ], "calculation": { "http://advaxis.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r267", "r273" ], "calculation": { "http://advaxis.com/role/ScheduleOfLeaseExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfLeaseExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLeaseIncomeLeasePayments": { "auth_ref": [ "r96", "r275" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.", "label": "Cash paid for operating lease liabilities" } } }, "localname": "OperatingLeaseLeaseIncomeLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfCashFlowInformationRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r266" ], "calculation": { "http://advaxis.com/role/ScheduleOfSupplementalBalanceSheetRelatedToLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating lease liability", "totalLabel": "Total operating lease liabilities", "verboseLabel": "Total" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/LeasesDetailsNarrative", "http://advaxis.com/role/ScheduleOfFutureMinimumLeasePaymentsUnderNon-cancellableLeasesDetails", "http://advaxis.com/role/ScheduleOfSupplementalBalanceSheetRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r266" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://advaxis.com/role/ScheduleOfSupplementalBalanceSheetRelatedToLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Current portion of operating lease liability", "verboseLabel": "Operating lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheets", "http://advaxis.com/role/ScheduleOfSupplementalBalanceSheetRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r266" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://advaxis.com/role/ScheduleOfSupplementalBalanceSheetRelatedToLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liability, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheets", "http://advaxis.com/role/ScheduleOfSupplementalBalanceSheetRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r265" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating right-of-use asset (net of accumulated amortization)", "terseLabel": "Operating lease, Right of use asset", "verboseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheets", "http://advaxis.com/role/LeasesDetailsNarrative", "http://advaxis.com/role/ScheduleOfSupplementalBalanceSheetRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r60" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Amortization of right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r270", "r273" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfOtherInformationRelatedToLeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r269", "r273" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted-average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfOtherInformationRelatedToLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r2", "r238" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "NATURE OF OPERATIONS" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/NatureOfOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r7", "r8", "r9", "r34" ], "calculation": { "http://advaxis.com/role/SummaryOfAccruedExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r30" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r54" ], "calculation": { "http://advaxis.com/role/StatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other (expense) income" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r55" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedLabel": "Cost of intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockConvertibleConversionPrice": { "auth_ref": [ "r167" ], "lang": { "en-us": { "role": { "documentation": "Per share conversion price of preferred stock.", "label": "Preferred stock conversion price" } } }, "localname": "PreferredStockConvertibleConversionPrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockLiquidationPreferenceValue": { "auth_ref": [ "r68", "r170" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.", "label": "Preferred Stock, Liquidation Preference, Value" } } }, "localname": "PreferredStockLiquidationPreferenceValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r16", "r165" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockRedemptionAmount": { "auth_ref": [ "r37", "r164" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The redemption (or callable) amount of currently redeemable preferred stock. Includes amounts representing dividends not currently declared or paid but which will be payable under the redemption features or for which ultimate payment is solely within the control of the issuer.", "label": "Preferred stock, redemption amount" } } }, "localname": "PreferredStockRedemptionAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r16", "r165" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r16", "r283" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.001 par value; 4,000,000 and 5,000,000 shares authorized, 0 shares issued and outstanding at January 31, 2022 and October 31, 2021." } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r4", "r25", "r26" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative", "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityTables", "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails", "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r56" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Net proceeds of issuance of common stock and warrants" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r56" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Net proceeds of issuance of Series D preferred stock" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r56" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Warrant exercises" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r139", "r342", "r343", "r344" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r28", "r135" ], "calculation": { "http://advaxis.com/role/ScheduleOfPropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Total property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r12", "r13", "r137", "r283", "r321", "r327" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://advaxis.com/role/ScheduleOfPropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment (net of accumulated depreciation)", "totalLabel": "Net property and equipment" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheets", "http://advaxis.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r12", "r137" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "SCHEDULE OF PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReceivablesNetCurrent": { "auth_ref": [ "r18", "r24", "r283", "r326", "r339" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.", "label": "Net gain on leases" } } }, "localname": "ReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r197", "r276", "r277" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r197", "r276", "r280", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r226", "r296", "r347" ], "calculation": { "http://advaxis.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r65", "r313", "r323" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted cash", "periodEndLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheets", "http://advaxis.com/role/StatementsOfCashFlows", "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r20", "r182", "r223", "r283", "r324", "r337", "r338" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r74", "r75", "r76", "r78", "r83", "r85", "r121", "r220", "r221", "r222", "r228", "r229", "r245", "r334", "r336" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r101", "r102", "r105", "r110", "r111", "r115", "r116", "r117", "r184", "r185", "r297" ], "calculation": { "http://advaxis.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r49", "r70", "r101", "r102", "r105", "r110", "r111", "r115", "r116", "r117", "r120", "r147", "r148", "r149", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r256", "r320" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "verboseLabel": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative", "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityTables", "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails", "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "SUMMARY OF ACCRUED EXPENSES" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/AccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfAnti-dilutedSecuritiesExcludedFromDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "SCHEDULE OF ANTI -DILUTED SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "auth_ref": [ "r196" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.", "label": "SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY" } } }, "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "SUMMARY OF SHARE BASED COMPENSATION EXPENSE" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "auth_ref": [ "r186", "r187" ], "lang": { "en-us": { "role": { "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.", "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r203", "r217", "r224" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r247", "r248" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r126", "r128" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "SUMMARY OF INTANGIBLE ASSETS" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r122", "r123" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "SUMMARY OF OUTSTANDING AND EXERCISABLE OPTIONS" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r206", "r212", "r213" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "SUMMARY OF CHANGES IN STOCK OPTION PLAN" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "auth_ref": [ "r180" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.", "label": "SUMMARY OF STOCKHOLDERS EQUITY" } } }, "localname": "ScheduleOfStockholdersEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecurityDeposit": { "auth_ref": [ "r39" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.", "label": "Security deposit" } } }, "localname": "SecurityDeposit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeriesDPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series D preferred stock or outstanding series D preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series D Preferred Stock [Member]" } } }, "localname": "SeriesDPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r59" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share based compensation", "verboseLabel": "Share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows", "http://advaxis.com/role/SummaryOfShareBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Shares, Vested and Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfChangesInStockOptionPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Weighted Average Exercise Price, Vested and Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfChangesInStockOptionPlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Shares, Cancelled or Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfChangesInStockOptionPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Weighted Average Exercise Price, Cancelled or Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfChangesInStockOptionPlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r219" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Aggregate Intrinsic Value, Ending", "periodStartLabel": "Aggregate Intrinsic Value, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfChangesInStockOptionPlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r208", "r219" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Shares, Outstanding, Ending Balance", "periodStartLabel": "Shares Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfChangesInStockOptionPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Outstanding, Ending", "periodStartLabel": "Weighted Average Exercise Price, Outstanding, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfChangesInStockOptionPlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r202", "r205" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Exercise Price Range, lower limit" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "auth_ref": [ "r211" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.", "label": "Number Outstanding, Options Exercisable" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Number Outstanding, Options Outstanding" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Exercise Price Range, upper limit" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Stock Price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r219" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Aggregate Intrinsic Value, Vested and Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfChangesInStockOptionPlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Contractual Life In Years, Vested and Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfChangesInStockOptionPlanDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Share-based compensation arrangement by share-based payment award, options, nonvested, number of shares" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Contractual Life In Years, Beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfChangesInStockOptionPlanDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.", "label": "Weighted Average Exercise Price, Options Exercisable" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Contractual Term Exercisable, Options Exercisable" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.", "label": "Weighted Average Exercise Price, Options Outstanding" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Contractual, Options Outstanding" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Share purchase price" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r66", "r73" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r15", "r16", "r17", "r68", "r70", "r87", "r88", "r89", "r91", "r93", "r98", "r99", "r100", "r120", "r147", "r151", "r152", "r153", "r156", "r157", "r165", "r166", "r170", "r174", "r180", "r256", "r364" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical", "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative", "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r38", "r46", "r47", "r48", "r74", "r75", "r76", "r78", "r83", "r85", "r97", "r121", "r180", "r182", "r220", "r221", "r222", "r228", "r229", "r245", "r258", "r259", "r260", "r261", "r262", "r263", "r334", "r335", "r336", "r369" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative", "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails", "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical", "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative", "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails", "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r74", "r75", "r76", "r97", "r297" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical", "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative", "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails", "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r16", "r17", "r180", "r182" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Shares issued", "verboseLabel": "Advaxis public offerings, net of offering costs, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails", "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock-based compensation, shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r16", "r17", "r180", "r182" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stated value", "verboseLabel": "Advaxis public offerings, net of offering costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails", "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r17", "r21", "r22", "r70", "r119", "r120", "r256", "r283" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheets", "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r69", "r166", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r182", "r183" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityTables", "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative", "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityTables", "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails", "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityTables", "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL CASH FLOW INFORMATION" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r147", "r151", "r152", "r153", "r156", "r157" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Series D convertible preferred stock- $0.001 par value; 1,000,000 shares authorized, issued and outstanding at January 31, 2022; Liquidation preference of $5,250 at January 31, 2022.", "verboseLabel": "Temporary equity, carrying amount, attributable to parent" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheets", "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "auth_ref": [ "r10", "r163" ], "lang": { "en-us": { "role": { "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.", "label": "Temporary Equity, Par or Stated Value Per Share" } } }, "localname": "TemporaryEquityParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Authorized" } } }, "localname": "TemporaryEquitySharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r268", "r273" ], "calculation": { "http://advaxis.com/role/ScheduleOfLeaseExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfLeaseExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative", "http://advaxis.com/role/ScheduleOfAnti-dilutedSecuritiesExcludedFromDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Measurement input percentage" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected Term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted average number of common shares, basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://advaxis.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r133": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r139": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r143": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r146": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21564-112644" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r183": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r225": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r238": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "40", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123386189&loc=SL77918607-209975" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r274": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-06(3))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(d)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r348": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r349": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r351": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r352": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r353": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r354": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r355": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r356": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r357": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r358": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r359": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r361": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r362": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r363": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r364": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r365": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r366": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r367": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r368": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.27(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8,17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r73": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=SL77927221-108306" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" } }, "version": "2.1" } ZIP 76 0001493152-22-007099-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-007099-xbrl.zip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